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Urinary tract infection (UTI) is a common bacterial infection with substantial 
impact on quality of life and considerable health care expenditures across 
all ages.1;2 Approximately half of all women will once experience an UTI 
during their lifetime. Moreover, elderly and patients with underlying illnesses 
like diabetes mellitus or urologic abnormalities are at increased risk.3;4 It is 
expected that the incidence of UTI will continue to rise, given the increase 
in life expectancy and prevalence of diabetes mellitus in the next decades.
Classification
In the literature, various classifications of UTIs have been used, based on 
location of the infection, presence of fever and/or presence of complicat-
ing patient factors, which make the terminology and classification rather 
complex.
Firstly, based on the location, UTIs can be classified into ‘lower UTI’ and 
‘upper UTI’. When UTI is limited to the lower urinary tract (urethra and blad-
der), symptoms may include dysuria, urgency, frequency, hematuria and/or 
suprapubic pain, reflecting the presence of bladder infection (lower UTI or 
cystitis). If symptoms of lower UTI are accompanied by fever or chills, flank 
pain, nausea or vomiting, the upper urinary tract is also involved (upper UTI, 
kidney infection or pyelonephritis). In men, those symptoms may also reflect 
infection of the prostate (prostatitis). (Figure 1)
Another way of classifying UTIs is labelling UTI as ‘uncomplicated’ or ‘com-
plicated’ by taking into account certain patient characteristics. The term ‘un-
complicated’ is usually restricted to premenopausal, non-pregnant women 
with no known anatomical or functional abnormalities of the urinary tract 
or other comorbidities.5-7 However, some authors advocate to consider UTIs 
in women with well controlled diabetes mellitus or postmenopausal women 
without urological sequelae to be ‘uncomplicated’ too.8 All other UTIs are by 
definition ‘complicated’, e.g. men and patients with urological abnormalities.
To make it a some more complex, international guidelines use a combina-
tion of the above mentioned classifications: acute uncomplicated cystitis, 
acute uncomplicated pyelonephritis, complicated UTI and acute complicated 
pyelonephritis, and in addition for men several categories of prostatitis are 
distinguished.6;8-13
Given the broad range of classifications of UTIs in the literature, it makes 
sense to classify UTI patients uniformly according to their clinical presenta-
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tion, in which fever is the main determinative clinical factor. Fever in UTI 
indicates that the infection is not limited to the bladder mucosa, but invasive 
and spread locally of systemically. Although an exact anatomical distinction 
can often not be made only on clinical symptoms, febrile UTI thus reflects the 
presence of a parenchymal inflammation of the urinary tract and the ensu-
ing host response, in which the bladder, prostate, kidney, blood circulation, 
lymph nodes of the pelvis or a combination of those can be involved. In this 
thesis, we will use febrile UTI as the clinical syndrome of interest, because 
this is how patients present, and fever mainly determines the appropriate 
clinical approach. According to the discussed classifications, febrile UTI in-
cludes complicated UTI with fever, acute (un-)complicated pyelonephritis, 
acute prostatitis and urosepsis.
Pathogenesis
The majority of UTIs is caused by bacteria from the intestine that ascend 
through the urethra to the bladder and kidneys. Escherichia coli is by far 
the most common uropathogen, causing up to 80% of UTIs, followed by 
other bacteria such as Klebsiella species, Proteus mirabilis and Pseudomonas 





















Figure 1. Lower UTI is limited to the urethra and bladder. Uropathogens may translocate to the prostate in 
men (prostatitis) and/or ascend to the kidney (acute pyelonephritis) and blood stream (urosepsis) causing 
a febrile upper UTI (adapted from 14).
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IPeriurethral colonization with a uropathogen usually is one of the critical 
initial steps in the pathogenesis of UTI. Most uropathogens originate from 
the rectal microbiota and enter the bladder via the urethra.17 The urinary 
tract is normally well protected against microbial invasion by a variety of 
host defense mechanisms. The main defense mechanisms of the host against 
colonization of the bladder are dilution and micturition. However, several 
behavioural and environmental risk factors can facilitate the colonization and 
influence the susceptibility of the host. Anatomical or functional abnormali-
ties that prevent complete emptying of the bladder, like urethral stenosis, 
benign prostate hypertrophia may increase the chance of colonization with 
uropathogens. Behavioural risk factors associated include voiding dysfunc-
tion, bladder catheterization and sexual intercourse.18-20 After colonization, 
the next step in pathogenesis is the adhesion of uropathogens to the epithe-
lial bladder and kidney cells and invasion into the tissue. After adherence, 
uropathogens are protected against wash-out by urine flow. Whether sub-
sequent UTI occurs is the result of a dynamic interaction between the host 
and uropathogen.
Uropathogens have proven themselves to be a formidable opponent to the 
human host defense, capable of survival and rapid adaption in the relatively 
hostile environment of the urinary tract due to virulence factors. Virulence 
factors enable bacteria to overcome local host defences, enter and multiply 
within the urinary tract and invade the uroepithelium. Examples of such 
virulence factors, which have been studied in particular in Escherichia coli 
strains, include adhesins like fimbriae, siderophores, polysaccharide coat-
ings, proteases and toxins.21;22 Fimbriae, hair-like organelles, play a major 
role in the adhesion of Escherichia coli to the uroepithelial cells. The most 
important are type-1 fimbriae and P-fimbriae. Type-1 fimbriae cause adhe-
sion to epithelial cells of the vagina, urethra and bladder, whereas P-fimbriae 
(type-2 fimbriae) adhere to kidney cells. In more than 70% of all E. coli 
strains of patients with acute pyelonephritis, such P-fimbriae are found.15
Despite the discussed first line of host defense, uropathogens may thus 
sometimes persist in the urinary tract due to effective virulence character-
istics. Then, antimicrobial properties of the uroepithelium and the innate 
immune system of the urinary tract become critical to the host response to 
uropathogens. The uroepithelium produces several antimicrobial peptides, 
amongst others cathelicidin LL37, β-defensins and uromodulin, as part of the 
innate immune response.23;24 Such antimicrobial peptides possess a direct 
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toxic activity. In addition, defensins e.g. can enhance innate responses by 
causing mast cell degranulation and by promoting neutrophil chemotaxis. 
Uromodulin adheres to fimbriae of uropathogenic E. coli, thus preventing its 
attachment to the epithelium. Uromodulin also has an immunomodulatory 
function.25 If the antimicrobial peptides fail to completely kill and wash-out 
the invading pathogens, the innate immune response is initiated in order 
to eliminate the invading microbes. Toll-like receptors (TLR) are key initial 
molecules in the pathogenic cascade of UTI.26 Bacterial recognition leads 
to cytokine (like IL-6, IL-8) and chemokine responses and recruitment of 
inflammatory cells.
The role of adaptive immunity in UTI remains controversial, but does not 
seem to play a primary role in the protection against bacteria, as is also 
reflected in the frequent recurrent UTIs observable especially in young 
women.25;27
Both antimicrobial properties of the urinary tract and the innate immune 
response to the presence of bacteria in the kidney may be influenced by 
genetic predisposition, as has been shown recently.28-32
Treatment
In the last decade, treatment of UTI has become more and more complicated 
by rising antimicrobial resistance of Enterobacteriaceae, the most common 
uropathogens of UTI. In the Netherlands, fluoroquinolones, amoxicillin-cla-
vulanic acid and trimethoprim-sulfamethoxazole are yet the preferred agents 
for oral treatment of febrile UTI. Fluoroquinolones are recommended as first 
choice empirical agent, particularly because there is a relatively low rate of 
antimicrobial resistance.5;33-35 However, the extensive use of antimicrobials 
in veterinary and human health care practice has resulted in the emergence 
and dissemination of resistant pathogens in the community, endangering the 
efficacy of (oral) treatment options.36;37 In the Netherlands, a country known 
for its restrictive use of antibiotics and overall low rates of antimicrobial 
resistance, Escherichia coli resistance to fluoroquinolones increased from 3% 
in 2001 to 10-17% in 2014 with even higher rates at urology services.38;39 
In order to select the most appropriate empirical antimicrobial oral therapy, 
it is very important to know which patients are at particularly risk for e.g. 
fluoroquinolone-resistant uropathogens. However, data on host-related and/
or environmental risk factors for fluoroquinolone resistance in community-
acquired febrile UTI are limited.
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IWith a lack of new antimicrobial classes in development,
40 it is increasingly 
important to develop strategies to maintain and even increase effectiveness 
of available antimicrobials. Optimization of treatment duration represents 
one such important strategy, because the development and spread of anti-
microbial resistance is closely related to the total amount of antimicrobials 
used in countries.41 The duration of antimicrobial therapy exerts differential 
selecting pressure on gut flora which leads to selection of resistant strains 
and reduction of resident commensal bacteria paving the road for e.g. 
Clostridium difficile infection.42 Moreover, the potential adverse effects of un-
necessary extended treatment periods reach beyond the individual treated: 
the longer antimicrobials are taken and excreted into the environment, the 
more pressure is exerted on the ecological balance of bacteria outside the 
human gut.43
Although febrile UTI is a relatively common and potentially severe infection, 
yet the optimal duration of treatment has not been established with the 
exception of uncomplicated cystitis and acute pyelonephritis in otherwise 
healthy women. Young women without comorbidities can be treated for fe-
brile UTI with a 1-week regimen of fluoroquinolones provided a low level of 
fluoroquinolone resistance,44 or, if proven susceptible, with a 2-week course 
of trimethoprim-sulfamethoxazole.35;45-47 In contrast, there is less conformity 
on therapeutic approaches for other patient categories, as most randomized 
trials have excluded male patients, the elderly, and those with urinary tract 
abnormalities or underlying systemic illnesses.
Because of a lack of randomized treatment duration trials, current guidelines 
usually recommend antimicrobials for 7-14 days, with longer durations in 
special circumstances such as chronic bacterial prostatitis.5;48-50
It can be concluded that, despite the importance of minimal yet optimally ef-
ficacious duration of treatment, the evidence on optimal treatment duration 
of febrile UTI is scarce. We therefore initiated the FUTIRST- (Febrile Urinary 
Tract Infection Randomized Short Treatment) trial, a randomized, placebo-
controlled double-blind non-inferiority study including consecutive adults 
presenting with a community-acquired febrile UTI. Patients were recruited 
at 35 primary care centers and 8 affiliating regional emergency departments 
in the Leiden-The Hague region (Figure 2). They were randomly assigned 
to receive ciprofloxacin 500 mg orally twice daily for 7 days or for 14 days. 
The aim of this study was to determine whether the efficacy and safety of a 
7-day antimicrobial regimen (short treatment) is similar to a 14-day regimen 
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(standard treatment) in a unselected population with community-acquired 
febrile UTI.51
Apart from that, we performed a prospective observational multicentre 
cohort study. The aim of this study is to clarify the clinical relevance of 
urine and blood biomarkers, as well as genetic markers, for the prediction 
of severity and course of febrile UTI. Although several markers of febrile UTI 
(e.g. MR-proADM) have been identified, little is known of clinical relevance 
and specificity of biomarkers for disease progression and prognosis of the 
patient. The benefit of addition of urine and/or blood (bedside) biomark-
ers to readily-available clinical information will be evaluated with respect to 
patient’s prognosis and management. Moreover, although selective genetic 
control of innate immunity (e.g. IL-6, IL-8) is presently being unravelled, 
little is known of the clinical relevance of such combined underlying genetic 
mechanisms.
To obtain these data, the participating patients were thoroughly followed 
clinically, and microbiological data and blood and urine samples were col-
lected at different time points (Table 1).
Patients were recruited both in primary care and at regional emergency de-
partments (Figure 2), reflecting a real-life, full spectrum of invasive UTI. The 
prognostic value of a certain biomarker measured in a febrile UTI patient at 
e.g. the emergency department is not one-to-one applicable to a febrile UTI 
patient presenting at a primary care center. The inclusion of both patients 
with a relatively mild illness as well as those with a life-threatening condition 
would allow us to investigate the prognostic value of biomarkers in various 
subgroups separately.





Figure 2. Participating study sites (adapted from 51)
Table 1. Flowchart of data collection in febrile UTI patients (adapted from 51)
Assessment
Days after enrollment
0 3-4 24-32 84-92
Enrollment x      
Demography x      
Clinical data x x x x
Urine culture x   x  
Blood culture x      
Plasma sample x x x  
Urine sample x x x  
DNA sample x    
Adverse events x x x x
Survival   x x x
Contact - in person x x x  
Contact - by phone       x
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Outline of the thesis
The aim of this thesis is to clarify the clinical relevance of urine and blood 
biomarkers, as well as genetic markers, for the prediction of severity and 
course of febrile UTI. Furthermore, this thesis focuses on the optimal dura-
tion of antimicrobial treatment.
In Chapter 1, we assess potential risk factors for resistance to fluoroqui-
nolones in patients with febrile Escherichia coli UTI. Both host-related risk 
factors and environmental risk factors like contact with health care workers 
and animals were included.52
The review in Chapter 2 highlights the main evidence from randomized 
trials on the optimal treatment duration of community-acquired febrile UTI.53
Chapter 3 describes the FUTIRST-trial, a randomized, placebo-controlled 
non-inferiority multicentre trial on treatment duration of febrile UTI.51 In this 
trial, short treatment duration (7 days) is compared to standard (14 days) 
duration of oral ciprofloxacin with respect to clinical and microbiological cure 
both in primary care and in admitted patients.
The cohort study in Chapter 4 evaluates the effect of pre-existing diabetes 
on presentation and microbiological and clinical outcome of febrile UTI. The 
effect of diabetes and concurrent illnesses is assessed separately.54 Do dia-
betic patients with febrile UTI indeed have a complicated course or not?
Although several markers of febrile UTI (e.g., procalcitonin) have been iden-
tified, little is known of clinical relevance and specificity of biomarkers for 
disease progression and prognosis of the patient. Chapter 5 evaluates the 
prognostic value of the plasma biomarker midregional pro-adrenomedullin 
(MR-proADM) in predicting bacteraemia, need for hospital admission and 
a complicated course of the infection. Moreover, this study compares the 
prognostic value of MR-proADM with more conventional biomarkers like C-
reactive protein (CRP), leucocyte count and procalcitonin (PCT).55
Chapter 6 focuses on the host defense of febrile UTI, especially on its rela-
tion with the occurrence of bacteraemia. The study investigates the urinary 
production of cytokines (IL-6, IL-8) and antimicrobial peptides (cathelicidin 
LL37, β-defensin 2 and uromodulin) in febrile UTI. Moreover, the influence of 
plasma vitamin D level and genetic variations in host defense on the produc-
tion of these urinary proteins and the clinical course is assessed.56
Sepsis is associated with activation of the coagulation cascade. Micropar-
ticles expressing procoagulant tissue factor (MP-TF) are released in blood 
concurrently with markers of inflammation and coagulation, and could play a 
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Imajor role in the onset of sepsis-related morbidity. In Chapter 7, we evalu-
ate whether the release of MP-TF into blood is accompanied by inflammatory 
and procoagulant changes in febrile E. coli UTI.57
Finally, in the general discussion, the major findings of all studies are sum-
marized and remaining questions and the implications for future research 
are discussed.
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To assess risk factors for fluoroquinolone resistance in community-onset 
febrile Escherichia coli urinary tract infection (UTI).
Methods
A nested case-control study within a cohort of consecutive adults with febrile 
UTI presenting at primary health care centres or emergency departments 
during January 2004 through December 2009. Resistance was defined using 
EUCAST criteria (MIC ciprofloxacin > 1.0 mg/L). Cases were subjects with 
fluoroquinolone-resistant E. coli, and controls those with fluoroquinolone-
susceptible isolates. Multivariable logistic regression analysis was used to 
identify potential risk factors for fluoroquinolone resistance.
Results
Of 787 consecutive patients, 420 had E. coli positive urine cultures. Of these, 
51 (12%) were fluoroquinolone resistant. Independent risk factors for fluo-
roquinolone resistance were urinary catheter (OR 3.1; 95% CI: 0.9-11.6), 
recent hospitalization (OR 2.0; 95% CI: 1.0-4.3) and fluoroquinolone use 
in the past six months (OR 17.5; 95% CI: 6.0-50.7). Environmental fac-
tors (e.g. contact with animals or hospitalized household members) were 
not associated with fluoroquinolone resistance. Of fluoroquinolone-resistant 
strains, 33% were resistant to amoxicillin/clavulanate and 65% to trim-
ethoprim/sulfamethoxazole; 14% were ESBL-positive compared to <1% in 
fluoroquinolone-susceptible isolates.
Conclusions
Recent hospitalization, urinary catheter and fluoroquinolone use in the past 
six months were independent risk factors for fluoroquinolone resistance in 
community-onset febrile E. coli UTI. Contact with animals or hospitalized 
household members was not associated with fluoroquinolone resistance. 
Fluoroquinolone resistance may be a marker of broader resistance, including 
ESBL-positivity.
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Introduction
Fluoroquinolones and trimethoprim/sulfamethoxazole are the preferred 
agents for oral treatment of febrile UTI. Fluoroquinolones are recommended 
to be the first choice, particularly because there is a relative low rate of anti-
microbial resistance1-4. However, the emergence of fluoroquinolone-resistant 
Escherichia coli in the community may limit oral treatment options5. Reported 
rates of E. coli resistance to ciprofloxacin in UTI vary widely over the years 
and between countries, ranging from <1% to 38%6,7. In The Netherlands, a 
country known for its restrictive usage of antimicrobials and overall low rates 
of antimicrobial resistance, E. coli resistance to ciprofloxacin increased from 
3% in 2001 to 11% in 2008 with even higher rates in patients at urology ser-
vices8,9. Moreover, fluoroquinolone resistance in E. coli isolates is frequently 
associated with resistance to other classes of antibiotics10. Therefore, there 
is a need for knowledge of risk factors for fluoroquinolone-resistant E. coli 
in patients presenting with febrile UTI in order to better select the most 
appropriate empirical antimicrobial oral treatment.
Previous studies on fluoroquinolone-resistant E. coli primarily have focused 
on host-related risk factors such as older age, prior fluoroquinolone usage, 
urinary tract disorders and hospitalization7,11-16. Others have studied the 
emergence of E. coli resistance in the environment and found household 
members, pets and livestock colonized with resistant E. coli strains to be 
possible sources of human infection17-20. To our knowledge, these potential 
environmental risk factors for fluoroquinolone resistance have not been as-
sessed in a general population presenting with community-onset febrile UTI 
or acute pyelonephritis.
We therefore conducted a multicentre nested case-control study to identify 
host-related and environmental risk factors for fluoroquinolone resistance in 
adults presenting with community-onset febrile UTI. In addition, the relation 
with extended spectrum beta-lactamase (ESBL)-positivity.
Patients and methods
We conducted a nested case-control study from a prospective multicentre 
cohort study. Participating centres were 35 primary health care centres and 
emergency departments of 7 hospitals, all clustered into one single area of 
the Netherlands. From January 2004 till December 2009, consecutive pa-
tients who presented with febrile UTI were considered for enrolment in the 
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study. The local ethics committees approved the study and all participants 
provided written informed consent.
Inclusion criteria were age of 18 years or above, fever (≥ 38.0 oC) and/or a 
history of fever and chills within 24 h before presentation, at least one symp-
tom of UTI (dysuria, frequency, urgency, perineal pain, flank pain or costo-
vertebral tenderness) and a positive nitrite dipstick test or leukocyturia as 
defined by a positive leukocyte esterase dipstick test or the presence of more 
than 5 leukocytes per high-power field (pyuria) in a centrifuged sediment. 
Exclusion criteria were current treatment for urolithiasis or hydronephrosis, 
pregnancy, hemo- or peritoneal dialysis, a history of kidney transplantation 
or known presence of polycystic kidney disease. Patients were only included 
once in the study.
Cases were eligible patients with urine culture-confirmed febrile UTI caused 
by fluoroquinolone-resistant E. coli. Patients with febrile UTI due to fluoro-
quinolone-susceptible E. coli served as controls.
Procedures
Demographic, clinical and microbiological data were collected within 24-48 h 
upon notification. This was done by qualified research nurses or the clinical 
investigators (CvN, WEvdS) by reviewing the medical record completed with 
an interview by telephone or in person using a standardized questionnaire 
including host-related variables. All patients were empirically treated with 
antibiotics according to local policy (oral ciprofloxacin 500 mg twice daily for 
outpatients and for inpatients cefuroxime ± gentamicin intravenously). Based 
on the culture results, hospitalized patients were subsequently switched to 
oral antibiotic treatment (first choice ciprofloxacin 500 mg twice daily).
As data on environmental exposures were initially not collected, we con-
tacted patients for a second time in March 2010. All cases were selected for 
additional interview and for each case, two controls were selected matched 
by centre and date of inclusion. A standardized questionnaire was used 
containing the following dichotomous items present within 3 months before 
initial inclusion: household member with UTI, recent hospitalization, working 
in health care facility, ownership and/or contact with pets or livestock and 
receipt of home health care support. The interviewer was blinded to the 
antimicrobial susceptibility outcome of the isolated E. coli strains.
Definitions
Recurrent UTI was defined as two or more episodes in the last six months 
or three or more episodes of UTI in the last year. A urinary tract disorder 
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was defined as the presence of any functional or anatomical abnormality of 
the urinary tract excluding the presence of a urinary catheter or history of 
nephrolithiasis. These two latter variables were analyzed separately. Data 
regarding recurrent UTI and antibiotic use in the past 6 months were miss-
ing in 5 and 13 patients respectively. Missing values of these categorical 
variables were considered to indicate the absence of that characteristic.
Microbiological analysis
Clean midstream-catch urine cultures were obtained before starting anti-
microbial therapy and were analyzed using local standard microbiological 
methods. In case of a urinary catheter the urine sample was collected from 
the port of the catheter. A positive urine culture was defined as bacterial 
growth over 103 cfu/mL urine or a bacterial monoculture over 102 cfu/mL 
urine in the presence of pyuria21. Urine cultures revealing growth of 2 or more 
different bacterial species reflecting mixed skin or gut flora, were considered 
to indicate contamination21. Susceptibility tests were done from the selective 
media using the Vitek2 system (bioMerieux). MIC breakpoints for resistance 
were based on EUCAST criteria (www.eucast.org). E. coli isolates with 
ciprofloxacin MIC values > 1 mg/L were considered to be fluoroquinolone-
resistant. In 16 E. coli isolates ciprofloxacin susceptibility was not specifically 
tested. Fifteen of these were norfloxacin susceptible and thus considered 
fluoroquinolone susceptible; one was resistant to norfloxacin and considered 
fluoroquinolone resistant.
ESBL production was phenotypically detected by double-disk diffusion test 
using ceftazidime/ceftazidime clavulanate and cefotaxime/cefotaxime clavu-
lanate or by E-test.
Statistical analysis
Descriptive analysis included means or percentages with 95% confidence 
intervals (CIs) or medians and ranges, as appropriate. Univariate analysis 
was performed using the Mann-Whitney U-test for continuous variables 
and Chi-square tests for categorical variables. All variables associated with 
ciprofloxacin resistance in univariate analysis with p < 0.2 were included in 
a multiple logistic regression model using backward selection method with 
conditional tests. Interactions between paired variables were tested. A two-
tailed P-value <0.05 was considered to indicate statistical significance. All 
analysis were performed using SPSS 17.0 (SPSS Inc, Chicago, IL, USA).




During the study period, 787 patients with febrile UTI were enrolled. E. coli 
was the most frequent causal uropathogen, present in 420 (53%) of the 
patients. Additional causative organisms were Klebsiella spp (4.1%) and 
Enterococcus faecalis (1.6%) and others (Figure 1). In 199 (25%) patients, 
the urine culture showed either no significant bacteriuria or mixed flora; 52% 




787 consecutive adults with 
febrile UTI 
January 2004 – December 2009 
420 patients with febrile 
 E. coli UTI   
 
 367 urine culture result other than E. coli 
   n (%) 
Enterococcus faecalis 13 (2) 
Klebsiella spp. 32 (4) 
Proteus spp. 18 (2) 
Pseudomonas aeruginosa 18 (2) 
Staphylococcus aureus   6 (1) 
Staphylococcus saprophyticus 9 (1) 
Enterobacter spp.   4 (1) 
other 23 (3) 
none or contaminated 199 (25) 











51 fluoroquinolone-resistant  






17 lost to follow-up 
 
9 died 
3 lost to follow-up 
1 refused participation 
102 controls selected for 
questionnaire on patient’s 
environment 
March 2010 
51 cases selected for 
questionnaire on patient’s 
environment 
March 2010 
38 cases with completed 
questionnaire 




Figure 1. Flowchart of participants in the study
A: analysis of host-related risk factors for fluoroquinolone resistance, 
B: analysis of environmental risk factors for fluoroquinolone resistance.
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Of 420 patients with E. coli positive urine cultures, 51 (12%) had a culture 
with a fluoroquinolone-resistant isolate (designated as cases) and 369 with a 
fluoroquinolone-susceptible isolate (designated as controls). The median age 
was 66 years [IQR: 45-78], 137 (33%) were men and 224 (53%) had co-
morbidity. Baseline characteristics of the study population are summarized 
in Table 1.
Out of the 369 controls, 102 were matched by centre and date of inclusion to 
the 51 cases for additional interview on environmental issues, but otherwise 
selected randomly. These 102 selected controls were comparable to the 
remaining 267 controls with respect to gender, age and comorbidity, except 
for diabetes mellitus that was more frequent in the selected controls (19% 
versus 11%, p = 0.047). During follow-up till March 2010, 9 cases and 11 
controls died. Of the remaining 42 cases and 93 controls, 38 cases (response 
rate 90%) and 74 controls (response rate 80%) participated (Figure 1).
Risk factors for fluoroquinolone-resistant E. coli
Univariate and multivariate potential risk factors for fluoroquinolone-resis-
tant E. coli are listed in Table 1. Significant univariable host-related risk 
factors were the presence of a urinary catheter (OR 6.0; 95% CI: 2.0-18.1), 
underlying urinary tract disorder (OR 2.3; 95% CI: 1.2-4.4), recurrent UTI 
(OR 2.2; 95% CI: 1.2-4.1), hospitalization past six months (OR 2.3; 95% 
CI 1.2-4.4) and fluoroquinolone usage past six months (OR 18.6; 95% CI: 
6.6-52.4). None of the environmental characteristics were significantly as-
sociated with fluoroquinolone resistance, with ORs all around 1.
Independent risk factors for fluoroquinolone-resistant E. coli in the multivari-
ate analysis were the presence of an urinary catheter (OR 3.1; 95% CI: 0.9-
11.6), recent hospitalization (OR 2.0; 95% CI: 1.0-4.3) and fluoroquinolone 
use in the past six months (OR 17.5; 95% CI: 6.0-50.7). Potential interac-
tions between variables (e.g. urinary tract disorder and presence of a urinary 
catheter), were additionally tested, but they did not significantly change the 
model. In total, 90 (21%) of the patients had at least one of those three risk 
factors accompanied with a 26.7% risk to have fluoroquinolone-resistant E. 
coli compared to 330 patients with no risk factor who had a 8.2% risk to 
have fluoroquinolone-resistant E. coli.
Microbiological outcome
Among 420 E. coli isolates tested, 12% were resistant to ciprofloxacin; 51% 
to amoxicillin; 11% to amoxicillin/clavulanate; 30% to trimethoprim/sulfa-
methoxazole; 5% to cefuroxime and 6% to gentamicin. Fluoroquinolone-
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resistant E. coli strains were frequently resistant to other antibiotic classes 
used for treatment of febrile UTI: 33% to amoxicillin/clavulanate and 65% to 
trimethoprim/sulfamethoxazole. The distribution of cross-resistance of the 
oral antibiotics used for febrile UTI is illustrated in Figure 2. The prevalence 
of ESBL-producing E. coli was low (2%) but differed significantly between 
cases and controls: 7 (14%) versus 1 (<1%) respectively ( p < 0.001). Of 
the 8 patients with ESBL-positive E. coli, 6 fulfilled the questionnaire; none 
of them had contact with animals. There were no statistically significant dif-
ferences in the frequency of fluoroquinolone-resistant E. coli in between the 
years 2004 through 2009 and there was no trend towards a gradual increase 
(data not shown).
Clinical outcome
Among the 51 patients with fluoroquinolone-resistant E. coli febrile UTI, 16 
(31%) were empirically treated with an inappropriate antibiotic, including 10 
patients who were treated with ciprofloxacin (Table 2). Median fever dura-
tion in patients receiving ciprofloxacin was 2 days [IQR 1-4]; 70% of those 
switched to another antibiotic after a median of 6 days [IQR 2-7]. Patients 
treated with cefuroxime plus gentamicin had slightly longer fever duration 
(median 3 days [IQR 2-4]) and switched in 71% to another antibiotic after a 



















FQs (n = 51, 12%) 
SXT (n = 126, 30%)  
AMC (n = 49, 12%) 





n = 81 
n = 22 
n =12 
n = 11 
n = 6 
n = 12 
n = 20 
n = 256 
Figure 2. Distribution of resistance to oral antibiotics in 420 patients with febrile E. coli UTI. SXT: trime-
thoprim/sulfamethoxazole, FQs: fluoroquinolones, AMC: amoxicillin/clavulanate.




In this study, we evaluated host-related and environmental risk factors for 
fluoroquinolone resistance in adults with community-onset febrile E. coli UTI. 
We identified recent hospitalization, the presence of a urinary catheter and 
fluoroquinolone usage in the past six months as independent host-related 
risk factors for resistance. Environmental dynamics, like contact with pets, 
livestock or hospitalized household members, were not identified as risk 
factors. To our knowledge, this is the first prospective study evaluating a 
combination of those risk factors for fluoroquinolone-resistant E. coli among 
adults with community-onset febrile UTI or acute pyelonephritis. These data 
suggest that development of fluoroquinolone resistance in a general popula-
tion at risk for febrile UTI is driven by individual fluoroquinolone usage rather 
than by within-household or animal-human transmission of resistant E. coli. 
However, this study does not exclude the suggested possibility of an animal 
origin of fluoroquinolone resistance via foodborne transmission22,23.
The strengths of this study are its prospective design and the broad popula-
tion of interest, reflecting daily practice of patients presenting with febrile UTI 
or acute pyelonephritis, as both primary health care centres and emergency 
departments participated.
There are however also some limitations. Our study had a relative small sam-
ple size of cases with fluoroquinolone resistance. However, to our knowledge 
this study is the largest prospective study on patients with fluoroquinolone-
resistant E. coli febrile UTI so far, as most previous studies were retrospec-
tive chart reviews of microbiological laboratory databases7,11-16. Such studies 








No. of patients 




Ciprofloxacin 10 10 (100) 2.0 [1.0-4.0] 7 (70) 6.0 [2.0-7.0]
Cefuroxime 19 3 (16) 2.0 [1.0-4.0] 17 (90) 5.0 [4.0-6.0]
Cefuroxime + gentamicin 14 1 (7) 3.0 [2.0-4.0] 10 (71) 6.5 [5.3-8.0]
Amoxicillin/clavulanate 5 2 (40) 2.5 [1.3-3.8] 3 (60) 3.0 [3.0-3.5]
Otherb 3 NA NA NA NA
NA: not applicable
Data are presented as median [IQR] unless otherwise stated
a Inappropriate empirical antibiotic treatment defined as E. coli resistant to the antibiotic given.
b Trimethoprim/sulfamethoxazole (n=1), ceftazidime (n=1), meropenem (n=1)
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may overestimate the prevalence of resistance among uropathogens from 
patients with community-onset UTIs. One study at US emergency depart-
ments had a similar prospective design including 1271 patients with acute 
pyelonephritis of which 689 were caused by E. coli 4. Yet, the prevalence of 
fluroquinolone-resistant E. coli in this study was 3-5% and too low to evalu-
ate risk factors for fluoroquinolone resistance. In our study the prevalence 
of fluoroquinolone resistance in E. coli was remarkably higher (12%) but 
consistent with a recent survey in The Netherlands 8.
We used a MIC breakpoint for ciprofloxacin resistance of > 1 mg/L according 
to EUCAST criteria. As to date different laboratories over the world use differ-
ent clinical MIC breakpoints for resistance, it is of interest that we found no 
differences in outcome of the patients with fluoroquinolone-resistant E. coli 
who were empirically treated with ciprofloxacin compared to those treated 
with appropriate antibiotics (Table 2). Moreover, the majority of patients 
recovered on ciprofloxacin as their fever resolved before the outcome of the 
urine culture became available and antibiotic treatment was subsequently 
switched. This may indicate that febrile UTI is to some extent a self-limiting 
disease or possibly ciprofloxacin treatment may be still effective in ranges of 
MICs > 1 mg/L. We could not explore this hypothesis further as we do not 
have results of the actual MICs of the fluoroquinolone-resistant isolates.
Several studies also found recent hospitalization14,15, urinary catheter11,13 and 
fluoroquinolone usage7,11-16 to be related with fluoroquinolone resistance. In 
addition, other risk factors were discovered like previous invasive procedures14, 
recurrent UTI12,14,15, older age7,11, presence of complicated UTI7, underlying 
chronic disease15,16 and urinary tract abnormalities11,15. All these risk factors 
for fluoroquinolone resistance seem biologically plausible and the differences 
in outcome of these studies likely reflect differences in study population. 
However, it should be noted that like our study, a recent meta-analysis dem-
onstrated that in a general population individual antibiotic usage is the driv-
ing force for resistance of urinary bacteria24. Though some studies identified 
foreign travel to be a risk factor for infections with an antimicrobial-resistant 
uropathogen, in particular a trimethoprim-sulfamethoxazole-resistant strain, 
this was not found for infections with fluoroquinolone-resistant E. coli.25-28 
We did not systematically collect data on foreign travel to explore this issue 
in our study.
Compared to previous studies we used an additional questionnaire to evaluate 
potential environmental risk factors for fluoroquinolone resistance. This was 
done retrospectively holding a risk for observer, recall and selection bias. Yet, 
Willize van der Starre - Binnenwerk - Completeproefv7.indd   33 28-10-15   13:14
Chapter 1
34
several measures were taken to minimize this. First of all, the interviewer was 
blinded to the data with respect to fluoroquinolone susceptibility making ob-
server bias unlikely. Secondly, when obtaining the questionnaire the patients 
were not specifically informed whether they had fluoroquinolone-resistant E. 
coli. Furthermore, cases and controls had comparable response rates. Thus 
recall bias is unlikely. Finally, the selected controls were comparable with the 
non-selected as they were randomly selected and matched only by centre 
and date of presentation with febrile UTI.
We did not find environmental risk factors for fluoroquinolone resistance. Thus 
our findings do not support the concern for an animal or human reservoir of 
fluoroquinolone resistance. This may contrast previous findings but it should 
be emphasized that the evidence for animal-human and human-human 
transmission of fluoroquinolone-resistant E. coli in UTI is limited to specific 
strains17,18,20,29. As each strain could have its specific mode and likelihood of 
transmission, our data do not contradict these studies. At least it suggests 
that to date such clones have not played a major role in a general Dutch com-
munity setting of patients at risk for febrile UTI. Further surveillance studies 
should include the genetic characterization of E. coli strains to confirm or 
refute the hypothesis that fluoroquinolone resistance in the community is 
driven by the introduction of clonal E. coli groups30. Furthermore, it must be 
emphasized that our study does not exclude a possible 2-hit mechanism for 
fluoroquinolone resistance, with an initial input of fluoroquinolone-resistant 
strains from food supply of colonized animals into the population followed 
by selection at the individual level by personal fluoroquinolone use. Further 
studies are urgently warranted to explore this hypothesis, particularly as the 
relation between animal food supply and fluoroquinolone-resistant E. coli in 
humans revealed conflicting results but at least indicate this is might be a 
major concern for the community.23,28,31,32
In case of the isolation of fluoroquinolone-resistant E. coli, we found ac-
companying high rates of resistance to other antibiotics: 33% to amoxicillin/
clavulanate and 65% to trimethoprim/sulfamethoxazole. Similar multidrug 
resistance rates were found in a large study in North America10. Moreover, 
14% of fluoroquinolone-resistant E. coli isolates in our study were ESBL-
positive compared to less than 1% in fluoroquinolone-susceptible isolates. 
This supports a previous finding that fluoroquinolone susceptibility in E. coli 
makes the presence of ESBL-positivity unlikely33. In this respect, this high-
lights the importance of risk factors for fluoroquinolone resistance as these 
may also be risk factors for ESBL production.
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The extent to which antibiotic resistance risk stratification could guide em-
pirical therapy for febrile UTI is unknown. This study demonstrates that the 
absolute risk of fluoroquinolone resistance increases by about 20% in pa-
tients with at least one of the three risk factors we identified, but even with 
no risk factor there was a 8% risk for fluoroquinolone resistance. Further 
studies are therefore be required in order to better stratify fluoroquinolone 
resistance risk in patients with febrile UTI.
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Although febrile urinary tract infections (UTIs) are relatively common in 
adults, data on optimal treatment duration are limited. Randomized con-
trolled trials specifically addressing the elderly and patients with comor-
bidities have not been performed. This review highlights current available 
evidence. Premenopausal, non-pregnant women without comorbidities can 
be treated with a 5-7 days regimen of fluoroquinolones in countries with low-
level of fluoroquinolone resistance, or, if proven susceptible, with 14 days of 
trimethoprim-sulfamethoxazole. Oral β-lactams are less effective compared 
with fluoroquinolones and trimethoprim-sulfamethoxazole. In men with mild 
to moderate febrile UTI, a 2-week regimen of an oral fluoroquinolone is likely 
sufficient. Although data are limited, this possibly holds even in the elderly, 
patients with comorbidities or bacteremia.
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Introduction
Urinary tract infections (UTIs) are among the most commonly encountered 
bacterial infections. In adults, UTIs can be classified into acute uncompli-
cated cystitis, acute uncomplicated pyelonephritis, complicated UTI, acute 
complicated pyelonephritis and for men several categories of prostatitis 
are distinguished.[1-3] The term ‘uncomplicated’ usually reflects UTIs in pre-
menopausal, non-pregnant women with no known anatomical or functional 
urological abnormalities or other comorbidities.[4] Some authors advocate 
to consider UTIs in postmenopausal women or women with well-controlled 
diabetes mellitus without urological sequelae also to be ‘uncomplicated’.[2] 
Given this various classifications of UTIs in the literature, it likely makes 
more sense to classify these patients uniformly according to their presenta-
tion in which fever reflects whether there is a parenchymal inflammation or 
not. From a scientific point of view, it is interesting to know whether the UTI 
involves the kidney, prostate, bladder, blood circulation, lymph nodes of the 
pelvis or a combination of those, but from a clinical point of view febrile UTI 
should be considered as tissue inflammation of the urinary tract whereas an 
exact anatomical distinction on clinical grounds can often not be made. In 
this article we will use febrile UTI as the clinical syndrome of interest because 
this is how patients present and fever mainly determines the appropriate 
treatment. According to the above mentioned classifications, febrile UTI in-
cludes complicated UTI with fever, acute prostatitis, acute (un-)complicated 
pyelonephritis and, as has been suggested, the urosepsis syndrome.[5]
The optimal treatment duration of febrile UTI has not been established yet, 
but current strategies recommend antimicrobial treatment for about 14 days 
in most patients.[4, 6-10] With the paucity of new antimicrobial classes in de-
velopment, it is increasingly important to develop strategies to maintain or 
even increase the effectiveness of the available agents. Dose and regimen 
optimization represents one such strategy. Antimicrobials are associated 
with considerable side effects (e.g. Clostridium difficile infection with the use 
of fluoroquinolones).[11-13] Moreover, longer duration of antimicrobial therapy 
with consequently selecting pressure on gut flora might lead to an enhanced 
risk of the selection of resistant strains.[14] In this respect, it is questionable 
whether the benefit of antimicrobial therapy for at least 14 days at the end 
of treatment still outweighs its potential side effects.
This review highlights the main research findings on treatment duration of 
community-acquired febrile UTI in non-pregnant adults. A summary of the 
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pivotal studies among antimicrobial treatment duration of adults with febrile 
UTI is given in Table 1.
Febrile UTI in women
The majority of UTIs in women are community-acquired uncomplicated 
cystitis that usually responds to a 3-day course of empiric antimicrobials. 
However, if UTIs are accompanied by fever, another treatment regimen will 
be required. Treatment guidelines for febrile UTI often only discuss acute 
uncomplicated pyelonephritis, defined as acute pyelonephritis in premeno-
pausal, non-pregnant and otherwise healthy women without any comorbid-
ity.[4] Although febrile UTI is a relatively common and potentially serious 
infection even in young women, few controlled trials have been conducted to 
define optimal therapy directly comparing the same drug given for different 
durations of therapy, though a number of publications compared various 
treatment durations between different antimicrobial agents. In one open 
label, single center randomized trial comparing two versus six weeks of oral 
therapy with trimethoprim-sulfamethoxazole or ampicillin in 60 women with 
acute uncomplicated pyelonephritis, 2-week therapy was as effective as 
6-week therapy with either drug. However, shorter duration of treatment 
resulted in fewer adverse effects, less frequent selection of resistant strains, 
and lower costs.[15] Trimethoprim-sulfamethoxazole was more effective than 
ampicillin due to more ampicillin-resistant strains and increased recurrence 
rate in ampicillin treated patients even with susceptible strains. With am-
picillin resistance in E. coli exceeding 50% in many countries worldwide, 
ampicillin should not be used as empirical treatment of febrile UTI.
Nitrofurantoin should not be used for the treatment of febrile UTI because it 
does not achieve reliable tissue or serum levels.[16]
Trimethoprim-sulfamethoxazole and fluoroquinolones
Talan and colleagues showed that even therapy duration less than 14 days 
is effective in young, healthy women.[17] This double-blind, multicenter 
randomized controlled trial compared a 7-day regimen of oral ciprofloxacin 
500 mg twice daily with a 14-day regimen of trimethoprim-sulfamethoxazole 
160/800mg twice daily for treatment of otherwise healthy women with mild 
to moderate pyelonephritis. An initial intravenous 1-g dose of ceftriaxone in 
the trimethoprim-sulfamethoxazole group or a 400-mg intravenous dose of 
ciprofloxacin in the ciprofloxacin group was allowed at the discretion of the 
doctor. At the 4-11 days post-therapy visit, ciprofloxacin had significantly 
higher microbiological (99% vs 89%, respectively) and clinical (96% vs 
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83%, respectively) cure rates, regardless of whether an initial intravenous 
dose of ciprofloxacin was given. Among trimethoprim-sulfamethoxazole-
treated women, microbiological eradication and clinical cure rates were 
significantly lower in women with a trimethoprim-sulfamethoxazole-resistant 
strain compared with those with a susceptible one. However, an initial intra-
venous dose of ceftriaxone significantly improved microbiological cure rate 
and moderately improved clinical cure rate in women with a trimethoprim-
sulfamethoxazole-resistant uropathogen. Bacteremia (all E. coli) was pres-
ent in 5.5% of the patients; 2/10 trimethoprim-sulfamethoxazole-treated 
subjects had bacteriologic persistence, all four ciprofloxacin-treated subjects 
achieved bacteriologic cure.
Additional evidence for a one week regimen of fluoroquinolones as effective 
and safe treatment for healthy young women was provided by two other 
articles, describing the same study.[18, 19] This double blind, randomized mul-
ticenter trial included both men and women with complicated UTI (without 
fever) and acute pyelonephritis (20-30%). Subgroup analysis of data about 
acute pyelonephritis[18] lend additional support that an oral 5-day regimen 
of a once-daily fluoroquinolone (levofloxacin 750 mg) or a 10-day regimen 
of ciprofloxacin 500mg twice daily (in 6.1% after initial intravenous cipro-
floxacin 400 mg twice daily) might be effective for mild to moderate febrile 
UTI, even in those with bacteremia or complicating factors like obstruction or 
presence of an urinary catheter. Another pyelonephritis study in hospitalized 
men and women,[20] prospectively comparing 10 days of norfloxacin 400 mg 
twice daily with 10 days of ceftibuten 200 mg twice daily, after receiving 
intravenous cefuroxime for 2-4 days in each group prior to randomization 
to the study drug, showed excellent clinical and bacteriological cure rates 
in both groups and lower bacterial relapse rates in patients treated with 
norfloxacin. The finding that a one week regimen of fluoroquinolones is 
both efficacious and safe for treatment of mild to moderate febrile UTI was 
further supported by a randomized comparative study demonstrating similar 
outcomes in comparing levofloxacin 250 mg once daily, ciprofloxacin 500 
mg twice daily and lomefloxacin 400 mg once daily, although in severe, 
invasive infections such a low dose of levofloxacin may result in marginal tis-
sue and blood concentrations.[21] So, in regions with an acceptable low level 
of resistance to fluoroquinolones, this class of antimicrobials represents the 
preferred agents for empirical oral treatment of febrile UTI. With increasing 
rate of fluoroquinolone resistance in the last decade, the question raises at 
which threshold of resistance prevalence we should switch to an alternative 
agent for empirical treatment. Since clinical and bacterial outcomes with 
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different levels of resistance are not well studied, the recommended thresh-
old of 10% fluoroquinolone resistance prevalence is mainly based on expert 
opinion.[4] For some areas in the world, the prevalence of fluoroquinolone 
resistance is >10%.[22, 23] Some experts advocate giving an initial dose of a 
long-acting parenteral antimicrobial, such as a 1-g dose of ceftriaxone or a 
consolidated 24-h dose of an aminoglycoside (e.g. one 5-7 mg/kg dose of 
gentamicin) in such situation.[4]
Oral β-lactams in women with febrile UTI
The data from Cronberg et al.[20] suggest inferior microbiological efficacy 
of oral cephalosporins compared with the fluoroquinolones, consistent with 
another Swedish study.[24] To our knowledge, there are no published stud-
ies on the efficacy of amoxicillin-clavulanate in the treatment of febrile UTI 
compared to trimethoprim-sulfamethoxazole or a fluoroquinolone. However, 
a single-blind randomized trial in women with acute uncomplicated cystitis 
comparing a 3-day oral regimen of amoxicillin-clavulanate 500/125 mg 
twice daily with ciprofloxacin 250 mg twice daily showed remarkable inferior 
clinical (60% and 77%, respectively) and microbiological (76% and 95%, 
respectively) cure rates in the amoxicillin-clavulanate-treated group, even 
in women infected with susceptible strains (60% in resistant versus 77% in 
susceptible strains). Most likely, the inferiority of β-lactams in the treatment 
of UTI is related to the lower rate of eradication of E. coli from the vagina in 
the amoxicillin-clavulanate group, maintaining a vaginal reservoir for infec-
tion.[25] Although not proven, these data are suggestive of an inferior efficacy 
of amoxicillin-clavulanate in febrile UTI.
Optimal treatment duration in young, otherwise healthy women
To summarize the above data regarding treatment duration of febrile UTI 
in young, non-pregnant women without comorbidities, a 5-7 day oral regi-
men of a fluoroquinolone is both efficacious and safe in mild to moderate 
febrile UTI given their superior clinical and bacteriological cure rates.[17-19] 
However, emerging fluoroquinolone resistance will possibly necessitate an 
initial dose of long-acting parenteral antimicrobial, such as a 1-g dose of cef-
triaxone or a consolidated 24-h dose of an aminoglycoside.[4] Trimethoprim-
sulfamethoxazole is also highly efficacious in febrile UTI if caused by a 
trimethoprim-sulfamethoxaxole-susceptible uropathogen[15] but current high 
rates of resistance to trimethoprim-sulfamethoxazole in many countries with 
corresponding failure rates for resistant strains make this agent an inferior 
choice for empirical therapy. When used empirically, combination with an 
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initial intravenous dose of ceftriaxone resulted in improved bacteriological 
and clinical cure rates.[17] When the uropathogen is susceptible, current 
evidence support a 14-day regimen;[17] shorter treatment duration has never 
been well investigated. Oral β-lactams are likely less effective compared 
with fluoroquinolones and trimethoprim-sulfamethoxazole.[15, 20, 24, 25] When 
used, a total course of 10-14 days of therapy is recommended.[4, 9, 10, 26] 
Probably, the same recommendations for treatment duration apply when 
the antimicrobial therapy was initially started intravenously (e.g. in case of 
severe sepsis or inability to take oral medication).
What do the guidelines say?
The above findings and treatment recommendations are in line with the 
recently updated IDSA-guideline.[4] The European Association of Urology 
(EAU) guideline recommends treating febrile UTI in premenopausal, oth-
erwise healthy women with levofloxacin 750 mg once daily for 5 days or 
ciprofloxacin 500 mg twice daily for 7-10 days; a 14-day regimen is advised 
for all other oral antimicrobials and in all other febrile UTI patients.[10] How-
ever, the guideline of the American College of Obstetricians and Gynaecolo-
gists (ACOG) recommends treating febrile UTI in all women (both pre- and 
postmenopausal) for 14 days; fluoroquinolones are considered first line 
oral therapy and, in areas where resistance rates are ‘low’, trimethoprim-
sulfamethoxazole is an acceptable alternative.[9] The guideline of the Dutch 
College of General Practitioners on the management of UTI recommends for 
outpatient treatment of adult patients with signs of tissue invasion including 
fever an oral regimen of either amoxicillin-clavulanate 500/125 mg three 
times a day, trimethoprim-sulfamethoxazole 160/800mg twice daily, or a 
fluoroquinolone (e.g. norfloxacin 400 mg twice daily or ciprofloxacin 500 mg 
twice daily) for 10 days.[26]
Febrile UTI in ‘complicated’ patients
While treatment recommendations of febrile UTI are quite straightforward in 
young, healthy, non-pregnant women with short oral antimicrobial courses 
on an outpatient basis (provided they are able to take oral medication 
and have no severe sepsis), there is a lack of conformity on therapeutic 
approaches for other (sometimes referred as ‘complicated’) categories 
of febrile UTI patients, like men, postmenopausal women, the elderly or 
patients with urological abnormalities or indwelling urinary catheter. Oral 
antimicrobial treatment regimens and optimal treatment duration have 
hardly been studied in the latter categories. Most studies focus exclusively 
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on febrile UTI in young, healthy women, or consist of a very heterogeneous 
study population with both women and men of all ages and a broad range of 
comorbidities, reducing the power and making subgroup analysis sometimes 
hardly to perform. There are no published trials specifically conceived to 
delineate optimal treatment duration in those categories, except for men. 
Currently, a randomized placebo-controlled study comparing a 7 to 14 day 
of antimicrobial therapy in consecutive patients with febrile UTI is ongoing to 
provide evidence within this category of ‘complicated’.[27] The results of this 
study are expected to become available in 2012.
Febrile UTI in men
UTI is very uncommon in otherwise healthy, young and middle-aged men. 
A Norwegian study reported an estimated annual incidence of 6-8 UTIs per 
10,000 men aged 21-50 years. Incidence increases with age because of uro-
logical abnormalities and instrumentation.[28] Since more than 90% of men 
with febrile UTI have a concomitant infection of the prostate, as measured 
by transient increases in serum PSA and prostate volume,[29] the goal of 
treatment is not only to sterilize the urine but also to reach sufficient antimi-
crobial concentration in the prostate. Therefore, antimicrobials reaching free 
concentrations in prostatic fluid and prostatic tissue that exceed the mini-
mum inhibitory concentrations of most common causative bacteria should be 
chosen for therapy. Fluoroquinolones have such favourable pharmacokinetic 
properties and antibacterial spectra.[30] Trimethoprim also achieves adequate 
concentrations in the prostate and is an alternative to fluoroquinolones 
provided the bacteria are susceptible to this antimicrobial.[31] As described 
earlier in this article and demonstrated in some mixed trials with a minority 
of men, therapy with β-lactams may result in lower cure rates in men with 
febrile UTI.[20, 24]
There is an apparent lack of studies on optimal treatment duration of febrile 
UTI in men. We only found one study directly comparing different treatment 
durations in men.[32] In this open, prospective and randomized trial, 72 men 
with community-acquired febrile UTI (without a chronic indwelling catheter) 
were treated with ciprofloxacin 500 mg twice daily for two or four weeks. All 
responded successfully with resolution of fever and symptoms. There was 
no significant difference in bacteriological cure rate 2 weeks post-treatment 
between patients treated for 2 or 4 weeks (89% versus 97%, 95% CI for 
difference in proportions –3% to 19%), nor after 1 year (59% versus 76%, 
95% CI –5% to 39%). The cumulative clinical cure rate after 1 year was 
72% and 82%, respectively (95% CI –10% to 30%). Recurrences after 1 
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year comprised asymptomatic bacteriuria (48%), symptomatic lower UTI 
(23%) and another episode of febrile UTI (29%). A tendency towards more 
recurrences in the 2-week group could be attributed to a larger proportion 
of men with urological lesions requiring surgical interventions (26% versus 
12%) in that group. The results should be interpreted with some caution 
given the wide confidence interval for the differences in cure rate, but this 
study suggests a 2-week course of ciprofloxacin 500 mg twice daily may be 
an adequate treatment for febrile UTI in men.
Another Swedish study lent additional support for a 2-week regimen of oral 
fluoroquinolones in men.[24] In this randomized, double-blind trial, adult men 
and women with a presumptive diagnosis of acute pyelonephritis (defined 
as febrile UTI) were randomly assigned to receive a 14-day course of oral 
treatment with either norfloxacin 400 mg twice daily or cefadroxil 1g twice 
daily. Of 197 patients enrolled, 16 (29.5%) men were treated with norfloxa-
cin and 12 (21.1%) with cefadroxil. In this subgroup, a 14-day regimen of 
norfloxacin was highly effective, regardless of the presence of bacteremia or 
complicating factors such as diabetes mellitus or urinary tract abnormalities, 
with significantly higher bacteriological cure rate than with cefadroxil, both 
at 3-10 days (100% versus 73%, respectively) and up to 2 months after 
cessation of treatment (88% versus 75%, respectively).
The same results in men were obtained from a third Swedish trial which 
used step-down treatment; initial intravenous treatment with cefuroxime 
was followed by either norfloxacin 400 mg twice daily or ceftibuten 200 mg 
twice daily for 10 days.[20] Thus, these studies provided evidence that men 
with mild to moderate febrile UTI may be safely treated at home with a 14 
days regimen of an oral fluoroquinolone.
Febrile UTI in the elderly and patients with comorbidities
Oral ciprofloxacin has a high bioavailability and a broad spectrum of activity 
against uropathogens. Therefore, Mombelli and colleagues analyzed the ef-
ficacy of ciprofloxacin in the empirical management of severe febrile UTIs.[33] 
In a multicenter prospective randomized study patients with serious (includ-
ing febrile) UTI were randomized in the hospital setting to empirical antibiotic 
treatment with ciprofloxacin received either orally or intravenously. Excluded 
were patients with severe sepsis, inability to take oral medication or renal 
obstructive disease. In this study, 141 patients participated; 39% were men, 
42 had co-morbidity (e.g. diabetes mellitus) and 35% had bacteremia. There 
were no infection-related deaths and no patients required an early change 
of antibiotics because of worsening clinical status during the initial empiri-
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cal phase of treatment. The rates of microbiological failure (3% in the oral 
versus 2% in the intravenous treatment group) and of unsatisfactory clinical 
response (4% oral versus 3% intravenous) were low. A treatment change 
was eventually required in 14% of the patients assigned to the oral and 7% 
of the patients assigned to the intravenous regimen, mainly because of the 
isolation of enterococci or ciprofloxacin-resistant organisms in pretherapy 
urine specimens. There were no differences in outcome between the two 
regimens in premenopausal versus postmenopausal women. Unfortunately, 
treatment duration in both groups was not stated. The authors concluded 
that in the hospital setting oral ciprofloxacin is as effective as the intra-
venous regimen in the initial empirical treatment of serious UTI, including 
the bacteremic form. They hypothesize the oral regimen can be used for 
outpatient treatment even in serious UTI. Our own study among primary 
health care centers (PHCs) and emergency departments (EDs) supported 
this hypothesis.[34] We performed a prospective observational cohort study 
including consecutive non-pregnant adults with febrile UTI. Of 395 evalu-
able patients, 153 were recruited by their GP and treated as outpatients; 
146 (95%) patients received oral ciprofloxacin 500 mg twice daily for 10-14 
days. The remaining 242 patients were recruited at EDs of which 35 (14%) 
were treated as outpatients with oral ciprofloxacin and 207 (86%) were 
admitted and empirically treated with cefuroxime ± gentamicin. Median age 
was 63 years [IQR 42-77], 34% were male and 58% had comorbidity, all 
characteristics comparable between both groups. Bacteremia was present 
in 10% of the outpatients and 27% of the inpatients. During follow-up, 8 
(5%) of PHC-group were hospitalized because of suspected deteriorating 
sepsis, progressive illness or persistent symptoms; none of them required 
ICU-admission nor were there any attributable deaths. Clinical cure rates 
at 30 days were high in both groups (90% in PHC and 89% in ED-group, 
respectively) and persistent at least until 3 months follow-up. Bacteriological 
outcomes were not reported. Thus, the outcome of patients treated with oral 
ciprofloxacin on an outpatient basis suggests that among selected adults 
with febrile UTI many can be safely treated at home using a 10-14 day regi-
men of oral fluoroquinolones, including men, the elderly and patients with 
comorbidity or bacteremia.
Besides this observational study, there is remarkably little evidence in the 
literature regarding the optimal treatment duration of febrile UTI in the 
elderly or patients with comorbidity like diabetes mellitus or urological 
abnormalities, despite high prevalence, since most randomized trials have 
excluded patients with underlying systemic illnesses or urinary tract abnor-
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malities. Current treatment durations are mainly based on expert opinion; 
recommendations often do not differ from that in non-diabetic, young and 
otherwise healthy patients.[4, 9, 10, 35] Therefore, randomized therapeutic tri-
als to define the optimal treatment duration in these patient categories are 
urgently needed.
Cather-related febrile UTI
A substantial part of the UTIs in elderly is catheter-related, but also in patient 
of any age with catheter-related febrile UTI it is not well known what the 
optimal duration of treatment is. We found one trial prospectively comparing 
treatment with either a parenteral aminoglycoside or oral ciprofloxacin 500 
mg twice daily for 7-10 days in catheterized patients in a chronic care facility 
with complicated UTI (58.5% febrile UTI) and urinary tract abnormalities 
(e.g. neurogenic bladder, obstruction), the majority being men.[36] Whether 
the urinary catheter has been replaced before start of treatment was not de-
scribed. Clinical cure 5-9 days post-therapy was about 80% in both groups, 
and 69% versus 58% 28-30 days post-therapy in the ciprofloxacin and 
aminoglycoside group, respectively. Bacteriological cure, defined as sterile 
urine culture, was achieved in the ciprofloxacin and aminoglycoside group in 
63% and 15% 2-5 days after first dose and in 21% and 23% 5-9 days post-
therapy, respectively. This trial, which is quite difficult to interpret because 
of uncertainty about catheter replacement before start treatment, suggests 
that ciprofloxacin 7-10 days at least clinically might be sufficient for treating 
catheter-related febrile UTI in men but more studies are needed to further 
explore this observation.
Conclusion
Based on the current evidence in the literature (Table 1) we conclude 
that premenopausal, non-pregnant and otherwise healthy women can 
be treated orally with 5-7 days of adequately dosed fluoroquinolones or, 
if proven susceptible to the urinary isolate, with 14 days of trimethoprim-
sulfamethoxazole. Oral β-lactams are probably less effective in comparison 
with fluoroquinolones and trimethoprim-sulfamethoxazole. In all other 
patients with febrile UTI, optimal treatment duration is still unknown and 
should, awaiting randomized controlled trials, probably be at least 14 days. 
Although approximately 10% of patients with uncomplicated febrile UTI have 
bacteremia, there is no evidence that bacteremia has prognostic significance 
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or warrants longer therapy in an otherwise healthy individual when using an 
antibiotic regimen ensuring adequate tissue and blood concentrations.
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In adults with febrile urinary tract infections (fUTIs), data on optimal treat-
ment duration are limited, especially in men, the elderly and patients with 
comorbidities.
Methods
A randomized placebo-controlled double-blind multicenter non-inferiority trial 
among 35 primary care centers and 7 emergency departments of regional 
hospitals in the Netherlands. Consecutive women and men aged ≥18 years 
with a presumptive diagnosis of community-acquired fUTI were randomly 
assigned to receive ciprofloxacin 500 mg orally twice daily for 7 days or for 
14 days.
The primary endpoint was the clinical cure rate through the 10- to 18-day 
post-treatment visit.
Results
Of 357 patients included, 200 were eligible for randomization; 97 patients 
were randomly assigned to 7 days of ciprofloxacin and 103 patients to 14 
days of ciprofloxacin. Overall, in an intention to treat analysis, clinical cure 
occurred in 85 (90%) patients treated for 7 days and in 94 (95%) of those 
treated 14 days (difference 4.5%; 90% CI -1.7 to 10.7; p=0.114, non-
inferiority confirmed). In women, clinical cure was 94% and 93% in those 
treated for 7 and 14 days, respectively (47 of 50 vs 54 of 58; p=0.426). In 
men, however, clinical cure was 86% after 7 days treatment and 98% in 
those treated 14 days (38 of 44 vs 40 of 41; p=0.031).
Conclusions
In women including postmenopausal women and those with comorbidities, 
fUTI can be treated successfully with oral ciprofloxacin for 7 days. In men, 
7 days of antibiotic treatment for fUTI is inferior to a 14-day course of oral 
ciprofloxacin.
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Introduction
In the last decade, treatment of urinary tract infection (UTI) has become 
more complicated by rising antimicrobial resistance of Enterobacteriaceae, 
the most common uropathogens.[1] With a scarcity of new antimicrobial 
classes in the development pipe-line, it is essential to develop strategies 
to maintain effectiveness of available antimicrobials.[2] Therefore, among 
strategies to control resistance, the determination of an optimal duration 
of treatment is essential in addition to optimization of diagnostics to target 
treatment and antibiotic stewardship concerning antibiotic choice and dose. 
Shortening of antimicrobial therapy will lead to less selection pressure on the 
gut microbiome with benefits to both the individual patient as well as eco-
logical environment including reduction of antibiotic resistance development.
[3] Even in a common infection like UTI, there is a scarcity of controlled 
randomized studies that address minimal yet optimally efficacious duration 
of UTI treatment. With respect to febrile UTI (fUTI) or acute pyelonephritis, 
trials have usually focused on young women with uncomplicated UTI and 
have addressed optimal treatment duration by comparing the same drug 
for different durations of therapy, or compared various treatment durations 
of different antimicrobial agents. Recently, a randomized placebo-controlled 
trial showed that community-acquired acute uncomplicated pyelonephritis 
in women of all ages can be safely and efficaciously treated with oral cipro-
floxacin for 7 days.[4] Clearly, such findings need to be extended to men and 
patients with significant comorbidities. In the present investigator-initiated 
randomized trial of treatment duration, we use fUTI as the clinical syndrome 
of interest because this is a broadly recognized specific clinical presentation 
of patients. Consecutive patients with fUTI were included, including men and 
women with comorbidities, and treated with ciprofloxacin for 7 days or 14 
days. The aims of the study were to compare clinical and bacteriological cure 
both at short term and long term.
Methods
Study design and patients
We conducted a randomized placebo-controlled double-blind multicenter 
non-inferiority trial; the protocol has been published previously.[5]
Consecutive women and men aged 18 years or older with a presumptive 
diagnosis of community-acquired fUTI established by primary care physician 
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or on presentation at hospital’s emergency department (ED) were recruited. 
Eligible patients had all of the following criteria: fever of ≥ 38.2°C and/or 
a history of feeling feverish with shivering or rigors in the past 24 hours, 
one or more symptoms suggestive of UTI (i.e. dysuria, frequency, urgency, 
perineal or suprapubic pain, costovertebral tenderness or flank pain) and 
positive urine nitrate test and/or pyuria (positive leucocyte esterase test 
or >5 leucocytes per high-power field in a centrifuged sediment). Patients 
enrolled were competent to provide written informed consent. Exclusion cri-
teria for study entry were: known allergy to fluoroquinolones, pregnancy or 
lactation, polycystic kidney disease, permanent renal replacement therapy, 
kidney transplantation, residence outside The Netherlands and inability to 
speak or read Dutch.
Contra-indications for randomization were: isolation of ciprofloxacin-resistant 
causal uropathogen, presence of renal abscess, metastatic infectious foci 
or underlying chronic bacterial prostatitis as defined by recurrent UTI with 
the same uropathogen. Patients enrolled with fUTI but not randomized to 
trial medication, remained in the observational part of the study to assess 
outcome.
The independent medical ethics committees of the participating centers 
approved the study protocol. The trial was registered at ClinicalTrials.gov 
[NCT00809913] and trialregister.nl [NTR1583].
Randomization and antimicrobial treatment
Patients were randomized in a 1:1 ratio stratified per center and sex, to 
receive either a 7-day or a 14-day regimen of antimicrobial treatment. In 
the second week, treatment was continued double-blinded, with either cip-
rofloxacin 500 mg or placebo orally twice daily, according to randomization 
code. In inpatients, the treating physician could administer discretionary 
empirical intravenous antibiotics at the start of treatment according to local 
guidelines (in all hospitals participating: a β-lactam antibiotic ± aminogly-
coside). These patients were switched as soon as deemed possible to open 
label oral ciprofloxacin (non-blinded) up to the 7th day after inclusion. The 
decision whether to treat as outpatient or inpatient, was made by the attend-
ing physician based on clinical judgment.
Further details upon randomization, trial medication, microbiological meth-
ods and study procedures are previously published.11
Willize van der Starre - Binnenwerk - Completeproefv7.indd   62 28-10-15   13:14
63
Treatment duration of febrile UTI (FUTIRST-trial)
3
Main outcome measures
The primary endpoint was the clinical cure rate through the 10- to 18-day 
post-treatment visit (short-term clinical cure). Clinical cure was defined as 
being alive with absence of fever and resolution of UTI symptoms (either 
absence of symptoms or at least 2 points improvement on a 0 through 5 
points severity score), without additional antimicrobial therapy (for relapse 
of UTI). Secondary outcome measures were bacteriological cure through the 
10- to 18-day post-treatment visit, clinical cure rate through the 70- tot 
84-day post-treatment visit (cumulative clinical cure), all-cause mortality, 
adverse event rate determined 10-18 days and 70-84 days post-treatment, 
and rate of UTI relapses. In addition, outcome measures were analyzed as 
stratified by specific subgroups (i.e., men, patients with complicated UTI, 
postmenopausal women, patients with any comorbidity and bacteremic UTI). 
Bacteriologic cure was defined as eradication of the study entry uropathogen 
with no recurrence of bacteriuria (pathogen growth <104 cfu/mL in women 
or <103 cfu/mL in men of a midstream urine culture combined with disap-
pearance of leucocyturia).[6]
Statistical analysis
The primary endpoint was analyzed on the intention-to-treat (ITT) popula-
tion, including all randomized patients who received at least one dose of the 
study drug, and on the per-protocol (PP) population, including all randomized 
patients who had been given the study drug for a minimum of 24 hours (in 
case of treatment failure) or who had been taken at least 80% of the study 
drug (in case of clinical cure).
The study sample size was calculated on the basis of a clinical cure rate of 
10 percentage points lower at short-term follow-up in the 7-day treatment 
arm with the assumption of a 90% clinical cure rate in patients treated for 
14 days.[7, 8] We adopted 10% as the margin of non-inferiority as sug-
gested previously.[9] As we are only interested in non-inferiority and not in 
equivalence, the sample size calculation was based on a one-tailed alpha of 
0.05. Assuming a non-inferiority margin of 0.10, 1-tailed alpha of 0.05 and a 
power of 0.90, the required sample size per group was 200. This implies that 
the 90% confidence interval of a two-tailed Chi-square test should not cross 
the predefined risk difference of 10% lower clinical cure rate, or equivalently, 
the one-sided p-value is less than the 0.05 significance level.[10] Interim 
analyses were done after randomization of 100 and 200 patients. After the 
second interim analysis, the principal investigators, who obviously were still 
blinded with respect to treatment allocation, noted that the overall cure rate 
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was 92% implying that the trial already had reached sufficient power (e.g. 
comparable with the power in a recently published similar trial).[4] Besides 
this, the overall cure rate was remarkably different for women and men (94% 
versus 91%). For men the principal investigators estimated and concluded 
the trial would likely end in futility, since the high overall cure rate in men was 
considered to be unlikely unless very large differences in cure rate between 









Age (years) 60 (48-72) 61 (40-73) 63 (49-75) 0.277
Male sex 44 (45%) 42 (41%) 58 (37%) 0.247
Urologic history
Indwelling urinary catheter 3 (3%) 2 (2%) 12 (8%) 0.024
Urinary tract disorder* 28 (29%) 28 (27%) 52 (33%) 0.296
Recurrent UTI^ 19 (20%) 19/100 (19%) 47/147 (32%) 0.007
Comorbidity
Diabetes 12 (12%) 17 (17%) 25 (16%) 0.709
Malignancy 3 (3%) 5 (5%) 17 (11%) 0.012
Heart failure 12 (12%) 6 (6%) 19 (12%) 0.340
Cerebrovascular disease 5 (5%) 5 (5%) 13 (8%) 0.210
Chronic renal insufficiency 3 (3%) 2 (2%) 10 (6%) 0.070
COPD 10 (10%) 11 (11%) 23 (15%) 0.236
Immunocompromised 3 (3%) 8 (8%) 14 (9%) 0.209
Presentation
At emergency department 59 (61%) 68 (66%) 145 (92%) <0.001
Antibiotic pretreatment 23 (24%) 29 (28%) 56 (36%) 0.048
Fever duration, hours 30 (15-48) 36 (20-60) 48 (19-96) 0.081
Dysuria 82/95 (86%) 78/102 (77%) 102/145 (70%) 0.019
Flank pain 57/96 (59%) 67/102 (66%) 91/144 (63%) 0.914
Suprapubic pain 51/96 (53%) 48/100 (48%) 72/145 (50%) 0.876
Perineal pain 4/96 (4%) 7/98 (7%) 8/140 (6%) 0.986
Outpatient treatment 45 (46%) 45 (44%) 23 (15%) <0.001
Positive urine culture 69 (71%) 68 (66%) 107 (68%) 0.944
Positive blood culture 20/88 (23%) 15/98 (15%) 45/153 (29%) 0.012
Positive urine and/or blood culture 75 (77%) 70 (68%) 118 (75%) 0.571
Initial intravenous dose(s) of antibiotics 48 (50%) 55 (53%) 133 (85%) <0.001
Data presented as number (%) or median (IQR)
* any functional or anatomical abnormality of urinary tract except urinary catheter
^ ≥3 UTIs in past 12 months or ≥2 UTIs in past 6 months
“ randomized (both 7 and 14 days ciprofloxacin) vs not-randomized patients
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the treatment arms were assumed. As this was considered either not-realistic 
or the justification to halt trial inclusion because then non-inferiority was 
evidently rejected, we decided to stop the trial at this point.
Descriptive statistics were used to describe the baseline characteristics in 
each arm with Chi-square tests for binomial and categorical data and Mann-
Whitney tests for continuous data. All analyses were performed using SPSS 
20.0 (SPSS Inc., Chicago, IL, USA).
Results
Between November 2008 and May 2013, 357 patients with a diagnosis of 
fUTI were enrolled into the study. Of these, 200 were randomly assigned 
to receive ciprofloxacin for 7 days (n=97) or 14 days (n=103). Reasons for 
exclusion from randomization, ITT and PP analyses are listed in Figure 1.
Of the 157 non-randomized patients, 119 (76%) were evaluable for short-
term efficacy and 116 (74%) for cumulative efficacy.
Baseline characteristics of the study population are summarized in Table 1. 
Randomized, evaluable subjects in the two treatment arms were well 
matched with respect to demographic characteristics and presentation on 
study entry. The 157 patients who were not randomized, generally had more 
comorbidities and were more ill as more were referred to the ED. Additional 
details are listed in the Supplement. Baseline urine cultures were performed 
in 341 patients (96%) (Table 2). In 99 (28%) patients, urine culture showed 
either no significant bacteriuria or a mixed flora; in over half of these cases 
(58%), patients were pre-treated with antibiotics (in the group randomized 
to 7 days of ciprofloxacin: 13 (59%), and to 14 days of ciprofloxacin: 20 
(63%)); a similar percentage pertained to those not randomized: 23 (51%),
Blood cultures were obtained in 339 patients of which 80 (24%) had bactere-
mia with growth of E. coli in the majority of the cases (n=67, 84%).
Both treatment regimens resulted in a high clinical cure rate at short-term 
follow-up in ITT population: 90% vs 95% in patients treated with ciprofloxa-
cin for 7 or 14 days, respectively (Table 3). The difference in short-term 
clinical cure rate between both treatment arms was 4.5% (90% CI -1.7 
to 10.7, p-value non-inferiority test 0.114), thus the confidence interval 
surpassed the predefined non-inferiority margin of 10%. The median time 
to defervescence did not differ between the two groups: 2 (IQR 1-2) days 
in 7-day ciprofloxacin, 2 (IQR 1-3) days in 14-day ciprofloxacin. Short-term 
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clinical cure was 85% in non-randomized patients, whereas median time to 
defervescence amounted to 2 (IQR 1-3) days.
Short-term clinical cure rates were analyzed in preset subgroups of patients. 
In women, short-term clinical cures for 7- and 14-day arm were 47 of 50 
(94%) vs 54 of 58 (93%), respectively. In men, clinical cure rates differed 
significantly between those treated for 7 or 14 days (38 of 44 [86%] vs 40 of 
41 [98%], p=0.031) (Figure 2A and 2B). Clinical cure rates in patients with 
stepdown treatment were 41 of 47 (87%) and 48 of 52 (92%), in 7- and 14-
day arm, respectively. Clinical cure rates were somewhat higher in patients 
treated with oral ciprofloxacin right from enrollment (44 of 47 [94%] vs 46 of 
47 [98%], respectively for 7- and 14-day arm). Patients with positive blood 
cultures had higher clinical cure rates when treated with ciprofloxacin for 14 
days compared to 7 days (15 of 15 [100%] vs 18 of 20 [90%]).
No differences were noted in cure rates between women with a complicated 
fUTI treated for 7 or for 14 days (33 of 35 [94%] vs 34 of 37 [92%]). 
Moreover, clinical cure rates did not differ in postmenopausal women treated 
for 7 or 14 days (28 of 30 [93%] vs 31 of 33 [94%]. Detailed information on 
subgroup analyses among men and women are listed in Figure 2A and 2B, 
respectively. Both treatment regimens post-randomization were well toler-
ated with no differences in side effects.
Post treatment urine cultures (at day 28-32) were obtained in 93 of 94 (99%) 
patients assigned to 7 days of ciprofloxacin, in 92 of 99 (93%) patients as-
signed to 14 days of ciprofloxacin, and in 109 of 119 (92%) non-randomized 
patients, with the short-term follow-up visit. Bacteriologic cure was 91% 
in the 7-day treatment arm, 97% in patients treated with ciprofloxacin for 
14 days, and 86% in non-randomized patients (Table 3). More details upon 
clinical and microbiological outcomes are listed in the Supplement.
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Short-term efficacy (n=94) (n=99) (n=119)
 Clinical cure 85 (90%) 94 (95%) 4.5% (-1.7 to 10.7) 0.114 101 (85%)
 Bacteriologic cure 86/93 (91%) 89/92 (97%) 4.3% (-1.2 to 9.8) 0.101 94/109 (86%)
Cumulative efficacy (n=94) (n=94) (n=116)
 Clinical cure 87 (93%) 86 (91%) -1.1% (-7.6 to 5.5) 0.394 88 (76%)
Per-protocol population (n=92) (n=93)
Short-term efficacy (n=92) (n=92) NA
 Clinical cure 83 (90%) 87 (95%) 4.3% (-2.1 to 10.8) 0.135
 Bacteriologic cure 84/91 (92%) 83/86 (97%) 4.2% (-1.5 to 10.0) 0.114
Cumulative efficacy (n=92) (n=87)
 Clinical cure 85 (92%) 79 (91%) -1.6% (-8.5 to 5.3) 0.352
Data presented as number (%), unless otherwise indicated. NA: not applicable.
Short-term efficacy: endpoints assessed at 10- to 18-days post-treatment visit.
Clinical cure: being alive with absence of fever and resolution of UTI symptoms through post-treatment visit with 
no additional antimicrobial therapy for a relapse of UTI prescribed.
Bacteriologic cure: elimination of study entry uropathogen or pathogen growth <10^4 colony forming units/mL 
(women) or <10^3 colony forming units/mL (men) combined with disappearance of leucocyturia.
Cumulative efficacy: endpoint assessed at 70- to 84-days post-treatment visit.




Ciprofloxacin for 7 days Ciprofloxacin for 14 days
Escherichia coli 65 (68%) 65 (59%) 85 (51%)
Klebsiella spp. 2 (2%) 4 (4%) 13 (8%)
Proteus spp. 1 (1%) 6 (5%) 6 (4%)
Pseudomonas aeruginosa – – 2 (1%)
Enterococcus spp. 1 (1%) – 8 (5%)
Staphylococcus spp. – – 1 (1%)
Other^ 3 (3%) 3 (3%) 8 (5%)
None or contaminated culture 22 (23%) 32 (29%) 45 (27%)
Data presented as number (%). Urine culture performed in: 7 days ciprofloxacin: 91 (94%), 14 days ciprofloxacin: 
100 (97%), non-randomized: 150 (96%)
* some patients had multiple isolates; ciprofloxacin 7 days: n=6, ciprofloxacin 14 days: n=10, not randomized n=17
^ ciprofloxacin 7 days: Proteus mirabilis (1), Citrobacter sedlakii (1), Citrobacter koseri (1), Candida spp. (2)
 ciprofloxacin 14 days: Morganella morganii (1), β-hemolytische streptokok group B S. agalactiae (2)
 not randomized: Serratia marcescens (1), β-hemolytic streptococci group B (1), Enterobacter cloacae (1), Streptococ-
cus bovis (1), Citrobacter koseri (1), Morganella morganii (1), Proteus mirabilis (1), β-hemolytische streptokok group A 
(1)
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Discussion
Our findings show that community-acquired febrile urinary tract infection 
can be safely and efficaciously treated with oral ciprofloxacin for 7 days in 
women, including the elderly with significant comorbidity, and irrespective 
of severity of disease at presentation. However in men, the 7-day treatment 
was significantly inferior to 14 days of treatment.
The main strength of this trial is its pragmatic nature reflecting daily clini-
cal practice with the inclusion of consecutive patients with fUTI, both men 
and women, irrespective of age and underlying medical conditions, with the 
notable exception of those with severe kidney disease, antibiotic allergy and 
pregnancy. Several hospitals were involved, including a referral university 
hospital, and general practitioners who enrolled about one fourth of our 
patients. Therefore, patients recruited into the study are considered repre-
sentative of individuals with acute community-acquired fUTI, encompassing 
acute pyelonephritis and prostatitis. Of note, the findings hold for both the 
intention-to-treat and the per protocol analysis, underlying the high compli-
ance by patients randomized with respect to the treatment protocol and 
precluding that poor study procedures may have concealed differences in 
patient management.
In contrast, the group of patients who were not randomized (because of 
the isolation of ciprofloxacin-resistant causal uropathogen, renal abscess or 
underlying chronic bacterial prostatitis) had a significantly higher treatment 
failure rate.
Our study lacks statistical power to draw confident conclusions on the vari-
ous subgroups because of the limited number of patients enrolled. However, 
further enrollment was precluded by the already significant difference in 
outcome between 7 and 14 days of treatment in the male subgroup.
Our findings extend recent findings of a highly similar controlled random-
ized study done in women with acute pyelonephritis in Sweden, showing 
non-inferiority of 7 and 14 days of antimicrobial treatment.[4] Although that 
study did not exclude the elderly or those severely ill, their patient group 
was younger with less comorbidity and complicated UTI than that enrolled 
in our study.
In men, our results indicate an increase in rate of clinical and bacteriological 
treatment failure after the 7-day treatment as compared to 14 days. Of note, 
this lack of efficacy could not be attributed upfront to a propensity of pros-
tatitis in men, as the difference was especially clear in those men presenting 
with clinically evident costovertebral tenderness, although the number of 
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cases constrained a purposeful exploration of subgroups. Given the identical 
efficacy of the 7-day and 14 -day treatment in women, and the absence of 
a relation with manifest or possible prostatitis as reason for the inferiority of 
7-day treatment in men, our findings cannot reliably explain this outcome. 
There is a lack of studies on optimal treatment duration of fUTI in men. One 
study directly compared different treatment duration in an open, prospective 
and randomized trial in 72 men with community-acquired fUTI showing simi-
lar bacteriological cure rates with ciprofloxacin 500 mg orally twice daily for 
either 2 or 4 weeks.[11] Similarly, a randomized, double-blind trial in Swe-
den lent support for the efficacy of 14 day treatment with fluoroquinolones 
in men.[12] Taken together, the studies confirm that at present, a 14-day 
treatment regimen of fluoroquinolones is the minimum period necessary for 
optimal therapy of fUTI in men. Recently however, a retrospective analysis 
of a large database of male veterans indicated that more than 7 days of 
antibiotic treatment (the vast majority being treated with ciprofloxacin) was 
not associated with a reduction of UTI recurrence.[13] In addition, this study 
showed that treatment with β-lactams was associated with a higher risk of 
recurrence as compared to fluoroquinolone treatment. Furthermore, they 
showed that UTI recurrence was independently associated with comorbidities 
and age. As in our study about half of the patients were initially treated with 
a β-lactam intravenously, implying less penetration into the prostrate,[14] 
this may have influenced our results and possibly this may explain the larger 
difference in cure rates within the subgroup of men with stepdown treat-
ment. Interestingly, in line with this we found no significant difference in men 
who were solely treated with ciprofloxacin whereas in men aged less than 
50 years, there was a similar cure rate with antibiotic treatment for 7 or 14 
days. Future studies should address whether in men less than 50 years, fUTI 
can be efficaciously treated with 7 days of ciprofloxacin.
Given the consistency of our findings and those of the recent study in 
Sweden[4], we conclude that women can be treated orally with 7 days of 
adequately dosed fluoroquinolones, unless the urinary isolate is proven not 
susceptible to this antibiotic. Ciprofloxacin was chosen as treatment because 
of its reliable intestinal resorption and bioavailability, and excellent anti-
microbial activity against a broad spectrum of susceptible gram-negative 
microorganisms, the most common etiologic microbiological agents in UTI, 
making it a drug of choice in both outpatient as well as hospital setting. As 
a surplus, activity against perineum and vagina colonizing Enterobacteria-
ceae may help prevent early recurrences.[15] Current results obtained with 
ciprofloxacin may likely be extrapolated to the other fluoroquinolones with 
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gram-negative activity but not to other antibiotic classes. An important con-
cern has been the rise of ciprofloxacin resistance in the community, i.e., up 
to 15% of Enterobacteriaceae currently being resistant in The Netherlands, 
that, if it continues at the current rate, may prelude the use of fluoroqui-
nolones as first-choice empiric oral treatment of fUTI. Of great concern, in 
other countries this figure has been reported as high as 40 to 50%.[16, 
17] In countries with concurrent high rates of co-trimoxazole resistance in 
Enterobacteriaceae, there may be no oral antibiotic option left for general 
practitioners to treat fUTI at home, raising health care costs. These findings 
underscore the importance of controlling antimicrobial resistance, through 
antibiotic stewardship including the administration of antibiotics with optimal 
duration.
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In the 7-day treatment arm, 23 (24%) patients had been pretreated for 
presumptive UTI with: norfloxacin (n=1, 4%), none with ciprofloxacin, 
nitrofurantoin (n=5, 22%), trimethoprim ± sulfamethoxazole (n=3, 13%), 
amoxicillin ± clavulanic acid (n=12, 52%), phosphomycin (n=1, 4%) and 
others (n=1, 4%). Of those randomized to 14 days ciprofloxacin, 29 (28%) 
had been pretreated with ciprofloxacin (n=3, 10%), norfloxacin (n=1, 3%), 
nitrofurantoin (n=6, 21%), trimethoprim ± sulfamethoxazole (n=7, 24%), 
amoxicillin ± clavulanic acid (n=8, 28%), others (n=3, 10%) and unknown 
(n=1, 3%). In the non-randomized group, 56 (36%) had been pretreated 
with ciprofloxacin (n=8, 14%), norfloxacin (n=2, 6%), nitrofurantoin (n=8, 
14%), trimethoprim ± sulfamethoxazole (n=7, 13%), amoxicillin ± clavu-
lanic acid (n=21, 38%), phosphomycin (n=1, 2%), others (n=4, 7%) and 
unknown (n=5, 9%).
About half of the patients were initially treated with intravenous antibiotics, 
and this did not differ between treatment arms: in the 7 days of ciprofloxacin, 
48 (50%) patients (cefuroxime n=21, 44%; cefuroxime + gentamicin n=22, 
46%; other n=5, 10%) and in the 14 day, 55 (53%) patients (cefuroxime 
(n=32, 58%), cefuroxime ± gentamicin (n=20, 36%), ciprofloxacin i.v. 
(n=1, 2%) and other antibiotics (n=2, 4%)). In the non-randomized group, 
133 (85%) patients had initial dose(s) of intravenous antibiotics, i.e., cefu-
roxime (n=61, 46%), cefuroxime ± gentamicin (n=49, 37%), ciprofloxacin 
(n=4, 3%) and other (n=18, 14%). Of note, the median time till switch 
from intravenous to oral antibiotics was 3 days (IQR 2-4), and did not differ 
between the groups.
Clinical outcome
During short-term follow-up, nine patients assigned to ciprofloxacin for 7 
days had a clinical recurrence. Three patients had an episode of (afebrile) 
acute cystitis at day 17, 18 and 20, whereas six patients had an additional 
episode of fUTI at day 9, 14, 15, 17, 20 and 26 after treatment. Among pa-
tients assigned to 14 days of ciprofloxacin, one patient had an acute cystitis 
at day 30 and four patients had recurrent fUTI at day 8, 9, 19 and 20.
For cumulative clinical cure rate, 94 patients were evaluable in each treat-
ment arms. Clinical cure rates were high: 93% vs 91% in patients treated 
with ciprofloxacin for 7 of 14 days (Table 3). During late follow-up, seven 
patients assigned to 7 days had a clinical recurrence. Six patients had an 
Willize van der Starre - Binnenwerk - Completeproefv7.indd   76 28-10-15   13:14
77
Treatment duration of febrile UTI (FUTIRST-trial)
3
episode of (afebrile) acute cystitis at day 38, 40, 56, 63, 64 and 83 and one 
patient had an additional episode of fUTI. Among patients assigned to 14 
days, seven patients had an (afebrile) acute cystitis at day 40, 44, 71 and 77 
(n=3 day unknown) and one patients had recurrent signs of fUTI at day 90.
One patient assigned to ciprofloxacin for 7 days was readmitted at day 9 
because of treatment failure, and was treated intravenously with cefuroxime 
followed by oral ciprofloxacin for 14 days, now with good clinical response. 
None of the patients assigned to the 14-days treatment arm were readmitted 
because of treatment failure.
During the study period, no patients given 7 days of ciprofloxacin died. One 
patient, an 84-year old man assigned to 14 days of ciprofloxacin, died on day 
92 due to pneumonia and sepsis. Five non-randomized patients died during 
follow-up due to concurrent medical problems.
With respect to side effects, one patient who received placebo, discontinued 
trial drug because of mucosal candida infection (day 2 after start placebo). 
Five patients on ciprofloxacin discontinued trial drug because of itching 
exanthema (n=2, both on day 3, i.e., day 10 of treatment) or feeling tired 
(n=3; day 1,3 and 5). During trial drug period, patients reported the fol-
lowing adverse events in 7- and 14 days treatment arm: nausea (7% vs 
4%), vomiting (2% vs 1%), diarrhea (3% vs 2%), headache (16% vs 4%), 
dizziness (10% vs 9%), itching exanthema or rash (4% vs 4%) and myalgia 
(10% vs 12%).
Microbiological outcome
In the group assigned to 7 days of ciprofloxacin, seven patients had asymp-
tomatic bacteriuria at short-term follow-up (five with E. coli, one with Kleb-
siella oxytoca and one with Enterococcus faecalis). Three patients treated 
with ciprofloxacin for 14 days had asymptomatic bacteriuria at short-term 
follow-up (one with E. coli, one with E. faecalis and one with coculture of E. 
faecalis and S. aureus). Fifteen non-randomized patients had asymptomatic 
bacteriuria at short-term visit: seven with E. coli, one with E. coli and E. 
faecalis, one with Klebsiella spp and S. saprophyticus, one with Proteus spp, 
two with E. faecalis, one with E. faecalis and P. aeruginosa, one with P. 
aeruginosa and one with Enterobacter cloacae.
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Evaluate the impact of diabetes mellitus on the clinical presentation and 
microbiological and clinical outcomes of febrile urinary tract infection (UTI).
Research design and methods
A prospective observational multicenter cohort study including 858 adults 
with community-onset febrile UTI presenting at seven emergency depart-
ments and 35 primary care units. The effect of pre-existing diabetes on 
presentation, microbiological and clinical outcome was assessed and multi-
variable logistic regression performed to establish whether diabetes was an 
independent risk factor for a complicated course.
Results
Of 858 patients, 140 had diabetes (93% type 2 diabetes). Patients with 
diabetes were older, more frequently male, and had a higher rate of cardio-
vascular and urinary tract comorbidities. Diabetes was not associated with 
longer fever duration or prolonged hospital admission. Patients with diabetes 
more often had bacteremia at presentation, ICU admission, recurrent UTI, 
asymptomatic bacteriuria and mortality during 30 days of follow-up. However, 
when adjusted for possible confounders, diabetes was not an independent 
risk factor for any of these complications, although women with diabetes 
were at increased risk of asymptomatic bacteriuria after one month. The 
higher prevalence of complications in diabetics was mainly explained by an 
increased prevalence of cardiovascular comorbidity and higher age.
Conclusions
Although it is widely held that patients with diabetes have a more compli-
cated course of infections, our data show that diabetes is not independently 
associated with adverse outcomes in an unselected population of patients 
with febrile UTI. Cardiovascular comorbidity and increased age are the main 
risk factors for a complicated course.
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Introduction
Diabetes mellitus affects about 6% of the population worldwide, and this 
number is expected to grow in the coming years.(1,2) Asymptomatic bac-
teriuria in diabetes - a common finding in up to one quarter of patients 
- predisposes to urinary tract infections(UTIs).(3,4) This increased risk of 
acquiring UTIs in diabetic patients is clear.(5,6) It is less clear whether 
UTIs in diabetic patients compared to non-diabetic patients follow a more 
complicated course, although various treatment guidelines reflect this per-
ception.(7,8) In previous studies on diabetes and the outcome of febrile 
UTI, diabetes was associated with a higher rate of bacteremia and a longer 
duration of hospitalization and fever.(9-11) Two studies reported a higher 
mortality(10,12) and a recent meta-analysis demonstrated an increased 
hazard ratio for death from infection other than pneumonia (HR 2.39).(13) 
On the contrary, increased mortality was not associated with diabetes in a 
large review of hospitalizations due to pyelonephritis.(14)
However, these studies specifically focusing on urinary tract infections in 
diabetes are limited by small sample size, inadequate adjustment for con-
founding and varying inclusion criteria.
Therefore, this prospective observational cohort study was performed to 
evaluate the impact of diabetes on the clinical presentation of febrile UTI 
and its microbiological and clinical outcomes.
Research design and methods
We conducted a prospective observational multicenter cohort study including 
consecutive patients with febrile UTI from January 2004 until January 2011. 
Participating centers were 35 primary health centers and the emergency 
departments of 7 hospitals, all clustered in one area of the Netherlands. The 
local ethics committees approved the study and all participants provided 
written informed consent.
Inclusion criteria were age ≥ 18 years, fever (≥ 38.0°C) and/or a history 
of fever or shaking chills within 24 hours before presentation, at least one 
symptom of UTI (dysuria, perineal pain or flank pain) and a positive nitrite 
dipstick test or leucocyturia as defined by a positive leucocyte esterase 
dipstick test or the presence of more than five leucocytes per high-power 
field in a centrifuged sediment. Exclusion criteria were current treatment for 
urolithiasis or hydronephrosis, pregnancy, known allergy to fluoroquinolones, 
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receipt of hemo- or peritoneal dialysis, a history of kidney transplantation, 
or known presence of polycystic kidney disease. Patients were only included 
once in the study.
Procedures
Demographic and clinical data were collected at baseline, at 3-4 days and 28-
32 days after enrollment. Microbiological data were collected at baseline and 
since August 2006 a second urine culture was obtained after 28-32 days. The 
presence of diabetes was included in the standard questionnaire at baseline, 
which was filled out by qualified research nurses or the clinical investigator 
by reviewing the medical record completed with a patient interview. When 
diabetes was newly diagnosed during admission, the patient was regarded 
as diabetic patient. In case the patient was lost to follow-up, mortality was 
assessed using interviews from patient’s GP and/or hospital chart review 
and/or local governmental mortality registries. Blood and urine cultures 
were performed using standard microbiological methods. MIC breakpoints 
for resistance were based on EUCAST criteria (www.eucast.org).
Definitions
A urinary tract disorder was defined as the presence of any anatomical 
or functional abnormality of the urinary tract excluding the presence of 
a urinary catheter or history of nephrolithiasis. These two variables were 
analyzed separately. Recurrent UTI was defined as two or more episodes of 
UTI in the last six months, or three or more episodes of UTI in the last year. 
The isolation of coagulase-negative staphylococci from the blood culture 
was considered to indicate contamination and thus absence of bacteremia. 
Adequate treatment was defined as appropriate antibiotic treatment, tak-
ing into account the causal uropathogen(s) in urine- and blood culture and 
its resistance pattern. Asymptomatic bacteriuria was defined as the growth 
of ≥105 CFU/mL of a uropathogen in a midstream urine sample collected 
28-32 days after enrolment without symptoms suggesting UTI (dysuria/flank 
pain/fever).(15) Recurrent UTI was defined as the growth of ≥103 CFU/mL 
of a uropathogen in a midstream urine sample collected 28-32 days after 
enrolment plus ≥1 symptom suggesting UTI.(16,17) Due to logistic reasons, 
in 500 patients (58%) a urine culture at 28-32 days after inclusion could be 
obtained; outcomes of asymptomatic bacteriuria and recurrent UTI could 
only be assessed in these patients.
Data on bacteremia were missing in 51 patients because no blood cultures 
were performed at presentation. Survival data were lacking in four patients 
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due to loss to follow-up; those patients were excluded from analysis of 30-
day mortality. All patients were relatively young (22, 24, 26 and 67 years), 
and three had no underlying illnesses except for a stroke in the medical 
history of a 67-year old male, so risk of mortality is low.
Statistical analysis
Descriptive analysis included means with standard deviation (SD) or medians 
with interquartile range (IQR), as appropriate. Comparison of groups was 
performed using the Mann-Whitney U-test or unpaired t-test for continuous 
variables and the Chi-squared test for categorical variables. Odds ratios and 
95% confidence intervals were calculated. Factors included in the logistic 
regression models for adverse outcomes (bacteremia, asymptomatic bac-
teriuria, recurrent UTI and 30-day mortality) using Enter selection method 
were age, sex, comorbidities, bacteremia at presentation (for 30-day mortal-
ity), and receiving an adequate antibiotic treatment (for recurrent UTI) if 
the p value was <0.2. Interactions between paired variables were tested. A 
two-tailed p-value <0.05 was considered to indicate statistical significance. 
All analyses were performed using SPSS 20.0 (SPSS Inc, Chicago, IL, USA).
Results
Of 858 consecutive patients, 140 had diabetes (130 (93%) type 2 diabetes), 
of which 41 (30%) used insulin, and 19 (14%) were managed by diet only. 
Diabetic patients were older (median age 73 [IQR 60-81] vs 64 [IQR 42-77] 
years), more frequently male (48% vs 35%, p 0.006), more often presented 
at the emergency department (86% vs 76%, p 0.008) and had a higher rate 
of cardiovascular and urinary tract comorbidities compared to 718 patients 
without diabetes. Further baseline characteristics of the study population are 
summarized in Table 1.
Signs and symptoms
Patients with diabetes had comparable signs and symptoms at presenta-
tion compared to non-diabetic patients, except for systolic blood pressure 
(138 ± 25 mmHg vs 129 ± 22 mmHg, respectively) and flank pain (50% 
versus 65%, respectively). After correction for age (both continuous and in 
quartiles), diabetes no longer had a significant influence on the absence of 
flank pain in the diabetic patients.




In 809 patients (94%), a urine culture was performed at baseline. Escherichia 
coli was the most common isolated uropathogen in both diabetic and non-dia-
betic patients (Table 2). Klebsiella spp. (9% vs 4%), Enterococcus spp. (11% 
vs 3%) and Staphylococcus spp. (5% vs 2%) were isolated more frequently 
in diabetic patients. Also urine culture of diabetic patients more frequently 
revealed more than one uropathogen (11% vs 4%). A comparable distribution 






Age, median [IQR] years 66 [46-78] 73 [60-81] 64 [42-77] <.001
Male sex 320 (37) 67 (48) 253 (35) .006
Antibiotic pre-treatment 254 (30) 48 (34) 206 (29) .189
Urologic history
 Urinary tract disorder* 210 (24) 48† (34) 162 (23) .005
 Indwelling urinary catheter 58 (7) 16 (11) 42 (6) .016
 Recurrent UTI‡ 269 (31) 54 (39) 215 (30) .044
Comorbidity
 Malignancy 91 (11) 19 (14) 72 (10) .230
 Heart failure 128 (15) 39 (28) 89 (12) <.001
 Cerebrovascular disease 112 (13) 25 (18) 87 (12) .074
 Chronic renal insufficiency 78 (9) 26 (19) 52 (7) <.001
 Chronic obstructive pulmonary disease 118 (14) 28 (20) 90 (13) .023
Presentation
 At emergency department 662 (77) 120 (86) 542 (76) .008
 Shaking chills 489/783 (63) 79/125 (63) 410/658 (62) .851
 Dysuria§ 613 (76) 102 (83) 511 (75) .065
 Flank pain 526/837 (63) 66/132 (50) 460/705 (65) <.001
 Fever duration at presentation, median hours [IQR]|| 30 [12-60] 36 [15-72] 29 [12-60] .397
 Heart rate >90 beats/minute 448/850 (53) 73/139 (53) 375/711 (53) 1.000
 Systolic blood pressure, mean mmHg ± SD 130 ± 23 138 ± 25 129 ± 22 <.001
 Diastolic blood pressure, mean mmHg ± SD 72 ± 14 72 ± 16 72 ± 14 .940
Data are presented in n (%) unless otherwise stated. UTI  =  urinary tract infection, IQR  =  interquartile range, 
SD = standard deviation.
* defined as any functional or anatomical abnormality of the urinary tract except urinary catheter and history of 
nephrolithiasis.
† prostatic hypertrophy (20), malignancy of the urinary tract (6), neurogenic bladder (5), status after nephrectomy 
(3), and other anatomical or functional disorders of the urinary tract (14)
‡ defined as ≥ 3 UTIs in the past 12 months or ≥ 2 UTIs in the past 6 months
§ not recorded in patients with an indwelling urinary catheter
|| recorded in 660 patients
Willize van der Starre - Binnenwerk - Completeproefv7.indd   84 28-10-15   13:14
85
Diabetes mellitus and the course of febrile UTI
4
of uropathogens among diabetic and non-diabetic patients was seen in an 
analysis excluding patients with an indwelling urinary catheter (n =753).
Resistance patterns of E. coli urinary isolates were comparable between dia-
betic and non-diabetic patients: amoxicillin-clavulanic acid (17% vs 12%), 
trimethoprim-sulfamethoxazole (25% vs 30%) and ciprofloxacin (19% vs 
12%), even when only patients without indwelling catheter and without 
antibiotic pre-treatment were analyzed (data not shown).
Baseline blood cultures were performed in 807 patients (94%). Diabetic 
patients more often had bacteremia (29% vs 20%). Also in patients with low 
bacterial counts in their urine culture (< 105 CFU/mL), bacteremia was more 
prevalent in diabetic patients versus non-diabetic patients (22% vs 16%, 
respectively). In the latter comparison patients with a urinary catheter or 
patients who had received antibiotic pre-treatment were excluded (Table 4).
Clinical outcome
Upon presentation, diabetic patients were more frequently admitted to the 
hospital (81% vs 64%). Moreover, they were more frequently admitted to 
the intensive care unit during hospitalization (6% vs 3%). However, when 
admitted, fever duration and length of hospital stay were comparable. Dia-
betic patients were more often bacteremic at presentation (30% vs 22%). 
After one month, diabetic patients had a higher rate of asymptomatic bacte-
riuria (13% vs 9%; OR 1.5, 95% CI 0.8-3.0), recurrent UTI (9% vs 3%; OR 
2.9, 95% CI 1.2-7.2) and mortality (6% vs 2%; OR 3.3, 95% CI 1.3-8.0), 
although absolute numbers were low (Table 3). In a subgroup analysis of 
diabetic patients, use of insulin was not associated with any of the adverse 
outcomes.
Table 2. Uropathogens isolated from urine culture at inclusion
Uropathogen Diabetes (n=133) No diabetes (n=676)
Escherichia coli 69 (52) 393 (58)
Proteus spp. 5 (4) 23 (3)
Klebsiella spp. 12 (9) 28 (4)
Pseudomonas aeruginosa 4 (3) 18 (3)
Enterococcus spp. 14 (11) 19 (3)
Staphylococcus spp. 6 (5) 10 (2)
Candida spp. 0 (0) 2 (0,3)
Other 14 (11) 89 (13)
None/ contaminated 23 (17) 121 (18)
Data are presented as n (%). Urine culture was not performed in 49 patients.




After adjusting for possible confounders, independent risk factors for bac-
teremia were age (OR 1.0, 95% CI 1.0-1.0) and chronic renal insufficiency 
(OR 1.9, 95% CI 1.1-3.1) but diabetes was not (OR 1.2, 95% CI 0.8-1.8). 
Risk factors for 30-day mortality were age (OR 1.1, 95% CI 1.1-1.2) and 
heart failure (OR 3.2, 95% CI 1.2-8.9). Diabetes was not a significant risk 
factor for mortality (OR 2.0, 95% CI 0.7-5.8). Similarly, bacteremia was not 
associated with mortality (OR 1.6, 95% CI 0.6-4.4). None of the variables 
we studied were independently associated with recurrence of UTI during 30 
days of follow-up (Table 3).
Also, diabetes was not independently associated with asymptomatic bacte-
riuria after one month (OR 1.1, 95% CI 0.5-2.5). Only having an indwelling 
catheter was significantly associated (OR 8.0, 95% CI 3.6-17.7). Potential 
interactions between variables (e.g diabetes mellitus and sex) were addition-
ally tested, but they did not significantly change the models, except for 
asymptomatic bacteriuria. Of female diabetic patients, 15% had asymptom-
atic bacteriuria after one month compared to 4% in female non-diabetic 
patients (OR 4.3, 95% CI 1.5-11.9). In male, 11% of diabetic patients had 
asymptomatic bacteriuria compared to 17% in non-diabetic (OR 0.6, 95% CI 
Table 3. Relation between diabetes mellitus and clinical and microbiological outcome of 858 patients pre-














Hospital admission 575 (67) 114 (81) 461 (64) 2.4 [1.6-3.8] -
Hospitalization duration (days), 
median [IQR]
6 [4-9] 6 [4-11] 6 [4-8] - -
ICU admission 32 (4) 9 (6) 23 (3) 2.1 [0.9-4.6] -
Bacteremia at presentation 185/807 (23) 40/134 (30) 145/673 (22) 1.6 [1.0-2.3] 1.2 [0.8-1.8]
Defervescence1 (days), median [IQR] 2 [1-3] 2 [1-3] 2 [1-3] - -
30-day mortality 21/854 (2) 8 (6) 13/714 (2) 3.3 [1.3-8.0] 2.0 [0.7-5.8]
Microbiological2
30-day asymptomatic bacteriuria3 49/500 (10) 12/92 (13) 37/408 (9) 1.5 [0.8-3.0] 1.1 [0.5-2.5]
30-day recurrent UTI4 21/500 (4) 8/92 (9) 13/408 (3) 2.9 [1.2-7.2] 2.2 [0.7-6.8]
Data are presented in n (%) unless otherwise stated. UTI = urinary tract infection, OR= odds ratio, CI = confidence 
interval, IQR = interquartile range, ICU = intensive care unit
1 recorded in 667 patients: 105 (75%) diabetic patients and 562 (78%) non-diabetic patients
2 of 500 patients with a urine culture performed after 30 days
3 defined as the growth of a uropathogen ≥105 in a midstream urine sample without symptoms of UTI
4 defined as the growth of a uropathogen ≥103 in a midstream urine sample plus ≥1 symptom(s) of UTI
5 univariate and multivariate OR of risk factor diabetes mellitus for the corresponding outcomes
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0.2-1.7). So, there is an important interaction between diabetes and sex for 
the risk of asymptomatic bacteriuria (adjusted OR 0.1, 95% CI 0.02-0.7 for 
male diabetic patients).
Conclusions
In this prospective observational multicenter cohort study, diabetes mellitus 
was not independently associated with increased mortality or a complicated 
outcome of febrile urinary infection compared to non-diabetic patients. The 
prevalence of adverse outcomes was higher in diabetic patients, but mainly 
attributable to concurrent illnesses, especially cardiovascular comorbidities, 
and a higher age of the diabetic population. This is in line with the fact that 
most of the diabetic patients had type 2 diabetes.
Clinical symptoms of febrile UTI were comparable between diabetic and 
non-diabetic patients, apart from the observation that diabetic patients ex-
perience less flank pain, as was reported previously.(9) This might possibly 
be explained by diabetic neuropathy, although diabetes had no significant 
influence on the absence of flank pain in the diabetic patients after correction 
for age.
The lack of flank pain in a substantial part of the study population shows 
once more that flank pain has a low predictive value in the identification of 
complicated UTI, whereas presence of fever effectively excludes the pres-
ence of a non-complicated UTI. Therefore, the determination of fever in 
patients with suspected UTI should be the starting point in further diagnostic 
and therapeutic steps, because that is the most reliable distinction between 
cystitis/urethritis and UTIs associated with tissue invasion.






<103 1/1 (100%) 1/9 (11%)
103-104 1/2 (50%) 2/17 (12%)
104-105 0/7 (0%) 7/36 (19%)
>105 19/59 (32%) 65/277 (23%)
Total 21/69 (30%) 76/343 (22%)
Analysis performed in all patients with positive urine culture; patients pretreated with antibiotics or patients with 
indwelling urinary catheter were excluded from analysis.
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Although diabetic patients had a nearly similar clinical presentation except 
for flank pain, they more often had bacteremia. Interestingly, bacteremia did 
not affect duration of fever and hospitalization. The higher rate of bacteremia 
might be partly due to presentation later in the course of UTI, as suggested 
by a longer fever duration before inclusion. Another explanation could be 
that their immune response is less efficient. Various in vitro, animal and a 
few patient studies investigated the host response in diabetes,(18,19) which 
seems to be altered and could predispose diabetic patients to e.g. recurrent 
infection. Of these, several mechanisms could explain our clinical findings.
Firstly, although the systemic cytokine response to infection seems not to 
be altered,(18,20) a lower pro-inflammatory cytokine amount was found in 
urine from diabetic patients with asymptomatic bacteriuria,(18) possibly re-
flecting an attenuated local immune response. This could be the explanation 
why in this study, like another study(21), less virulent uropathogens, such as 
Enterococcus spp., more often were cultured in diabetic patients. However, 
these differences also could be due to more frequent usage of antibiotics or 
more hospital admissions of diabetic patients, as Enterococcus spp. are fre-
quent causative micro-organisms of nosocomial infections.(22,23) Secondly, 
even when the same uropathogen is involved, there could be a better adhe-
sion of bacteria on the uroepithelium by their type 1 fimbriae, as was shown 
in E. coli, especially in poorly controlled diabetic patients.(24) In our study, 
we did not systematically collect the level of control of diabetes at presenta-
tion. As a consequence, this findings could not be confirmed within our group 
of diabetic patients. However, considering the similar clinical presentation in 
both groups, this phenomenon might be more responsible for the acquisition 
of UTI and not associated with different presentation or outcome of UTI. 
Lastly, more bladder voiding problems are encountered in diabetic patients 
due to autonomic dysfunction,(25) which leads to stasis of urine and possibly 
higher risk of bacterial growth and lack of bacteriologic cure.(26,27)
Our findings support previous reports on the lack of an association between 
diabetes per se and an increased mortality in urinary tract infection. Age 
and comorbidity, especially heart failure in our study, were more predictive 
of mortality and should be accounted for, as was also demonstrated in a 
study of elderly patients with urosepsis.(28) Another study of 206 elderly 
patients with febrile UTI did show a higher mortality in diabetic patients, 
but here no correction was made for comorbidity.(10) A retrospective cohort 
study comparing diabetic persons with age and sex matched controls found 
a higher risk ratio for death due to infectious diseases, but did not report 
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febrile UTI specific mortality and did not take into account possible differ-
ences in comorbidities between diabetic persons and controls.(29) Similarly 
in other infections, such as community-acquired pneumonia, a higher risk of 
death in diabetic patients was assumed to be associated with a higher inci-
dence of acute kidney injury and acceleration of underlying cardiovascular 
disease.(20) Therefore, when diabetes patients have cardiovascular or renal 
complications of disease, these conditions will be the main determinants of 
outcome in infections.
Diabetes mellitus was not an independent risk factor for asymptomatic 
bacteriuria after one month in our study population. However, there was 
an significant interaction between diabetes and sex, showing an increased 
risk of asymptomatic bacteriuria in women with diabetes compared to 
men. This is supported by previous research, which showed that women 
with diabetes have a higher risk of asymptomatic bacteriuria compared to 
healthy women(19,30-32). The results in men however are not supported by 
a recent meta-analysis, which demonstrated also a higher prevalence of as-
ymptomatic bacteriuria in men with diabetes compared to healthy men.(32)
Our study do not find support for an increased duration of antimicrobial 
treatment of febrile UTI in diabetic compared to non-diabetic patients, since 
clinical and microbiological outcomes after one month did not differ sig-
nificantly between both groups, and diabetic and non-diabetic patients were 
treated alike.
In conclusion, our data show that diabetes is not independently associated 
with adverse outcomes in an unselected population of patients with febrile 
UTI, although it is widely held that patients with diabetes have a more com-
plicated course of infections. Cardiovascular comorbidity and increased age 
are the main risk factors for a complicated course of febrile UTI.
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Bacterial infections such as febrile urinary tract infection (fUTI) may run a 
complicated course which is difficult to foretell on clinical evaluation only. 
Because the conventional biomarkers erythrocyte sedimentation rate (ESR), 
leukocyte count, C-reactive protein (CRP) and procalcitonin (PCT) have a 
limited role in the prediction of a complicated course of disease, a new bio-
marker - plasma midregional pro-adrenomedullin (MR-proADM) - was evalu-
ated in patients with fUTI. We conducted a prospective multicentre cohort 
study including consecutive patients with fUTI at 35 primary care centres and 
8 emergency departments. Clinical and microbiological data were collected 
and plasma biomarker levels were measured at presentation to the physi-
cian. Survival was assessed after 30 days. Of 494 fUTI patients, median age 
was 67 [IQR 49-78] years, 40% were male; two third of them had significant 
co-existing medical conditions. Median MR-proADM level was 1.42 [IQR 0.67-
1.57] nmol/L; significantly elevated MR-proADM levels were measured in 
patients with bacteraemia, those admitted to the ICU, and in 30- and 90-day 
non-survivors, as compared to patients without these characteristics. The 
diagnostic accuracy for predicting 30-day mortality in fUTI, reflected by the 
area-under-the-curve of receiver operating characteristics were: MR-proADM 
0.83 (95%CI: 0.71-0.94), PCT 0.71 (95%CI: 0.56-0.85); whereas CRP, ESR 
and leukocyte count lacked diagnostic value in this respect. This study shows 
that MR-proADM assessed on first contact predicts a complicated course of 
disease and 30-day mortality in patients with fUTI and in this respect has a 
higher discriminating accuracy than currently available biomarkers ESR, CRP, 
PCT and leukocyte count.
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Introduction
Urinary tract infections (UTIs) are one of the most common bacterial in-
fections. Febrile UTI (fUTI), reflecting acute pyelonephritis, prostatitis or 
urosepsis, is a potentially serious infection with a mortality rate of about 
0.3%, but in bacteremic fUTI the mortality may be as high as 7.5-30% (1;2). 
Moreover, bacteraemia in fUTI is associated with prolonged hospitalization 
and a complicated course (3-5), and occurs in up to 30% of those admitted 
to hospital and in 15% of patients treated at home (6). Evaluation of clinical 
symptoms fails to provide accurate guidance to the clinician which patients 
have bacteraemia or who may run a complicated course, and which patients 
may be safely treated at home. At present, there is a lack of robust inflamma-
tory biomarkers that may help determine severity of disease in fUTI (7;8). A 
promising new biomarker is midregional pro-adrenomedullin (MR-proADM). 
Adrenomedullin (ADM) has been detected in a variety of tissues including 
kidneys. It has immune modulating, metabolic and bactericidal activity, and 
is involved in regulation of complement activity (9-12). Reliable plasma 
measurement of ADM is challenging due to half-life time of 22 minutes (13). 
MR-proADM, the more stable mid-regional fragment of adrenomedullin, has 
been identified in plasma of patients with septic shock (13-15).
The aim of the present study is to assess the prognostic value of plasma 
MR-proADM in adult patients with fUTI with respect to bacteraemia, need 
for hospital admission and a complicated course, as compared to current 
available biomarkers like blood leukocyte count, erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP) and procalcitonin (PCT).
Patients and methods
We conducted a prospective observational multicentre cohort study of pa-
tients presenting with a presumptive diagnosis of fUTI from January 2004 
until March 2011. Participating centres were 35 primary care centres and 
8 emergency departments (ED) in the Netherlands as described previously 
(6,8). The local ethics committees approved the study and all participants 
provided written informed consent. Over 7 years, we established a cohort 
of 869 patients. From this database, we randomly selected (every other 
patient, e.g. the 1st, 3rd,5th, etc.) frozen plasma samples of 494 patients for 
measurement of MR-proADM.
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Inclusion criteria were age ≥18 years, fever (≥38.0 °C) and/or a history 
of fever or shaking chills within 24 hours before presentation, at least one 
symptom of UTI (dysuria, perineal pain or flank pain) and a positive nitrite 
dipstick test or leucocyturia. Exclusion criteria were current treatment for 
urolithiasis or hydronephrosis, pregnancy, hemo- or peritoneal dialysis, 
history of kidney transplantation or presence of polycystic kidney disease. 
Patients were only included once.
Procedures and definitions
Clinical data and laboratory values were collected within 24 hours of enrol-
ment by standardized questionnaires and reviewing the medical record. All 
patients were empirically treated with antibiotics according to local and na-
tional policy. Blood cultures and clean midstream-catch urine cultures were 
obtained before starting antimicrobial therapy and analysed using standard 
microbiological methods. Bacteraemia was defined as growth of any patho-
gen in the blood culture, except coagulase-negative staphylococci.
Plasma ethylenediaminetetraacetic acid (EDTA) blood samples were col-
lected, centrifuged and stored at -80 °C within two hours of patient en-
rolment. MR-proADM and PCT levels were measured after completion of 
all study enrolments, using a Time Resolved Amplified Cryptate Emission 
technology assay (TRACE®, Kryptor Compact, MR-proADM sensitive and PCT 
sensitive; Thermofisher - Brahms AG; Henningsdorf, Germany). The median 
concentration of MR-proADM in a cohort of healthy individuals was 0.39 
nmol/L (97.5th percentile: 0.55 nmol/L) (16). According to the manufacturer 
recommendation we tested MR-proADM levels for different cut-off values 
(16;17). Results of PCT measurement to predict bacteraemia have been 
described previously (8). Measurements of CRP, ESR and leukocyte count 
were only done at enrolment when indicated by the attending physician. All 
eight participating EDs applied similar techniques. CRP was measured using 
immunoturbidimetric assay, cut-off values varied from 6-10 mg/L. ESR was 
measured using Westergren method, cut-off values: <20mm/hour for males 
and females ≤50 years, 30mm/hour for females > 50 years and 15mm/hour 
for males >50 years. Leukocyte count was measured using flow cytometry, 
cut-off value: 10.0 x109/L. Data on biomarkers available in our study popula-
tion were: CRP (n=319), ESR (n=158), leukocyte count (n=372) and PCT 
(n=321).
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End points
MR-proADM values were evaluated for their predictive acumen of primary 
and secondary endpoints, in comparison to that of the other biomarkers. The 
primary endpoint was 30-day mortality. Secondary endpoints were presence 
of bacteraemia at admission, need for hospital admission as estimated by 
the Acute Pyelonephritis Severity Index score (APSI score), and need for ICU 
admission. The APSI score is a prediction rule allocating points to age, sex, 
nursing home residency, comorbidities, and vital signs at presentation (18).
Statistical analysis
The histogram of biomarker values were skewed and log-normalized before 
analysis. Descriptive analysis included means with confidence intervals (CIs) 
or medians and ranges, as appropriate. Univariate analysis was performed 
using ANOVA, student’s t-test or where appropriate Mann-Whitney U-test for 
continuous variables and Chi-square tests for categorical variables. Continu-
ous variables were added into the models as continuous variables (except for 
the APSI-score) and log-normalized if data were not normal distributed. The 
APSI-score was analysed as a binary variable, using a cut-off value of 100 
points, based on previous data (18).
To assess the prognostic ability of MR-proADM compared to PCT and other 
conventional biomarkers in predicting the primary and secondary endpoints, 
AUC of ROC-curves were calculated. The main conclusion regarding the pre-
dictive ability of MR-proADM was based on this analysis. For each biomarker 
corresponding positive and negative predictive values and likelihood ratios 
were calculated for standardized cut-off values in predicting the primary 
endpoint. Kaplan-Meier survival curves were generated to illustrate survival 
probability and clinical outcome for different levels of MR-proADM. The log 
rank test was used to test the difference between survival curves. Survival 
analysis was performed on the whole cohort, ROC-analysis and sensitivity 
analysis on the subset of patients with data on the concerning biomarkers 
available. A p-value <0.05 was considered to indicate statistical significance. 
SPSS software (SPSS Inc., Chicago, Ill, version 20.0) was used for statistical 
analysis.
Results
In total 494 patients were randomly selected from our existing database 
resource. There were no significant differences between our study population 
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and the remainder of the database population, except for having a signifi-
cantly older population (p=0.027) with significantly more diabetics (25%; 
p<0.001) in the selected study group (data not shown). Median age of our 
study population was 67 [IQR 49-78] years, 40% were male and 66% had 
co-existing medical conditions. Of 376 patients included at the Emergency 
Department, 329 (88%) were hospitalized. None of the patients recruited in 
primary care were hospitalized. (Table 1).
Table 1. Baseline characteristics of 494 patients presenting with febrile UTI
Characteristic Febrile UTI patients n = 494
Age, median years [IQR] 67 [49-78]
Male sex 198 (40)
Antibiotic pre-treatment 171 (35)
Comorbidity
 Any 325 (66)
 Diabetes mellitus 121 (25)
 Malignancy 56 (11)
 Heart failure 76 (15)
 Cerebrovascular disease 73 (15)
 Chronic obstructive pulmonary disease 77 (16)
 Chronic renal insufficiency 54 (11)
Urologic history
 Urinary tract disordera 126 (26)
 Indwelling urinary catheter 40 (8)
 Recurrent UTIsb 158 (32)
Presentation
 At emergency department 376 (76)
 Shaking chills 290 (59)
 Dysuriac 366 (74)
 Flank pain 283 (57)
 Fever duration at presentation, median hours [IQR] 32 [16-66]
 Heart rate >90 beats/minute 258 (52)
 Systolic blood pressure, mean mmHg ± SD 130 ± 23
 Diastolic blood pressure, mean mmHg ± SD 72 ± 14
Data presented as n (%) unless otherwise stated. UTI=urinary tract infection, IQR=interquartile range, SD=standard 
deviation.
a any anatomical or functional abnormality of the urinary tract except urinary catheter and history of nephroli-
thiasis.
b defined as ≥ 3 UTIs in the past 12 months or ≥ 2 UTIs in the past 6 months.
c not recorded in patients with indwelling urinary catheter.
Willize van der Starre - Binnenwerk - Completeproefv7.indd   100 28-10-15   13:14
101
Biomarkers in febrile UTI
5
In the ED group, 30-day mortality was 3% (n=12) versus an absence of 30-
day mortality in the primary care group. A total of 101 (22%) patients with 
blood cultures taken at presentation (n=463) presented with bacteraemia, 
with significantly more patients in the ED group (n=90/347, 26%, p<0.001). 
Nineteen (5%) of ED patients were admitted to the ICU, of these two died. 
(Table 2).
MR-proADM versus other biomarkers in predicting 30-day mortality
To define the prognostic accuracy of different biomarkers for predicting 
30-day mortality, ROC analyses were performed. The AUC for MR-proADM 
(n=494) was 0.83 (95%CI 0.71-0.94), leukocyte count (n=372): 0.44 
(95%CI 0.26-0.62), ESR (n=158): 0.60 (95%CI 0.43-0.78), CRP (n=319): 
0.59 (95%CI 0.37-0.81) and PCT (n=321): 0.71 (95%CI 0.56-0.85). Based 
on the constructed AUCs, MR-proADM has a higher discriminating accuracy 
for predicting 30-day mortality as compared to the other conventional bio-
markers.
The 97.5th percentile cut-off value of normal provided by the manufacturer 
is 0.55 nmol/L but in our target group this cut-off lacks specificity. Thus, the 
PPV, NPV and likelihood ratios for different MR-proADM cut-off values were 
calculated (Table 3). Our data indicates a plasma MR-proADM level of 1.00 
nmol/L was the optimal cut-off value to stratify 30-day mortality in patients 
with fUTI. Using this cut-off, we calculated a sensitivity of 91.7% with a 
specificity of 48.0%; NPV 99.6%; PPV 4.3%; LR+ 1.8; LR- 0.2 (Table 3).
Table 2. Overview of primary and secondary endpoints in 494 patients with febrile UTI
Endpoint Febrile UTI patients (n= 494)
Bacteraemia at presentationa 101/463 (22)
Hospitalization duration (days), median [IQR] 4 [0-7]
ICU admission 19 (4)
APSI score >100b 77 (16)
Mortality
day 3 2/492 (0.4)
day 30 12/485 (3)
day 90 19/474 (4)
Data are presented in n (%) unless otherwise stated. IQR  =  interquartile range, ICU  =  Intensive Care Unit, 
APSI = Acute Pyelonephritis Severity Index.
a no blood culture performed in 31 patients.
b prediction rule allocating points to age, sex, nursing home residency, comorbidities and vital signs at presenta-
tion; patients with APSI score <100 can be safely treated at home without risk of readmission and mortality.
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Need for hospital admission
In the prediction of need for hospitalization, as based on an APSI score >100 
points, MR-proADM outperformed PCT (n=321 patients with both data avail-
able) given the AUC for MR-proADM of 0.82 (95% CI 0.77-0.88) compared to 
0.69 (95%CI 0.62-0.77) for PCT. For prediction of bacteraemia, MR-proADM 
and PCT performed about equally (MR-proADM: AUC 0.78 (95%CI 0.72-0.85) 
and PCT 0.81 (95%CI 0.75-0.87)). As the predictive values might have been 
influenced by antibiotic (pre)treatment (in 35% of the patients), analysis 
was also done separately in those with and without antibiotics on study 
enrolment (n=113 vs n=208). Corresponding AUCs for MR-proADM were 
0.75 (95%CI 0.65-0.85) and 0.79 (95%CI 0.70-0.88), and for PCT 0.80 
(95%CI 0.71-0.89) and 0.80 (95%CI 0.72-0.88) respectively, indicating that 
antibiotic pretreatment did not alter the predictive value of MR-proADM with 
respect to bacteraemia. In the prediction of either bacteraemia or need for 
hospital admission, CRP, ESR and blood leukocytes lacked predictive power 
(all AUC <0.60). For prediction of the need for ICU admission, pro-ADM and 
PCT performed almost identical (i.e., AUC of 0.77 and 0.75, respectively, 
n=321).
MR-proADM and clinical parameters
In addition to 30-day mortality, median MR-proADM level was significantly 
correlated with bacteraemia (bacteremic versus non-bacteremic patients: 
1.60 [IQR 1.01-3.28] versus 0.96 [IQR 0.61-1.37] nmol/L), need for ICU-
admission (ICU versus non-ICU patients: 2.01 [IQR 1.37-4.61] versus 1.04 
[IQR 0.65-1.50] nmol/L) and APSI score (1.95 [IQR 1.27-2.90] nmol/L in 
patients with a score >100 points versus 0.94 [IQR 0.62-1.36] nmol/L in pa-
tients with a score ≤100 points). Furthermore, MR-proADM levels increased 
with age and were significantly higher in patients with heart failure and 
chronic renal insufficiency.
The Kaplan-Meier curves showed no 30- or 90-day mortality in patients with 
MR-proADM levels in the 1st quartile (n=123) of the whole group. In the 2nd 
quartile (n=124) three events occurred, four in the 3rd quartile (n=124), 
and eleven in the 4th quartile (n=123). All three events in the 2nd quartile 
occurred late in current disease episode: day 16, 27 and 33. One event in 
the 3rd quartile occurred on day 3, the other three occurred late after disease 
onset (day 41, 42 and 66). Events in the 4th quartile occurred primarily in 
the early stage of current disease episode. This suggests that events in the 
2nd and 3rd quartile are likely due to pre-existing co-morbidity, while events 
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in the 4th quartile occur as result of the current active disease (Figure 1). The 
30-day cumulative survival rate was 1.00 in the 1st quartile, 0.98 in the 2nd 
quartile (log rank p =0.157), 1.00 in the 3rd quartile (log rank p 1.00) and 
0.92 in the 4th quartile (log rank p =0.001). The 90-day cumulative survival 
rate was 1.00 in the 1st quartile, 0.98 in the 2nd quartile (log rank p =0.083), 
0.97 in the 3rd quartile (log rank p =0.046) and 0.91 in the 4th quartile (log 
rank p =0.001).
Discussion
The main finding of the present study is that MR-proADM, determined on first 
contact in a patient with presumptive fUTI, predicts a complicated course 
of disease necessitating hospital admission and admission to the ICU, and 








Figure 1. Kaplan-Meier curves of 90-day mortality according to quartiles of mid-regional pro-adreno-
medullin (MR-proADM)
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more accurately predicts outcome than currently used biomarkers. Further-
more, we found significantly higher plasma MR-proADM levels in patients 
presenting with bacteraemia. Given these characteristics, measurement of 
MR-proADM in patients with a presumptive diagnosis of fUTI may provide 
the clinician more accurate guidance than currently applied biomarkers, e.g., 
with respect to admission of high-risk patients, and thus help focus resources 
to the patients that need them most.
Strengths of this study are its prospective design in which fUTI patients were 
included in both primary care and hospital ED setting, reflecting a real-life, 
full spectrum of invasive UTI recognizable to every clinician. Also, the large 
sample size of a clinically and microbiologically well characterized disease 
group is a strength. To our knowledge, this is the first large prospective study 
focusing on the predictive value of MR-proADM in adult patients with fUTI, 
and making a comparison to currently available biomarkers of inflammation 
like PCT and CRP. Travaglino et al. showed that in febrile ED patients, MR-
proADM and PCT levels correlated with APACHE-II score and the combined 
use of both biomarkers might be helpful in predicting hospitaliztation (19).
There are also some limitations. We determined MR-proADM levels once, at 
first contact with the physician. This precludes the analysis whether a rise 
or decline in MR-proADM levels correlates to changes in the clinical course 
of disease, as has been determined for e.g. PCT (20). However, our findings 
show that having a single baseline value can provide clinicians guidance in 
predicting a complicated clinical course at the ED or primary care. This is 
where patients initially present and decisions have to be made regarding 
treatment and hospital admission. When interpreting MR-proADM, it should 
be taken into account that certain patient characteristics like age and heart 
failure may affect the plasma level of MR-proADM, as well as disease duration 
before presentation. A technical limitation might be that the measurement of 
MR-proADM and other biomarkers was done afterwards, and not immediately 
‘at the bedside’. However, it has been shown that frozen storage and conse-
quent freeze-thaw cycles of blood samples has no influence on the analyte 
and measured concentration (15;21). Finally, it should be realized that our 
findings pertain to fUTI and need be confirmed in other infectious conditions. 
Of note, similar findings have been made in other infectious states albeit 
usually in much smaller groups of patients and rarely prospectively (14;22-
25).
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We hypothesize that at least two mechanisms might be responsible for the 
marked increase of MR-proADM in fUTI. In vitro and in vivo studies have 
shown that the onset of inflammation is accompanied by changes in both ADM 
and pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) 
and interleukin-1 (IL-1). Plasma ADM levels are markedly increased in pa-
tients with septic shock, supporting the hypothesis that pro-inflammatory 
cytokines augment ADM production and may increase plasma levels of ADM 
(11;26-28). However, ADM is also capable of upregulation of interleukine-6 
in non-stimulated and LPS-stimulated macrophages, thereby suppressing 
LPS-induced TNF-α production (29). This suggests that ADM acts as part 
of a regulatory loop balancing pro-inflammatory cytokines with its anti-in-
flammatory actions. Since LPS and cytokine levels were not measured in our 
study, we cannot refute or confirm this hypothesis. Secondly, a decreased 
clearance of ADM by the kidneys may be – at least in part – responsible for 
increased proADM levels in fUTI. This is supported by our data with a higher 
median MR-proADM in patients with chronic renal insufficiency and studies 
that have shown a significant correlation between MR-proADM and creatinine 
levels (14;30).
In conclusion, we show that MR-proADM has a strong predictive value for 30-
day mortality in patients with fUTI compared to more conventional biomark-
ers. Next, studies may wish to confirm the selected cut-off value as a predic-
tor of complicated course and evaluate in daily follow up measurements of 
MR-proADM the relationship to treatment and clinical recovery. Such studies 
will establish whether MR-proADM could function as a new prognostic tool 
for guidance in risk stratification and clinical outcome in patients with fUTI.
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Febrile urinary tract infection (UTI) is a common bacterial disease that may 
lead to substantial morbidity and mortality especially among the elderly. 
Little is known about biomarkers that predict a complicated course. Our aim 
was to determine the role of certain urinary cytokines or antimicrobial pro-
teins, plasma vitamin D level, and genetic variation in host defense of febrile 
UTI and its relation with bacteremia.
Methods
A case-control study. Out of a cohort of consecutive adults with febrile UTI 
(n=787) included in a multi-center observational cohort study, 46 cases with 
bacteremic E.coli UTI and 45 cases with non-bacteremic E. coli UTI were 
randomly selected and compared to 46 controls. Urinary IL-6, IL-8, LL37, 
β-defensin 2 and uromodulin as well as plasma 25-hydroxyvitamin D were 
measured. In 440 controls and 707 UTI patients polymorphisms were geno-
typed in the genes CXCR1, DEFA4, DEFB1, IL6, IL8, MYD88, UMOD, TIRAP, 
TLR1, TLR2, TLR5 and TNF.
Results
IL-6, IL-8, and LL37 are different between controls and UTI patients, al-
though these proteins do not distinguish between patients with and without 
bacteremia. While uromodulin did not differ between groups, inability to 
produce uromodulin is more common in patients with bacteremia. Most 
participants in the study, including the controls, had insufficient vitamin D 
and, at least in winter, UTI patients have lower vitamin D than controls. 
Associations were found between the CC genotype of IL6 SNP rs1800795 and 
occurrence of bacteremia and between TLR5 SNP rs5744168 and protection 
from UTI. The rare GG genotype of IL6 SNP rs1800795 was associated with 
higher β-defensin 2 production.
Conclusion
Although no biomarker was able to distinguish between UTI with or without 
bacteremia, two risk factors for bacteremia were identified. These were in-
ability to produce uromodulin and an IL6 rs1800795 genotype.
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Introduction
Urinary tract infection (UTI) is one of the most common bacterial infections 
and has a high risk of recurrence. The predominant causal pathogen is uro-
pathogenic Escherichia coli and it is thought that innate immune responses 
to this pathogen can both control and predispose to subsequent recurrence 
of UTI [1]. Although UTI by itself rarely causes significant complications, 
fever indicates the presence of tissue inflammation that can be accompanied 
with bacteremia and the urosepsis syndrome that may eventually lead to 
septic shock and death [2].
We have set up a large prospective multicenter cohort study to investigate 
various aspects of febrile UTI [3–5]. In this study we focus on urinary mark-
ers of host defense, plasma vitamin D and the role of genetic variation.
The cytokines IL-6 and IL-8 are mediators of inflammation in response to 
bacterial infection, and when measured in plasma or serum these may be 
used as early biomarkers of infection. IL-6 and IL-8 levels are also known to 
be elevated in the urine of patients with UTI, whereas reportedly none are 
measurable in the urine of healthy controls [6–10].
The human body produces several antimicrobial proteins, amongst others 
cathelicidin LL37 and β-defensins, that are part of our first line defense 
against bacterial infections. These antimicrobial proteins are produced by 
epithelial cells, including those of the urinary tract [11,12]. Urinary cathelici-
din is elevated in children with pyelonephritis [11] and was recently reported 
to be also elevated in adult women during UTI [13]. Whether the amounts of 
cathelicidin or β-defensin produced in the urine of UTI patients is associated 
with disease severity such as bacteremia is unknown.
Uromodulin (also known as Tamm Horsfall protein) is the most abundant 
urinary protein in mammals. It adheres to fimbriae of uropathogenic E. coli, 
thus preventing its attachment to the epithelium. Uromodulin also has an im-
munomodulatory function [14]. In young women with recurrent UTI urinary 
uromodulin concentrations were similar to those in healthy controls [15]. 
Whether uromodulin lowers the risk for developing febrile UTI or associated 
bacteremia is unknown.
Vitamin D is known to play an important role in the first defense against bac-
terial infections; e.g. by induction of the antimicrobial proteins cathelicidin 
and β-defensin. High prevalence of vitamin D deficiency and insufficiency 
have been reported in elderly people (≥ 65 years) in the Netherlands [16,17] 
just as in many other regions around the world [18]. It has been shown in 
in vitro experiments that bladder epithelium from women taking vitamin D 
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supplements are capable of producing larger amounts of cathelicidin upon 
infection [19]. Thus vitamin D deficiency is believed to be an attributable 
factor in host susceptibility to UTI as has also been suggested in a recent 
case-control study [20]. Whether vitamin D status of UTI patients affects 
cathelicidin and β-defensin production in urine and the occurrence of bacte-
remia is unknown.
Many studies have found that host genetic factors influence susceptibility to 
human infectious diseases [21,22]. Also in UTI genetic factors likely play a 
role, as illustrated by the finding that positive family history is a risk factor 
for recurrent UTI [23] and reviewed in [1]. Studies evaluating the role of 
genetic factors in UTI were mainly performed in children [24–29]. No studies 
have investigated the contribution of host genetic factors to the development 
of UTI complicated by bacteremia.
The aims of the current study were: first, to investigate the production of 
cytokines and antimicrobial proteins in the urine of UTI patients in order to 
determine whether any of these proteins are risk factors for febrile UTI or 
predictive biomarkers for bacteremia; second, to determine whether plasma 
vitamin D is correlated with urinary protein production or clinical outcome; 
and third, to determine whether there is a correlation between genetic vari-
ants and the production of any of the proteins or occurrence of bacteremia.
Materials and Methods
Patients and controls
We conducted a prospective observational multi-center cohort study. Patients 
were recruited from 35 family practices and emergency departments of eight 
hospitals in the region. Consecutive patients (n=787) with a presumptive 
diagnosis of febrile UTI were considered for enrollment and those who met 
the entry criteria and provided written informed consent were included. In-
clusion criteria for the patients were: age ≥18 years, fever (≥38.0°C) and/or 
a history of fever and chills within 24 hours before presentation, at least one 
symptom of UTI (dysuria, increased urination frequency, urgency, perineal 
pain, flank pain or costovertebral tenderness) and a positive nitrite dipstick 
test or leukocyturia as defined by a positive leukocyte esterase dipstick test 
or the presence of more than five leukocytes per high-power field (pyuria) 
in a centrifuged sediment. Exclusion criteria were: pregnancy, hemodialysis 
or peritoneal dialysis, a history of kidney transplantation, known presence 
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of polycystic kidney disease or current treatment for urolithiasis or hydrone-
phrosis. From the patients with E. coli as the causal uropathogen 45 patients 
without bacteremia and 46 with bacteremia were randomly selected for the 
plasma and urine measurements (Figure 1). Controls (n=369) were recruited 
from the same primary healthcare centers and emergency departments if 
they were aged ≥18 years, had no symptoms of UTI, and provided written 
informed consent. Of these controls included from the primary health care 
centers, 46 non-febrile individuals were randomly selected for the plasma 
and urine measurements (Figure 1). The study was approved by the Medical 
Ethics Committee of the Leiden University Medical Center (approval number 
P08.065). Blood and urine samples were taken before the start of antimi-
crobial treatment. Plasma and urine were stored at -80°C within two hours 
after enrollment. Blood and urine cultures were analyzed using standard 
microbiological methods. DNA was isolated from white blood cells by a salt-
ing out method essentially as described [30] and stored at -20°C.
Figure 1. Selection of UTI patients and controls for the urine and plasma measurements
* and/or a history of fever and chills within 24 hours before presentation.
# symptoms of UTI: dysuria, increased urination frequency, urgency, perineal pain, flank pain or costovertebral 
tenderness.
^ urinary infection as determined by a positive nitrite dipstick test or leukocyturia as defined by a positive leuko-
cyte esterase dipstick test or the presence of more than five leukocytes per high-power field (pyuria) in a centri-
fuged sediment.
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Measuring proteins in urine
Protein specific enzyme-linked immunosorbent assays (ELISA) were used to 
determine concentrations in urine essentially according the manufacturer’s 
protocol with minor modifications. Urine samples were diluted two and ten 
times for the IL-6 ELISA, eight and 64 times for the IL-8 ELISA (Biosource). 
The detection limit of both ELISAs was 30 pg/ml. Urine samples were diluted 
four and 32 times for the LL37 ELISA (Hycult Biotechnology), the detection 
limit was 2 ng/ml. Urine samples were diluted four and 32 times for the 
β-defensin 2 ELISA (Antigenix America Inc), the detection limit was 10 pg/
ml. Urine samples were diluted 200 and 400 times for the Uromodulin ELISA 
(MD Bioproducts), the detection limit was 20 ng/ml. Optical densities were 
determined at 450 nm in an iMark microplate reader (Bio-Rad).
In order to account for the gravity of the urine, protein concentrations were 
divided by the urine creatinine concentration. Urinary concentrations of cre-
atinine were measured with the CREA plus (Cobas) enzymatic assay in an 
automated clinical chemistry analyzer.
Vitamin D assay
The concentration of 25-hydroxyvitamin D (25(OH)D) was determined in 
plasma by a competitive electrochemiluminescence immunoassay (ECLIA), 
essentially according to the manufacturer’s protocol (Elecsys Vitamin D Total 
assay, Roche Diagnostics). Based on consensus in the literature [31] we 
defined vitamin D deficiency as a plasma 25(OH)D concentration ≤20 ng/ml, 
relative vitamin D insufficiency at plasma 25(OH)D concentrations between 
20 and 30 ng/ml, and all concentrations ≥30 ng/ml as sufficient.
Genotyping
Of the 787 enrolled patients, 707 were included in the genotyping assays (of 
80 samples DNA was not isolated or of low quality), as well as 440 controls 
(369 controls from the cohort study as well as anonymous controls). Genotyp-
ing of polymorphisms was performed by use of a Sequenom MassArray plat-
form according to the manufacturer’s protocols (Sequenom, San Diego, USA). 
Multiplex assays were designed with Assay designer software (Sequenom). In 
brief, after a multiplex PCR on 5 ng of DNA, a primer extension reaction was 
performed to introduce mass-differences between alleles and, after removing 
salts by adding a resin, 15 nl of the product was spotted onto a target chip 
with 384 patches containing matrix. Mass differences were detected using a 
Bruker Autoflex MALDI-TOF mass spectrometer and genotypes were assigned 
real-time using Typer 3.1 software (Sequenom). Several samples representing 
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the various genotypes were sequenced to confirm the genotyping results. As 
quality control, 10% of samples were genotyped in duplo; no inconsistencies 
were observed. Primer and probe sequences can be found in Table 1.
Statistical analyses
All data were entered in an SPSS database (SPSS Inc., Chicago, IL, USA; 
version 20.0) for statistical analysis. Graphs were generated using GraphPad 
Prism (GraphPad Software Inc., San Diego, California, USA; version 5.01). 
Descriptive analysis included medians and ranges, or means or percent-
ages with standard deviation (sd), as appropriate. Univariate analysis was 
performed using the Student’s t–test, the Kruskal-Wallis test or the Mann–
Whitney U-test for continuous variables and the Pearson Chi-Square test for 
categorical variables. Measures for association were expressed as odds ratios 
(ORs) with their 95% confidence intervals (CI) for categorical variables.
Results
Description of patients and controls for urine and plasma measurements
During the study period, 787 patients with febrile UTI were enrolled. E. coli 
was the most frequent causal uropathogen, present in 420 (53%) of the 
patients. From these, 45 patients without bacteremia and 46 patients with 
bacteremia were selected and compared to 46 controls (Figure 1). Controls 
had a median age (58 years, IQR 49-75) comparable to UTI patients without 
bacteremia (63 years, IQR 46-75), but significant lower than UTI patients with 
bacteremia (73 years, IQR 60-82). The groups were comparable with respect 
to sex, BMI, use of immunosuppressants and vitamin D supplements. Further 
baseline characteristics of the study population are summarized in Table 2.
Cytokines in urine do not distinguish between patients with our 
without bacteremia
The production of the cytokines IL-6 and IL-8 was determined in urine samples 
from 44 UTI patients without bacteremia, 45 UTI patients with bacteremia 
and 46 controls. IL-6 was detected in 30 of all 89 (34%) UTI patients, in 12 of 
44 (27%) without bacteremia and in 18 of 45 (40%) with bacteremia, and in 
none of the controls. Due to the large number of samples with undetectable 
IL-6 in each group, the median IL-6 concentrations were the same in the three 
groups. Both patient groups are significantly different from the controls (each 
p<0.001) but not significantly different from each other (p= 0.21) (Figure 2A).
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IL-8 was detected in 77 of all 89 (87%) UTI patients, in 34 of 44 (77%) 
without bacteremia and in 43 of 45 (96%) with bacteremia, and in only four 
of the 46 controls (9%). The median value of the controls is 0.1 pg IL-8 /
µmol creatinine, of the UTI patients without bacteremia 91 pg/µmol and of 
those with bacteremia 232 pg/µmol. Both patient groups are significantly 
different from the controls (each p<0.0001) but not significantly different 
from each other (p= 0.06) (Figure 2B).
A positive correlation was demonstrated between IL-8 production and age 
(r=0.302, p<0.001), IL-6 production (r=0.534, p<0.001), and temperature 
at onset (r=0.516, p<0.001). IL-8 was not correlated with presence of uri-
nary tract disorders, recurrent UTIs or antibiotic pre-treatment.
Antimicrobial proteins in urine do not correlate with bacteremia
The antimicrobial protein β-defensin 2 was detected in 23 of all 89 (26%) UTI 
patients, in 10 of 44 (23%) with bacteremia and in 13 of 45 (29%) without 
bacteremia, and in five of the 46 controls (11%). Due to the large number 
of samples with undetectable β-defensin 2 in each group, the median con-
centrations were similar in the three groups. Only the UTI patient group with 
bacteremia was significantly different from the controls (p<0.05) (Figure 3A).
Urinary β-defensin 2 showed no correlation with age, IL-8 production and 
temperature at onset. The β-defensin 2 was also not correlated with presence 
of urinary tract disorders, recurrent UTIs or antibiotic pre-treatment.
Cathelicidin LL37 was detectable in 53 of all 89 (60%) UTI patients, in 23 
of 44 (52%) without bacteremia and in 30 of 45 (67%) with bacteremia, 
and in two of the 46 controls (4%). The median value of the controls is 
below the detection limit, of the UTI patients without bacteremia it is 1.2 
ng LL37/µmol creatinine and of those with bacteremia 2.6 ng/µmol. Both 
patient groups are significantly different from the controls (each p<0.0001) 
but not significantly different from each other (p= 0.23) (Figure 3B). LL37 
showed no difference in the presence of urinary tract disorders, recurrent 
UTIs and antibiotic pretreatment.
Lack of uromodulin in urine increases risk of bacteremia
Uromodulin was detectable in 78 of all 89 (88%) UTI patients, in 42 of 44 
(95%) without bacteremia and in 35 of 45 (78%) with bacteremia, and in 
42 of the 46 (91%) controls. The median value of the controls is 2366 ng 
uromodulin /µmol creatinine, of the UTI patients without bacteremia it is 
1941 ng/µmol and of those with bacteremia 1851 ng/µmol. The uromodulin 
production is not significantly different between the groups (Figure 3C).
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Most people produce uromodulin in the urine regardless of infection and it 
appears that inability to produce any uromodulin is more common in the 
patients with bacteremia than in patients without bacteremia (p=0.015). The 
odds ratio for developing bacteremia for UTI patients who do not produce 
uromodulin is 6.0 (95% CI: 1.2-29.2).
Uromodulin showed no correlation with blood leukocyte count, age, IL-8 or 
temperature at onset. Also, uromodulin did not differ in the presence of leu-
kocyturia, urinary tract disorders, recurrent UTIs or antibiotic pre-treatment.
Most participants in the study had insufficient vitamin D levels
Plasma 25(OH)D was measured in 46 controls, 43 UTI patients without 
bacteremia and 44 UTI patients with bacteremia. All groups had comparable 
median plasma 25(OH)D concentrations (Figure 4A and Table 3).
Figure 2. IL-6 or IL-8 concentrations do not distinguish UTI patients with bacteremia from those without 
bacteremia
IL-6 (Figure 2A) and IL-8 (Figure 2B) concentrations were determined in the urine of 46 controls (CON), 44 cases 
with febrile UTI without bacteremia (UTI–B), and 45 cases with febrile UTI with bacteremia (UTI+B). Cytokine con-
centrations depicted were corrected for urine gravity, for samples below the detection limit the corrected cytokine 
concentration was set to 0.1. Solid bars represent medians, for statistical analysis a Mann-Whitney test was used.
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Age in years, median [IQR] 58 [49 - 75] 63 [46 - 75] 73 [60 - 82]
Male sex 18 (39) 16 (36) 18 (39)
Comorbidity
Any 24 (52) 33 (73) 36 (78)
 Urinary tract disorder a 5 (11) 10 (22) 9 (20)
 Urinary catheter 0 (0) 2 (4) 3 (7)
 History of nephrolithiasis 5 (11) 4 (9) 5 (11)
 Recurrent UTIs b 1 (2) 16 (36) 6 (13)
 Diabetes mellitus 3 (7) 5 (11) 12 (26)
 Malignancy 2 (4) 2 (4) 4 (9)
 Hypertension 17 (37) 24 (53) 26 (57)
 Heart failure 0 (0) 5 (11) 8 (17)
 Cerebrovascular disease 1 (2) 5 (11) 12 (26)
 Chronic renal insufficiency 0 (0) 3 (7) 6 (13)
 COPD 2 (4) 7 (16) 3 (7)
Medication
 Immunosuppressants 1 (2) 1 (2) 4 (9)
 Vitamin D supplements 2 (4) 4 (9) 4 (9)
Season of inclusion
 Winter (Dec - Feb) 46 (100) 8 (18) 5 (11)
 Spring (Mar - May) - 6 (13) 10 (22)
 Summer (June - Aug) - 11 (24) 17 (37)
 Fall (Sept - Nov) - 20 (44) 14 (30)
BMI c
 Mean BMI in kg/m2 (sd) 26.5 (4.6) 26.6 (4.0) 27.3 (7.2)
Data are presented as n (%) unless otherwise stated. UTI  =  urinary tract infection, IQR  =  interquartile range, 
sd = standard deviation, COPD = chronic obstructive pulmonary disease, BMI = body mass index. a Defined as any 
functional or anatomical abnormality of the urinary tract except urinary catheter and history of nephrolithiasis.
b Defined as ≥2 UTIs in the last 6 months or ≥3 UTIs in the last 12 months. c Eight missing BMI data: 2 in controls, 1 
in UTI without bacteremia and 5 in UTI with bacteremia.







Median 25(OH)D in ng/ml [IQR] 17.6 [13.9 - 26.4] 19.5 [14.1 - 26.1] 17.9 [9.4 – 24.7]
vitamin D sufficient 6 (13%) 6 (14%) 8 (18%)
vitamin D insufficient 14 (30%) 15 (35%) 11 (25%)
vitamin D deficient 26 (57%) 22 (51%) 25 (57%)
UTI= urinary tract infection, IQR = interquartile range. Vitamin D sufficiency is defined as 25(OH)D of ≥30 ng/ml, 
vitamin D insufficiency is defined as 25(OH)D  >20 and  <30 ng/ml, vitamin D deficiency is defined as 25(OH)D 
of ≤ 20 ng/ml.
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Of the 133 individuals analysed, only 22 (17%) had a sufficient vitamin D 
level. More than half (n=73, 55%) had a vitamin D deficiency, while severe 
vitamin D deficiency (with 25(OH)D ≤10 ng/ml) was found in 25 participants 
(19%): 5 controls (11%), 8 UTI patients without bacteremia (19%) and 12 
UTI patients with bacteremia (27%). Because vitamin D concentrations vary 
by season, we examined the effect of seasonal variation on our findings. 
All controls were recruited in winter. Patients with UTI were included in all 
seasons: 58 (44%) in winter, 16 (12%) in spring, 27 (20%) in summer and 
32 (24%) in fall. The vitamin D concentration was significantly lower in UTI 
patients recruited in winter than in other seasons. More importantly, the 
controls that were all recruited in winter had a higher vitamin D concen-
tration compared to cases recruited in winter (17.6 [IQR 13.9-26.4] ng/ml 
vs. 13.0 [IQR 6.9-17.3] ng/ml, p=0.015) (Figure 4B). Cathelicidin LL37 (r= 
-0.69, p=0.436) and β-defensin 2 (r= -0.003, p=0.969) in the urine were 
not correlated with plasma vitamin D.
Figure 3. Antimicrobial protein concentrations do not distinguish UTI patients with bacteremia from those 
without bacteremia
Concentrations of the antimicrobial proteins β-defensin 2 (A) Cathelicidin LL37 (B) and Uromodulin (C) were deter-
mined in the urine of 46 controls (CON), 44 febrile UTI cases without bacteremia (UTI–B), and 45 febrile UTI cases 
with bacteremia (UTI+B). Protein concentrations depicted were corrected for urine gravity, for samples below the 
detection limit the corrected protein concentration was set to 0.1 (β-defensin 2, Cathelicidin LL37) or 10 (Uro-
modulin). Solid bars represent medians, for statistical analysis the Mann-Whitney U test was used.
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Distribution of genetic variation in cases and controls
In most infectious diseases, in addition to exposure, strain virulence and en-
vironmental factors, genetic host variations also play a role in susceptibility 
to disease. To determine whether genetic variations attribute to susceptibil-
ity to febrile UTI, we genotyped 15 single nucleotide polymorphisms (SNPs) 
in 12 genes of 440 controls and 707 febrile UTI patients (Table 4). All SNPs 
were in Hardy Weinberg equilibrium in the controls.
None of the SNP alleles (data not shown) or genotypes were found to be 
associated with susceptibility to febrile UTI when analyzing controls versus 
patients (Table 4). Because the presence of urinary tract disorders or chronic 
renal insufficiency may mask genetic effects we re-analyzed the data after 
exclusion of individuals with known urinary tract disorders or chronic renal 
insufficiency. This revealed that the TLR5 SNP rs5744168 was significantly 
Figure 4. Plasma vitamin D concentrations in controls and UTI patients
Plasma 25(OH) vitamin D concentrations were determined in 46 controls (CON) and 43 UTI patients without bac-
teremia (UTI-B) and 44 UTI patients with bacteremia (UTI+B) (A). Analysis of plasma 25(OH)D vitamin D concentra-
tions according to season of sampling (B). All controls were recruited in winter. 12 UTI patients were recruited in 
winter, 16 in spring, 27 in summer and 32 in autumn. Solid bars represent median concentrations; dotted lines 
represent upper limit of vitamin D deficiency (≤20 ng/ml) and lower limit of vitamin D sufficiency (≥30 ng/ml). The 
Mann-Whitney U test was used to determine whether groups were statistically different.
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genotypes, n (%) p-value
CXCR1 rs3138060 217C>G CC 380 (87.6%) 623 (88.3%) 0.581
in intron CG 52 (12.0%) 82 (11.6%)
GG 2 (0.4%) 1 (0.1%)
CXCR1 rs2234671 2608 G/C* GG 379 (87.1%) 620 (88.0%) 0.574
Ser276Thr CG 54 (12.4%) 84 (11.9%)
CC 2 (0.5%) 1 (0.1%)
DEFA4 rs28661751 A8P CC 427 (98.4%) 700 (99.3%) 0.373
CG 7 (1.6%) 6 (0.7%)
GG 0 0
DEFA4 rs736227 in 3’UTR TT 196 (45.4%) 324 (46.1%) 0.962
CT 196 (45.4%) 313 (44.5%)
CC 40 (9.2%) 66 (9.4%)
DEFB1 rs1800972 -44C>G* CC 264 (60.8%) 426 (60.4%) 0.450
-668C>G* CG 147 (33.9%) 252 (35.7%)
GG 23 (5.3%) 27 (3.8%)
IL6 rs10499563 -6331T>C* TT 277 (63.8%) 403 (57.4%) 0.100
CT 141 (32.5%) 269 (38.3%)
CC 16 (3.7%) 30 (4.3%)
IL6 rs1800795 -174G>C* GG 147 (33.7%) 249 (35.2%) 0.711
CG 209 (47.9%) 340 (48.2%)
CC 80 (18.4) 117 (16.6%)
IL8 rs4073 -251A/T* TT 130 (29.9%) 207 (29.4%) 0.985
AT 212 (48.7%) 346 (49.1%)
AA 93 (21.4%) 151 (21.5%)
MYD88 rs6853 in 3’UTR AA 331 (76.6%) 551 (78.6%) 0.120
AG 92 (21.3%) 145 (20.7%)
GG 9 (2.1%) 5 (0.7%)
UMOD rs4293393 5’ near gene TT 286 (65.9%) 460 (65.2%) 0.354
CT 127 (29.3%) 220 (31.1%)
CC 21 (4.8%) 26 (3.7%)
TIRAP rs8177374 S180L* CC 310 (71.1%) 498 (70.0%) 0.995
C539T* CT 116 (26.6%) 189 (26.7%)
TT 10 (2.3%) 16 (2.3%)
TLR1 rs5743618 1805 G/T* GG 179 (42.0%) 315 (45.4%) 0.379
S602I* GT 193 (45.3%) 285 (41.1%)
TT 54 (12.7%) 94 (13.5%)
TLR2 rs5743708 Arg753Gln* GG 408 (93.2%) 662 (93.8%) 0.773
R753Q* AG 30 (6.8%) 44 (6.2%)
AA 0 0
TLR5 rs5744168 R392X* CC 363 (84.2%) 626 (89.0%) 0.072
Arg392Stop* CT 63 (14.6%) 72 (10.2%)
1174C>T* TT 5 (1.2%) 6 (0.8%)
TNF rs1800629 -308 G/A* GG 282 (64.6%) 486 (68.8%) 0.170
in promoter AG 144 (33.0%) 197 (27.9%)
AA 11 (2.5%) 23 (3.3%)
* name used in the literature
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different between patients and controls (p=0.011). In addition we analyzed 
the distribution of genotypes between UTI patients with and those without 
bacteremia. The distribution of one SNP, rs1800795 in the gene IL6, was sig-
nificantly different as the genotype CC is more common among UTI patients 
with bacteremia (p= 0.009) (Table 5).
The production of proteins can often be correlated to genetic variations in 
for instance the promoter region or translation start site. Most individuals 
in which urinary protein concentrations were measured in this study were 
also genotyped, therefore we were able to investigate whether any of the 
genotypes were correlated to urinary protein production. A significant differ-
ence in β-defensin 2 production was found between the DEFB1 rs1800972 
genotypes, as most individuals with an CC or CG genotype did not produce 
β-defensin 2 while the three individuals with an GG genotype did (p=0.0002) 
(Figure 5). No significant correlations were found between other genotypes 
and protein production (data not shown).





bacteremia, n (%) p-value
IL6 rs1800795 CC 76 (15.0%) 37 (23.9%) 0.009
CG 257 (50.9%) 57 (36.8%)
GG 172 (34.1%) 61 (39.3%)
Figure 5. β-defensin 2 production is associated 
with a DEFB1 genotype
Concentration of the antimicrobial protein 
β-defensin 2 grouped per DEFB1 rs1800972 
genotype, the groups are significantly different 
(p=0.0002). Protein concentrations were corrected 
for urine gravity, for samples below the detection 
limit the corrected cytokine concentration was set 
to 0.1. Solid bars represent medians, for statistical 
analysis the Kruskal-Wallis test was used.




We analyzed various proteins in urine of UTI patients and controls from a 
prospective cohort study and found that while IL-6, IL-8 and cathelicidin 
LL37 are different between UTI patients and controls, these proteins, as well 
as β-defensin 2, cannot be used as biomarkers for bacteremia. We did find 
that while uromodulin production is in general not different between patients 
and controls, complete absence of uromodulin production in the urine is a 
strong risk factor for bacteremia. In addition we found that plasma vitamin 
D may have a protective effect against UTI as, at least in winter, vitamin D 
is lower in UTI patients compared to controls.
The strength of this study is that we have collected the largest prospective 
UTI cohort thus far with a clinically and microbiologically well-characterized 
disease group. Our emphasis in the analyses was on the identification of 
host defense risk factors for febrile UTI and predictive markers for bacte-
remia. Therefore we determined urinary proteins and plasma vitamin D in 
91 patients (of which 46 had bacteremia) and 46 controls, and genotyped 
polymorphisms in genes thought to play a role in UTI in a large number 
of patients (n=707) and controls (n=440). The three groups of individuals 
in which urinary proteins and plasma vitamin D were determined were in 
general well matched, except for age which was higher in patients with UTI 
and bacteremia.
In general, IL-6 and IL-8 levels are elevated in the urine of patients with UTI 
and children with acute pyelonephritis, whereas none are measurable in the 
urine of controls [6–10]. This study confirms that IL-6 and IL-8 are elevated 
in UTI patients; we did however also find four controls that produced IL-8. 
One of the controls had asymptomatic bacteriuria; for the other three it is 
unclear why they produce IL-8. Production of IL-8 has also occasionally been 
observed in healthy children [8,9]. While IL-6 and IL-8 are good biomarkers 
for infection, we found that they cannot distinguish between patients with 
or without bacteremia. In a Swedish study a significant difference in IL-6 
production was found between bacteremic and non-bacteremic patients, 24 
hours after inclusion [32]. In that study, UTI patients were all hospitalized, 
suggesting they had far more severe clinical symptoms than our patients 
who were largely recruited at family practices. In addition, similar to the 
samples in our cohort, at inclusion IL-6 production in the Swedish patients 
was not significantly different between patients with or without bacteremia 
[32].
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As previously reported in children and adults with UTI [11,13], we also found 
that urinary cathelicidin LL37 is elevated in adults with UTI and appears to 
be a biomarker for infection. Cathelicidin LL37 was however not different 
between patients with and without bacteremia, making it unsuitable as a 
biomarker for bacteremia.
β-defensin 2 has been previously shown by RT-PCR and immunohistochemis-
try to be produced in kidneys from patients with chronic upper UTI undergo-
ing nephrectomy but not in normal kidneys [12]. In addition it was reported 
that β-defensin 2 mRNA transcription by renal tubular cells in vitro could be 
upregulated by E. coli [33]. We determined the β-defensin 2 protein produc-
tion by ELISA and found that β-defensin 2 was detectable in the urine of a 
minority of both controls and patients and did not differ between them. There 
was also no difference in β-defensin 2 production between patients with or 
without bacteremia, making it unsuitable as a biomarker for bacteremia.
Nitschke et al observed that stimulation with IL-6 did not affect β-defensin 
2 production in renal tubular cells [33].We determined whether there was 
a relation between IL-6 and β-defensin 2 in urine. 30 out of 89 patients 
produce IL-6 and 23 out of 89 patients produce β-defensin 2 while only six 
produce both, which is even slightly less than the expected number (eight) 
if they are not correlated. This suggests that these two proteins are not 
induced by the same stimuli.
Uromodulin is known to be produced constitutively in urine and was pre-
viously reported not to be correlated with recurrent UTI in young women 
[15]. We found that the production also did not differ between the elderly 
patients and controls in our cohort or between patients with or without bac-
teremia. We did however observe that the inability to produce uromodulin 
in the urine greatly increased the risk of developing bacteremia (OR 6.0, 
95% CI: 1.2-29.2). Uromodulin is produced in the thick ascending loop of 
Henle and secreted into the urine via proteolytic cleavage. It is a known 
biomarker for kidney disease [34]. Of the 16 individuals who did not produce 
detectable uromodulin only a few had a condition that affected the kidneys: 
two patients with bacteremia had chronic kidney insufficiency and one other 
had urothelial cell carcinoma. One control had only one kidney but that in 
itself does not explain the lack of uromodulin production. Lack of uromodulin 
production in the urine appears to be a valuable biomarker for bacteremia in 
vulnerable UTI patients.
The majority of the individuals in our study had, according to commonly used 
standards [31], insufficient vitamin D in their blood, while severe vitamin D 
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deficiency was found in many as well. However, there is still debate about 
the definition of vitamin deficiency [35] but regardless of the criteria used 
we found comparable median plasma vitamin D concentrations between 
the three groups. Unfortunately, all samples for vitamin D measurement in 
controls were recruited in winter. That may mask a difference between UTI 
patients and controls. When comparing controls with patients recruited in 
the same season, controls had significantly higher plasma vitamin D. Previ-
ously, low vitamin D levels were shown to be associated with bacterial and 
viral infections [36]. A recent study also showed that vitamin D levels in 
patients with recurrent UTI were found to be lower than in controls [20]. 
However, in that study it was unclear whether recruitment of cases and con-
trols were equally distributed upon the different seasons. Based on in vitro 
experiments with bladder biopsies from women before and after vitamin D 
supplementation it has been suggested that the protective effect of vitamin 
D against UTI may be through the regulation of cathelicidin LL37 production 
in the bladder [19]. In this respect, one might expect that higher vitamin 
D levels might to some extent have a protective effect against invasive UTI 
and bacteremia via cathelicidin. We however did not find an association of 
plasma vitamin D with urinary cathelicidin LL37. Furthermore, there was no 
association between either vitamin D level or urinary cathelicidin LL37 with 
the presence of bacteremia.
We selected fifteen polymorphisms in genes with a known role in the rec-
ognition, the defense, or immune response to uropathogens (TLR1, TLR2, 
TLR5, TIRAP, MYD88, IL6, IL8, DEFA4, DEFB1, UMOD, CXCR1, TNF). None of 
the alleles or genotypes was associated with febrile UTI when analyzing all 
controls versus all patients. Because the presence of urinary tract disorders 
or chronic renal insufficiency may mask genetic effects we re-analysed these 
data after exclusion of individuals with known urinary tract disorders or 
chronic renal insufficiency. This revealed an association between TLR5 SNP 
rs5744168 and protection from UTI. The same SNP was previously found 
to be associated with increased susceptibility to recurrent UTI in Caucasian 
American women (339 recurrent UTI, 321 pyelonephritis, 317 controls) [26]. 
The discrepancy in the allele associated with protection from UTI suggests 
that the TLR5 SNP is not itself the functional variant causing the protective 
effect but rather linked to a functional variation in the vicinity. The different 
genetic backgrounds in the two studies may cause the functional variant to 
co-segregate with different alleles. The TLR5 polymorphism is also a lot more 
common in our population than in the Caucasian American population (CT 
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and TT 15.8% in our controls vs 7.4% in the Caucasian American controls) 
thus revealing a difference in distribution. More SNPs in and around TLR5 
need to be analyzed to pinpoint the causal variation.
Various other genetic variations have also been reported to be associated 
with protection from, or the risk of developing UTI [27]. We analyzed several 
of these but none were associated with febrile UTI in our cohort: the TLR2 
polymorphism Arg753Gln that was associated with UTI in Turkish children 
(124 patients, 116 controls) [24], the TLR1 1805T allele that was associated 
with pyelonephritis in Caucasian American women (339 recurrent UTI, 321 
pyelonephritis, 317 controls) [26] and five CXCR1 polymorphisms (of which 
we tested two) that were associated with acute pyelonephritis in a Swedish 
cohort (60 patients, 226 controls) [37]. These associations have thus far not 
been confirmed in other independent cohorts either. The lack of association 
in our cohort may be due to a difference in genetic background or due to the 
selection of elderly patients in our cohort, as at an elderly age comorbidity 
and an aging immune system may have more effect on susceptibility to UTI 
than subtle genetic variations. We analyzed the largest cohort so far (440 
controls and 707 patients) therefore the power to detect an association (if 
present) is greater than in the other cohorts.
We found one polymorphism, the IL6 SNP rs1800795, specifically the CC 
genotype, to be associated with development of bacteremia. This SNP is 
located in the promoter of IL6 and is known to affect the IL-6 concentra-
tion in blood plasma, with the GG genotype producing more IL-6 [38,39]. 
Unfortunately, because not enough individuals produce IL-6 in their urine 
we were unable to determine whether the GG genotype is also correlated 
with IL-6 production in urine. It is however likely that the CC genotype 
increases susceptibility to UTI due to low IL-6 production. In one study, a 
significantly higher urinary IL-6 production was found in bacteremic than 
in non-bacteremic patients, at 24 hr after inclusion [32]. In that study it 
was also found that IL-6 response kinetics were different in bacteremic and 
non-bacteremic patients, with IL-6 in non-bacteremic patients peaking early 
and declining afterwards while IL-6 in bacteremic patients peaks late and 
stays high [32]. It would be interesting to determine whether these response 
kinetics are under genetic control. In mouse models of bladder infection 
with uropathogenic E. coli, transcription of the il6 gene was found to be 
very highly upregulated at 2 hr and moderately upregulated at 24 hr after 
infection, with response kinetics varying between mouse strains, suggesting 
genetic control [40]. In addition, the causative uropathogen was also found 
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to influence the response kinetics, with group B streptococcus inducing a far 
less pronounced response than E. coli [41].
In conclusion, we did not identify a convenient biomarker that will allow us 
to distinguish between patients with or without bacteremia. We did find a 
risk factor, lack of uromodulin, that is present in few patients but greatly in-
creases their risk of developing bacteremia. In addition we identified several 
modest genetic associations, especially between TLR5 SNP rs5744168 and 
UTI and between IL6 SNP rs1800795 and occurrence of bacteremia.
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Inhibition of tissue factor, the primary initiator of coagulation in sepsis, at-
tenuates morbidity in primates infused with Escherichia coli. In a human 
endotoxemia model, microparticles expressing procoagulant TF (MP-TF) are 
released in blood concurrently with markers of inflammation and coagula-
tion. We investigated whether the release of MP-TF into blood is accompanied 
by procoagulant and inflammatory changes in patients with E. coli urinary 
tract infection.
Materials and methods
In a multicenter cohort study, we determined clinical disease severity us-
ing APACHE II scores and measured plasma MP-TF activity, TAT, sE-selectin, 
sVCAM-1, procalcitonin and monocyte count in blood of 215 patients with 
community-acquired febrile E. coli urinary tract infections.
Results
Plasma MP-TF activity on admission corresponded with clinical disease sever-
ity (APACHE II score; P=0.006) and correlated significantly but weakly with 
plasma markers of disease severity (sE-selectin, sVCAM-1, procalcitonin). 
Additionally, median plasma MP-TF activity was higher in patients than in 
healthy controls (197 vs. 79 fM Xa/min; P<0.0001), and highest in bacterae-
mic patients (325 fM Xa/min). MP-TF activity showed a weak inverse correla-
tion with monocyte count (rs -0.22; P=0.016) and a weak correlation with 
TAT (rs 0.23, P=0.017). After 3 days of antibiotic treatment, upon resolution 
of the infection, plasma MP-TF activity and TAT concentrations declined.
Conclusions
Microparticle-associated procoagulant tissue factor activity is related to 
disease severity and bacteremia in febrile E. coli UTI patients and may con-
tribute to the prothrombotic state in gram-negative sepsis.
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Introduction
Sepsis is associated with activation of the coagulation cascade, which may 
range from subclinical to widespread microvascular thrombosis and dissemi-
nated intravascular coagulopathy. Blood microparticles are highly mobile 
carriers of pro-inflammatory mediators and procoagulant proteins and could 
play a major role in the onset of sepsis-related morbidities and mortality.
Tissue factor (TF), the primary initiator of coagulation in vivo, is thought 
to play an important role in sepsis. In primates, inhibition of the tissue 
factor pathway with anti-TF monoclonal antibodies, tissue factor pathway 
inhibitor (TFPI) or active site-inactivated FVIIa attenuated coagulopathy 
and prevented acute lung injury, renal failure and mortality in septic shock 
caused by Escherichia coli [1-3]. Furthermore, in human endotoxemia mod-
els, coagulopathy improved following infusion of TFPI or recombinant human 
IL-10 (known to inhibit LPS-induced TF activity and monocyte TF-expression, 
respectively) [4, 5].
In a kinetic study of healthy volunteers challenged intravenously with puri-
fied E. coli lipopolysaccharide, we demonstrated that microparticles bearing 
functional procoagulant TF (MP-TF activity) are concurrently released with 
markers of inflammation and coagulation [6]. Interestingly, the subject with 
the most prominent clinical response to endotoxin also had the highest MP-
TF activity. The role of microparticles expressing tissue factor (MP-TF) in the 
pathogenesis of sepsis has not yet been elucidated.
As inflammatory conditions caused by an intact pathogen may similarly in-
duce shedding of MP-TF, we investigated the relation between MP-TF activity, 
bacteremia and clinical disease severity using the APACHE II score in a large 
cohort of patients with febrile E. coli urinary tract infection (UTI). In addi-
tion, we assessed whether MP-TF activity decreased upon resolution of the 
infection and explored the association between MP-TF activity, markers of 
disease severity (sE-selectin, sVCAM-1, procalcitonin) and blood monocyte 
count. Finally, we examined levels of thrombin-antithrombin complex (TAT) 
as a marker of coagulation in a subset of patients.
Materials and methods
Study design
From January 2004 to December 2009, we enrolled 787 consecutive patients 
presenting with community-onset febrile urinary tract infections at the emer-
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gency departments of seven hospitals and 35 affiliated primary healthcare 
centers in the western part of The Netherlands [7]. This multicenter cohort 
study was approved by the Medical Ethical Committees of the participating 
centers and all patients gave written informed consent.
Inclusion criteria were age ≥18 years, ear temperature ≥38.0°C or a history 
of fever and rigors within 24 hours prior to presentation, at least one symp-
tom of UTI (dysuria, frequent or urgent urination, perineal pain, flank pain or 
costovertebral tenderness), and positive nitrite dipstick test or leukocyturia. 
Leukocyturia was defined as a positive leukocyte esterase dipstick test or 
the presence of >5 leucocytes per high-power field in the urine sediment. 
Exclusion criteria were current treatment for urolithiasis or hydronephrosis, 
hemodialysis, kidney transplantation or polycystic kidney disease.
From the initial cohort of 787 patients, we selected all 420 patients in whom 
E. coli was cultured from the urine sample obtained upon admission. We 
excluded 156 patients with pre-existing disorders or severe co-morbidity, 
i.e. cancer, autoimmune disease, diabetes, cerebrovascular accident or heart 
failure, because elevated plasma levels of microparticles and MP-TF activity 
have been reported in patients with these disorders [8-12]. This exclusion 
criterion resulted in a cohort of 264 fairly healthy patients at the onset of their 
urinary tract infection, since abovementioned disorders and comorbidities 
were more prevalent amongst the majority of the critically-ill patients with 
the highest APACHE II scores. Another 49 patients were excluded because 
blood cultures or frozen plasma samples could not be retrieved, rendering a 
final study cohort of 215 patients.
As required by the study protocol, all patients received empirical intravenous 
or oral antibiotic treatment upon admission according to local hospital policy. 
Antimicrobial therapy consisted of intravenously administered cefuroxime 
(n=89; of which 39 in combination with gentamicin) or oral treatment with 
ciprofloxacin (n=106). A small number of patients (n=20) was treated with 
other oral or intravenous antibiotic agents directed against gram negative 
micro-organisms.
Healthy volunteers without history of fever or infectious disease were re-
cruited in the participating primary healthcare centers and amongst labora-
tory staff. Age and gender were similar to that of the study patients (63% 
female, median age 59 years [range 24-76]), as well as the protocol for 
blood collection and processing.
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Procedures and definitions
Clinical data and routine laboratory measurements were collected by the 
clinical investigators and qualified research nurses. Baseline data of the 
patients were obtained within 24 hours using a standardized questionnaire 
and by reviewing medical records. Double data entry was performed by two 
independent data managers and both entries were compared for discrepan-
cies.
We calculated the most commonly used clinical disease severity score for sep-
tic patients, the Acute Physiology and Chronic Health Evaluation II (APACHE 
II) score. Patients were allocated to previously reported score categories, 
allowing assessment of the severity of the disease and providing an estimate 
of in-hospital mortality risk (an APACHE II score of 1-4 corresponded with 
a 4% mortality rate, whereas APACHE II scores of 5-9, 10-14, and 15-19 
translated into an observed mortality rate of 8%, 15% and 25%, respec-
tively) [13]. Clean midstream-catch or catheter-port urine were collected 
upon admission and cultured using local standard microbiological methods. 
Urine samples were considered infected in case of bacterial growth >103 
CFU per ml urine or a bacterial monoculture >102 CFU per ml urine in the 
presence of leukocyturia.
Disease burden was systematically quantified in all 215 patients by taking 
blood cultures on admission. Patients were considered to have bacteremia 
when E. coli was cultured.
At baseline (day 0) and three days thereafter (day 3), venous blood samples 
were collected into EDTA [ethylenediaminetetraacetic acid] BD Vacutainer 
tubes (Franklin Lakes, NJ, USA) applying minimal venostasis and discard-
ing the first tube. Plasma was prepared by removing cells through a single 
centrifugation step at 3500 x g (5 minutes at room temperature). Aliquots 
were transferred immediately to polypropylene tubes and frozen at -80°C to 
enable future simultaneous analysis of day 0 and 3 samples. Sample pro-
cessing time from venepuncture to storage at -80°C was less than an hour 
for the majority of study patients and well within two hours for all patients 
as required by the study protocol. Plasma samples remained deep-frozen 
until analysis.
Isolation of microparticles and MP-TF activity assay
After thawing of deep-frozen EDTA-anticoagulated plasma samples, mic-
roparticles were pelleted and repeatedly washed with pH 7.45 filtered 0.32% 
citrate/PBS buffer (30 minutes at 18,890 x g with minimum brake, 20°C) 
thus diluting plasma constituents and EDTA more than 200-fold. The mic-
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roparticle suspension was subsequently recalcified and incubated in a 1:5 
ratio (v/v) with 10 mM pH 7.45 Hepes, 137 mM NaCl, 4 mM KCl, 5 mg/
ml ovalbumin, 50 nM hirudin, 6 mM CaCl2 and 25 μM negatively charged 
phospholipid vesicles (dioleoylphophatidylserine/dioleoylphosphatidylcholine 
1/9). TF/FVII complex formation was initiated by the addition of FVII (Kordia, 
The Netherlands). The reaction was started by the addition of S2765 (Chro-
mogenix, Italy) and FX (Kordia, The Netherlands). Subsequently, cleavage of 
the chromogenic substrate S2765 by the generated FXa was recorded during 
90 minutes (absorbance at 405 nm). Parallel experiments were performed 
in the absence of FVII and in the presence of excess polyclonal sheep anti-
human TF-IgG (Affinity Biologicals Inc., Canada) to demonstrate FVII and TF-
dependency, respectively. MP-TF activity, defined as FVII- and TF-dependent 
FXa formation, was calculated as previously described [8] and expressed 
as fM Xa/min in plasma assuming a 100% microparticle recovery. None of 
the plasma samples used for isolation of microparticles had been thawed 
before and all samples were analysed within one year after completion of the 
study. In previous experiments on plasma samples stored for more than 15 
months, we did not observe degradation of active TF on microparticles after 
prolonged frozen storage; the same MP-TF activity was found in aliquotted 
samples from 16 patients after prolonged frozen storage.
Nineteen healthy volunteers were recruited to establish reference values for 
MP-TF activity, although power calculations indicated that a sample size of 
merely 9-10 for each group would suffice to detect a statistical significant 
difference. We defined elevated plasma MP-TF activity as levels >172 fM 
Xa/min, indicating the 99th percentile of MP-TF activity of these 19 healthy 
controls (e.g. mean MP-TF activity + 2 SD).
Other assays
Endothelial activation and leukocyte recruitment play a key role in inflamma-
tion and are characterized by ectodomain shedding of adhesion molecules. 
As levels of soluble adhesion molecules have been related to disease severity 
[14], soluble E-selectin and VCAM-1 levels were measured by ELISA according 
to the manufacturer’s protocol (Diaclone, Besançon, France). Procalcitonin, 
a sensitive biomarker differentiating bacterial infection from non-infectious 
inflammation [15], was routinely measured using a Time Resolved Amplified 
Cryptate Emission technology assay (TRACE®, Kryptor compact, PCTsensi-
tive; Brahms AG; Hennigsdorf, Germany). C-reactive protein (CRP) levels 
were not measured considering the higher diagnostic accuracy of procalcito-
nin, which is already peaking at 8 hours following an infectious stimulus, in 
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contrast to 36 hours for CRP. To detect whether (subclinical) coagulation had 
occurred in vivo, thrombin-antithrombin complex, was quantified using an 
enzyme immunoassay according to the manufacturer’s protocol (Enzygnost, 
Malburg, Germany). TAT levels of > 4.2 μg/L were considered to be elevated.
Statistical analysis
As the distributions of biomarkers were skewed, univariate analysis was 
performed using the Mann-Whitney U-test. Additionally, (M)ANOVA was used 
to compare between APACHE II disease severity groups after correction for 
the skewed distribution by log-transformation of data. When appropriate the 
paired-samples T-test was performed on log-transformed data. Correlations 
were assessed using the Spearman’s rho (rs) test. P-values <0.05 were 
considered significant. For all analyses, SPSS Statistics software (version 
20.0; IBM Corporation, Armonk, NY, USA) was used.
Results
Patient characteristics
The median age in the study population of 215 patients with febrile E. coli 
UTI was 51 years (range 18-96 years) and 73% were female. Almost all 
patients were capable of daily self-care activities. The majority of patients 
(70.1%) had signs of pyelonephritis, 64.6% presented with rigors, while only 
22.3% had bacteremia confirmed by blood culture testing, and 37.1% re-
ported vomiting. Relevant comedication consisted of antihypertensive agents 
(23.3%) and agents to reduce the heart rate (10.2%). A large proportion of 
patients (63.3%) took antipyretics at the time of admission. Antibiotic treat-
ment was already started in 34 of 215 (15.8%) patients for a median period 
of 2 days (range 1-10 days) prior to inclusion, and switched upon inclusion 
in 32 of 34 patients.
As classified by the APACHE II disease severity score, most patients had a 
low mortality risk. Only thirty-four patients (15.8%) had an APACHE II score 
of 10-14, whereas 10 patients (4.7%) had an APACHE II score of 15-17 
corresponding with a mortality risk of 15% and 25%, respectively. None of 
the patients had an APACHE II score ≥ 18. Approximately half of the patients 
(n=107) was admitted to the hospital, from whom only one patient was 
directly admitted to the intensive care unit (ICU). None of the 215 patients 
died from urosepsis. Furthermore, none of the 215 patients was diagnosed 
with clinically manifest thrombosis.
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Disease severity and plasma MP-TF activity at baseline
Median plasma MP-TF activity was higher in patients with febrile E. coli UTI 
than in healthy subjects (197 fM Xa/min [IQR 113-398] vs. 79 fM Xa/min 
[IQR 57-126]; Fig. 1A). Patients with proven bacteremia had higher median 
plasma MP-TF activities (325 fM Xa/min [IQR 166-641 fM Xa/min] than pa-
tients with localized infection and negative blood cultures (186 fM Xa/min; 
IQR 110-324; Fig. 1B). Plasma MP-TF activity also corresponded with clinical 
disease severity as determined by APACHE II scores (Fig. 1C). Patients with 
APACHE II scores of 0-4 had a median plasma MP-TF activity of 152 fM Xa/
min [IQR 98-280], whereas patients in higher APACHE II score categories had 
higher median MP-TF activities: 227 fM Xa/min [IQR 123-501] for patients 
with an APACHE II score of 5-9, 259 fM Xa/min [IQR 144-599] for patients 
with an APACHE II score of 10-14, and 471 fM Xa/min [IQR 180-848] for 
patients with an APACHE II score of 15-17. The differences between the four 
APACHE groups as analyzed by ANOVA after log-transformation of mean 
MP-TF activity revealed a significant increase in differences between the four 
categories (P=0.006). Within each of the APACHE II score categories, the 
mean MP-TF activity was higher in patients with bacteremia than in those 
without. Overall, this effect of bacteremia on MP-TF activity was significant 
(P=0.031 in MANOVA).
Plasma disease severity markers sE-selectin and sVCAM-1 correlated moder-
ately with APACHE II score (rs 0.35 and 0.39, respectively; P<0.0001), but 
only weakly with MP-TF activity (rs 0.28 and 0.30, respectively; P<0.0001; 
n=213). Plasma procalcitonin showed a slightly better correlation with MP-TF 
activity (rs 0.35, P<0.0001).
MP-TF activity, TAT levels and monocyte count at baseline
As monocytes have been shown to be the sole hematopoietic source of TF 
and activated monocytes shed microparticles expressing procoagulant tissue 
factor [16, 17], we examined the correlation between MP-TF activity and 
blood monocyte count. From 117 of 134 patients (87.3%) presenting with 
febrile E. coli UTI at one of the emergency departments, monocyte counts 
were available. Monocyte counts showed a weak inverse correlation with 
plasma MP-TF activity (rs -0.22; P=0.016). Of 106 patients, plasma samples 
were available for determination of TAT levels. MP-TF activity correlated 
weakly with TAT (rs 0.23, P=0.017; n=106). Interestingly, monocyte count 
showed a moderate inverse correlation with TAT (rs -0.40, P=0.003; n=55). 
In contrast, MP-TF activity did not correlate with total leukocyte count (which 
in septic patients mainly consists of neutrophils).
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MP-TF activity and TAT on days 0 and 3
As all patients received antibiotic treatment upon admission, we examined 
MP-TF activity on day 3. In 98 patients, EDTA-anticoagulated plasma samples 
collected on day 3 were available allowing paired analysis of MP-TF activity 
on days 0 and 3 (Fig 2A). Overall, mean MP-TF activity declined with 95 fM 
Xa/min over 3 days of antibiotic treatment (P=0.0003; Paired-Samples T-
test after log-transformation). Although the overall MP-TF activity decreased, 
the MP-TF activity on day 3 showed a 1.2 to 22-fold increase in ten patients. 
Six of these patients remained febrile or showed signs of inflammation on 
day 3. Interestingly, the patient who experienced the highest increase in 
blood MP-TF activity from 183 to 3928 fM Xa/min was an elderly patient with 
proven bacteremia, who deteriorated clinically despite adequate oral antibi-
otic treatment. His urine contained >105 CFU’s and the time to positive blood 
culture was 12 hours. Although vomiting and diarrhea were not reported, 
this patient had prolonged fever and malaise. As for the eleven patients with 
the highest MP-TF activities (i.e. > 1500 fM Xa/min), symptoms improved 
Figure 1. Boxplot showing plasma MP-TF activity in (A) 19 healthy volunteers and 215 patients with fe-
brile E. coli UTI, (B) patients with localized disease and no bacteremia (n=167) vs. patients with bacteremia 
(n=48), and (C) patients with different APACHE II scores. Whiskers indicate the 10th and 90th percentile. De-
picted P-values were calculated using the Mann-Whitney U-test for panels A and B, and ANOVA after log-
transformation of data for panel C.
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promptly upon antibiotic treatment. Nine of the eleven patients had to be 
hospitalized for a median period of 7 days (range 2-28). From four of these 
eleven patients with MP-TF activities > 1500 fM Xa/min, day 3 samples were 
available showing a marked decrease in MP-TF activity to 98-265 fM Xa/min.
In 106 patients, TAT levels were determined. TAT ranged from < 2.0-145 
μg/l and was elevated in approximately 50% of patients. From 11 patients 
with MP-TF activities > 1500 fM Xa/min, TAT levels were available for 5 
patients, all being elevated, the patient with the highest MP-TF activity (3597 
fM Xa/min) having one of the highest TAT levels (133 μg/ml). Of 40 patients, 
plasma was available for paired analysis of TAT on day 3 (Fig 2B). Mean TAT 
declined with 7.6 μg/l (P=0.0096; paired-samples T-test after log-transfor-
mation). Interestingly, the patient with prolonged fever who showed the 
highest increase in MP-TF activity also showed one of the highest increases 
in TAT from 5.0 to 24.5 μg/ml. The second patient with an increase in TAT on 
Figure 2. MP-TF activity and TAT at baseline and on day 3 following antibiotic treatment. (A) Median MP-TF 
activity at baseline (183 fM Xa/min) was higher than on day 3 (129 fM Xa/min; P=0.002; n=98). Ten patients 
showed an increase in MP-TF activity on day 3. In the remaining 88 patients, MP-TF activity decreased or 
varied within the normal range (< 172 fM Xa/min). Interestingly, the patient with the highest increase in 
MP-TF activity on day 3 had deteriorated clinically despite antibiotic treatment (*). (B) Median TAT levels at 
baseline (3.7 μg/l) were higher than on day 3 (2.3 μg/l; P=0.003; n=40). The majority of patients showed a 
decline in TAT following resolution of the infection. Interestingly, the patient with the highest increase in 
MP-TF activity also exhibited one of the highest increases in TAT (*). Finally, paired-samples T-test after log-
transformation of data showed significant decrease in mean MP-TF activity and TAT levels (P=0.0003 and 
P=0.0096, respectively).
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day 3 (1.9 to 25.5 μg/ml) similarly showed a concurrent increase in plasma 
MP-TF activity from 261 to 365 fM Xa/min. This elderly lady had been treated 
with oral antibiotics for recurrent urinary tract infections in a nursing home. 
She presented with an APACHE II score of 17 and a deteriorating localized 
urinary tract infection despite antibiotic treatment.
Discussion
In this large cohort study of 215 patients with febrile E. coli UTI, which reflects 
daily clinical practice and entails the most commonly cultured pathogen from 
urine (i.e. over 70%), we demonstrate that functional procoagulant tissue 
factor on blood microparticles (MP-TF activity) is higher in patients than in 
healthy individuals and is associated with disease severity and the pres-
ence of bacteremia. After three days of antibiotic treatment, MP-TF activity 
declined coinciding with defeverescence and resolution of the infection. In a 
minority of patients, mostly with prolonged fever and inflammatory symp-
toms, an increase in MP-TF activity was observed on day 3. Interestingly, 
one bacteraemic patient with delayed resolution of his illness and another 
patient who deteriorated despite antibiotic treatment which was started prior 
to admission showed a marked increase in MP-TF activity on day 3 and a 
concurrent increase in TAT levels. These observations illustrate that height 
and kinetics of MP-TF activity reflect disease severity and clinical deteriora-
tion in sepsis and underscores an association of plasma MP-TF activity with 
coagulation in vivo.
There was a large interindividual variation in MP-TF response to E. coli and a 
considerable number of patients (42%) did not have elevated MP-TF activities 
on day 0. This may reflect differences in the genetic ability of patients to re-
spond to the pathogen (responders and non-responders) [6, 18], differences 
in plasma endotoxin concentrations [19] and differences in the time interval 
between the onset of E. coli infection and the time of inclusion into the study. 
Also, the exclusion of patients with co-morbidity may have resulted in the 
inclusion of a subgroup of patients who were less prone to bacteremia and 
severe inflammatory disease.
Our findings are in accordance with the observation by Aras et al. as well 
as our own previous observation that intravenous administration of E. coli 
LPS to healthy volunteers results in a marked but transient increase in pro-
coagulant tissue factor activity of blood microparticles isolated from EDTA 
and citrated plasma, respectively [6, 20]. Monocytes are thought to be the 
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sole hematopoietic source of TF and show significantly elevated levels of TF 
mRNA in vitro upon stimulation with E. coli LPS [16, 21]. It is highly likely, 
that the inflammatory response induced by invasion of an intact pathogen 
into urinary tract tissues similarly results in early activation of monocytes 
and the release of microparticles bearing TF [6], even though we only found 
a weak correlation between MP-TF activity and monocyte count. In our study, 
70% of the patients had symptoms of pyelonephritis and since glomeruli 
exhibit strong TF expression [22], apoptotic glomerular cells may hypotheti-
cally form an alternative source of MP-TF activity. Provided the availability of 
a monoclonal antibody able to reliably assess tissue factor on microparticles, 
multicolor flowcytometry experiments could aid in establishing the cellular 
source of MP-TF. However, only limited amounts of plasma were available 
from patients participating in this multicenter study. Since MP-MP fusion 
events are likely to occur in vivo, thus complicating the correct identification 
of the cellular source of MP-TF, and flowcytometry does not detect the small-
est microparticles due to limitations of the 488 nm laser light wavelength 
used, we did not further explore this.
Plasma MP-TF activity correlated weakly with TAT levels. This is not sur-
prising as TAT concentrations in vivo are subject to the dynamics of TAT 
formation and degradation. Furthermore, the formation of TAT occurs down-
stream in the coagulation cascade and is influenced by multiple other factors 
such as TF on activated monocytes, levels of procoagulant phospholipids 
on microparticles and activation of the intrinsic route of coagulation [23, 
24]. As yet, it is not known whether other forms of TF in plasma increase 
in infectious disease. Previously, we showed that in a human endotoxemia 
model the rise and fall of plasma TF antigen formed a mirror image of the 
monocyte count and that plasma TF antigen peaks earlier than plasma MP-TF 
activity [6]. Stimulation of monocytes may result in proteolytic cleavage of 
TF from the cell membrane (increase in soluble truncated TF), an increase 
in alternatively spliced TF and the shedding of MP-TF. However, truncated TF 
and alternatively spliced TF have strongly reduced (if at all) procoagulant ac-
tivity. MP-TF, as measured in our assay, may therefore be the most important 
procoagulant form of TF in plasma.
Nonetheless, procoagulant microparticles have been shown to contribute to 
thrombus formation in vivo [25, 26]. In agreement herewith, consumption 
of procoagulant microparticles was suggested in a small study of septic ICU 
patients with multiple organ dysfunction syndrome and coagulopathy [27]. 
In addition to their procoagulant properties, microparticles may also function 
as highly mobile carriers of TF and may transfer TF to other cells through 
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membrane fusion [16]. MP-TF may furthermore contribute to local contain-
ment of the infection through capture and even killing of fibrinogen binding 
bacteria within microthrombi [28].
In conclusion, we demonstrated that inflammatory conditions caused by an 
intact pathogen can induce the release of MP-TF into the circulation and that 
plasma MP-TF activity levels are associated with disease severity and bacte-
remia. Considering the link between inflammatory and TF-related pathways, 
future studies of the pathophysiological role of MP-TF in critically ill patients 
with severe sepsis, septic shock, multiple organ dysfunction syndrome and 
disseminated intravascular coagulopathy are warranted. Moreover, micropar-
ticles carrying functionally active tissue factor may well be desirable targets 
for therapeutic purposes as, hypothetically, inhibition of procoagulant tissue 
factor on circulating blood microparticles could abort disease progression 
and even lethality from E. coli septicemias.
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Summary and general discussion
Urinary tract infections (UTIs) are one of the most common infectious dis-
eases. Fever in UTI suggests the presence of tissue inflammation, and points 
to a diagnosis of acute pyelonephritis, prostatitis or urosepsis. Febrile UTI 
patients usually present at primary care centres with relatively mild disease. 
However, its course may be unpredictable as it may rapidly develop into 
septic shock, a life-threatening condition necessitating hospital emergency 
care. Evaluation of clinical symptoms often fails to provide accurate guidance 
to the clinician which patients may run a complicated course.
The overall aim of this thesis was firstly to provide evidence for the clinical 
implication of biomarkers in blood and urine, as well as genetic markers, for 
the prediction of the severity and course of febrile UTI. Secondly, this thesis 
focused on optimization of antimicrobial treatment of febrile UTI. The five 
main results of this thesis can be summarized as follows:
1. A recent hospitalization, an indwelling urinary catheter and most impor-
tantly, individual fluoroquinolone (FQ) use, are independent risk factors 
for the occurrence of a FQ resistant Escherichia coli as cause of febrile UTI 
(Chapter 1).
2. Women with febrile UTI, including postmenopausal women and those with 
comorbidities, can be safely and successfully treated with a short, i.e. 
7-day course of oral ciprofloxacin. In men, however, treatment duration 
should be at least 14 days (Chapter 3).
3. Diabetes mellitus per se does not affect the clinical presentation and 
course of febrile UTI, but concurrent illnesses (e.g. vascular complications 
of diabetes) and higher age of the diabetic population attribute to a more 
complicated course (Chapter 4).
4. MR-proADM, a marker of endothelial cell dysfunction, more accurately 
predicts a complicated course of disease than currently available inflam-
matory biomarkers (Chapter 5). Importantly, biomarkers derived directly 
from host defense mechanisms are not suitable to distinguish between 
febrile UTI patients with and without bacteremia (Chapter 6).
5. Microparticle-associated procoagulant tissue factor activity is related to 
disease severity and bacteraemia in febrile E. coli UTI and may contribute 
to the prothrombotic state in gram-negative sepsis (Chapter 7).
In this general discussion, the major findings of the studies will be highlighted 
with a focus on clinical implication. In addition, some methodological issues 
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and remaining questions will be discussed together with recommendations 
for future research.
Risk factors for antimicrobial resistance
In patients with febrile UTI, fluoroquinolones (FQs), amoxicillin-clavulanic 
acid and trimethoprim-sulfamethoxazole are the preferred agents for oral 
antimicrobial treatment, combining a reliable uptake in the gastrointestinal 
tract with excellent antimicrobial activity. Because of their pharmacokinetic 
profile (e.g. sufficient tissue level in the prostate)1 and particularly because 
of a relatively low rate of antimicrobial resistance compared to β-lactams 
and trimethoprim-sulfamethoxazole, FQs are the preferred empirical oral 
agents.2-5 However, FQ resistance of Escherichia coli, the most frequent etio-
logic bacterial pathogen in UTI, is now emerging in the community, which 
may limit its use to treat febrile UTI.6 Worldwide, reported rates of E. coli re-
sistance to ciprofloxacin are up to 38%.7-9 Even in the Netherlands, a country 
known for its restrictive use of antibiotics and overall low resistance rates, 
there are signs that the incidence of FQ-resistant E. coli is rising, especially 
among patients at urology services.10;11 The extensive use of antimicrobials 
in veterinary and human health care practice may be a potential threat for 
further emergence and dissemination of resistant pathogens in the com-
munity.6;12
Antimicrobial resistance is associated with prolonged symptoms and a com-
plicated course in patients with UTI.13;14 Moreover, FQ resistance in E. coli is 
frequently associated with resistance to other antimicrobial classes.15 There-
fore, when the choice of empirical antimicrobial therapy has to be made, it is 
important that the attending physician has knowledge about which patients 
are at a particular risk for a resistant causal uropathogen. However, there is 
an overall lack of data on risk factors for FQ resistance in community-acquired 
febrile UTI. Chapter 1 describes the results of a prospective, multicenter 
cohort study, in which host-related and environmental risk factors for FQ 
resistance in febrile E. coli UTI were evaluated. In addition, the impact of FQ 
resistance on clinical outcomes was assessed.
We found that individual use of FQs in the past six months was the most 
important of several risk factors for FQ resistance that also included a recent 
hospitalization and the presence of an indwelling urinary catheter. Environ-
mental risk factors, like contact with a household member with UTI or with 
livestock or pets, were not associated with FQ resistance. Thus, individual 
FQ use seems to be the driving force for FQ resistance, rather than within-
household or animal-human transmission of resistant E. coli. These findings 
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do not lend support for the concern of a human or animal reservoir causing 
FQ resistance, although it should be emphasized that the current evidence 
for human-human and animal-human transmission of FQ-resistant E. coli 
seems to be limited to specific strains.16-19 Moreover, FQ-resistant E. coli 
strains in e.g. a gut reservoir do need to have specific virulence factors, like 
P-fimbriae, to be able to adhere to the renal epithelium to cause a febrile 
UTI.20
Besides that, our study does not exclude a possible two-hit mechanism for 
FQ resistance with an initial input of FQ-resistant strains from e.g. food sup-
ply of colonized animals into the population followed by selection at the 
individual level by personal FQ use. Therefore, further studies are urgently 
warranted to explore this hypothesis, particularly as current data on the 
relationship between animal-derived food and FQ-resistant E. coli in humans 
reveal conflicting results, but at least indicate that this might be or become 
a major threat for the human community.21-24
FQ resistance was associated with high rates of cross resistance to amoxicillin-
clavulanic acid (33%) and trimethoprim-sulfamethoxazole (65%). Presence 
of extended-spectrum β-lactamase (ESBL) was almost excluded in case of 
FQ susceptibility. That highlights the importance of detection of risk factors 
for FQ resistance as these may also be risk factors for ESBL-production.
Interestingly, we found no differences in clinical outcome of patients with a 
FQ-resistant strain who were empirically treated with ciprofloxacin compared 
to those treated with ‘appropriate’ (i.e. based on susceptibility testing re-
sults) antibiotics. The majority of patients recovered on ciprofloxacin as their 
fever resolved before the outcome of the urine culture and susceptibility 
testing of the etiologic bacterial pathogen became available and antimicro-
bial treatment was subsequently switched. There are several explanations 
for this finding. Firstly, this may indicate that febrile UTI is to some extent 
a self-limiting disease, dealt with by host defense mechanisms that may 
be assisted by antibiotics but not totally depend on their action. Secondly, 
ciprofloxacin may be possibly effective in vivo even in ranges above in vitro 
resistance level used in our study (ciprofloxacin MICs > 1 mg/L according to 
EUCAST-criteria), as was also suggested in recent literature.25;26 The absence 
of a relation between FQ resistance (already 12% of the isolates in our study) 
and clinical outcome of febrile UTI in our study do question the clinical rel-
evance of detecting FQ resistance at the individual patient level. First of all, 
the number of patients in this study was limited and a ‘type I error’ (wrong-
fully rejecting the hypothesis that a difference exists) cannot be excluded, 
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the more so because the expected background mortality is low already. On 
the other hand, the main risk factor for FQ resistance, individual FQ use, can 
easily be detected by just taking a thorough recent pharmacological history 
in febrile UTI patients. In patients with recent FQ use, one might consider not 
to choose a FQ as empirical antimicrobial therapy or not solely rely on this 
class of antibiotics, although the clinical relevance of detecting FQ resistance 
in each individual patient may not hold.
Better still than predict among those with febrile UTI the individuals at risk 
for FQ resistance would be to preclude the emergence and spread of antimi-
crobial resistance in the community through strict hygiene and antimicrobial 
stewardship programs. One such strategy is the optimization of antimicrobial 
treatment duration.
Optimal duration of antimicrobial therapy
With a lack of new antimicrobial classes in the development pipeline,27 it is 
increasingly important to develop strategies to maintain and even increase 
the effectiveness of available antimicrobial agents. Optimization of treatment 
duration represents one such important strategy, because the development 
and spread of antimicrobial resistance is closely related to the total amount 
of antimicrobials used in countries.28 The duration of antimicrobial therapy 
exerts differential selecting pressure on gut flora which leads to selection 
of resistant strains and reduction of resident commensal bacteria paving 
the road for e.g. Clostridium difficile infection.29 Moreover, the potential 
adverse effects of unnecessary extended treatment periods reach beyond 
the individual treated: the longer antimicrobials are taken and excreted into 
the environment, the more pressure is exerted on the ecological balance of 
bacteria outside the human gut.30 Despite the importance of optimization of 
treatment duration, there is an overall scarcity of randomized controlled trials 
to study the minimal yet optimally efficacious duration of treatment, even in 
a common infection like UTI. Our review, described in Chapter 2, discusses 
the available literature. It showed that studies mainly focused on uncompli-
cated cystitis and acute pyelonephritis in otherwise healthy women. Young 
women without comorbidities can be treated for febrile UTI with a 1-week 
regimen of fluoroquinolones provided a low a priori level of fluoroquinolone 
resistance or, if proven susceptible, with a 2-week course of trimethoprim-
sulfamethoxazole.7;31;32 Oral β-lactams are probably less effective compared 
to fluoroquinolones and trimethoprim-sulfamethoxazole.2;33-35 In contrast to 
this, the optimal treatment duration for all other patient categories is still 
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unknown, as (most) randomized trials excluded male patients, the elderly, 
and those with urinary tract abnormalities or underlying systemic illnesses.
We therefore conducted a randomized placebo-controlled double-blind multi-
center non-inferiority trial to determine whether the efficacy and safety of a 
7-day course of ciprofloxacin was similar to a 14-day ciprofloxacin course in 
an unselected population of both men and women. Patients with community-
acquired febrile UTI were recruited at regional hospitals and primary care 
centers and clinical and microbiological cure rates were assessed. The results 
of this study are discussed in Chapter 3.
We found that community-acquired febrile UTI can be safely and efficaciously 
treated with a 7-day instead of 14-day course of oral ciprofloxacin in women, 
including the elderly with severe comorbidities, and irrespective of severity 
of disease at presentation. Both treatment regimens were highly effective in 
women: 94% vs 93% clinical cure at 2-3 weeks after the end of treatment 
(for 7 versus 14 days, respectively) and a comparable high bacteriological 
cure rate. Even in patients with positive blood cultures (~20%), the shorter 
treatment course was safe and effective, as we reported earlier.36 These 
results support and extend the findings from a previous Swedish study 
performed in women with acute pyelonephritis, showing non-inferiority of 
7- and 14-day antimicrobial treatment.37 However, although that trial did 
not exclude upfront elderly women or the severely ill ones, their patient 
group was significantly younger than ours, and moreover less frequently had 
serious underlying comorbidities.
In contrast herewith, 7-day treatment in men did not reach non-inferiority 
with a 14-day course of treatment, as shown by an increase in rate of clinical 
(14% vs 2%) and bacteriological treatment failure after a 7-day compared 
to a 14-day treatment course, irrespective of comorbidities or complicating 
factors. Of note, this lack of efficacy could not be attributed upfront to a 
propensity of prostatitis in men, as the difference was especially evident in 
men presenting with costovertebral tenderness, generally taken as a sign 
of pyelonephritis, although the numbers of cases limited a firm exploration 
of subgroups. Still, the findings suggest that all febrile UTI in men likely 
involves the prostate, irrespective of the presence of signs of pyelonephritis.
Unfortunately, the number of patients included in this study constrained a 
purposeful exploration of the results in subgroups, e.g. those treated in the 
hospital compared to those at home. Future studies are needed to address 
these issues in more detail.
Overall, we can conclude that in women including postmenopausal women 
and those with significant comorbidities, febrile UTI can be treated success-
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fully with a 7-day course of oral ciprofloxacin. In men, however, a short 
course leads to significantly more clinical failures than a 14-day course of 
ciprofloxacin, so men should be treated for at least two weeks. Likely, these 
results also hold for other fluoroquinolones with gram-negative activity, as 
they have shown being able to effectively eradicate susceptible Enterobac-
teriaceae from the vaginal and rectal flora, which may help prevent early 
recurrences35;38;39 However, the current results should not be one-to-one 
extrapolated to other antimicrobial classes.
An important concern is the rise of ciprofloxacin resistance in the community, 
i.e., up to 15% of Enterobacteriaceae currently being resistant in The Neth-
erlands.11 And more importantly, even higher resistance rates have been 
reported in other countries.8;9;40 If it continues at the current rate, this may 
well prelude the end of use of fluoroquinolones as first-choice empiric oral 
treatment for febrile UTI. As discussed in Chapter 1, clinical outcome is (as 
of yet) not affected by FQ resistance, although it is not imaginary that MICs 
will increase with emerging FQ resistance and therewith influence clinical 
outcome. In countries with high rates of trimethoprim-sulfamethoxazole 
resistance too, there may eventually be no oral antimicrobial left for primary 
care physicians to confidently treat febrile UTI at home, raising health care 
costs due to hospitalization.41 These findings underscore the importance of 
controlling antimicrobial resistance, through antibiotic stewardship includ-
ing the optimal duration of antimicrobial treatment and restricted use of 
ciprofloxacin: only in febrile UTI.
In the future, an alternative strategy could possibly be alteration of the gut 
microbiome, e.g. by fecal transplant, as is currently being practiced in C. dif-
ficile colitis,42;43 therewith decreasing the chance of periurethral colonization 
with resistant pathogens from the rectum. In women, there are promising 
results with vaginally applied lactobacilli,44 which maybe could also be used 
to alter the perineal flora. Another approach could be the application of intra-
vesical instillation of antibiotics like gentamicin, as is currently investigated 
in patients with recurrent UTI; such local application of antibiotics bypasses 
any effect of these on microbes in the gut.45;46 Several UTI-vaccines have 
been tested or are under development,47 based on adherence factors, toxins 
and surface polysaccharides. Most have to date only been tested in mouse or 
rate models or primates. The ideal UTI-vaccine is probably far in the future.48 
Finally, bacteriophage therapy is currently being investigated, a therapy to 
remove adhered uropathogens by deliberately infecting the bladder with 
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viruses. Bacteriophages – viruses or bacteria – adhere to and gain access to 
the bacterial interior and enter either into a lytic phase resulting in the bac-
terium bursting open and releasing numerous copies of the bacteriophage, 
or into a lysogenic phase, integrating into the bacterial DNA. Bacteriophages 
as therapeutic agents usually are manipulated and competent only for a lytic 
phase thereby killing the bacteria.49;50
Prediction of a complicated course
The course of a bacterial infection like febrile UTI can be unpredictable. Early 
recognition and therapeutic interventions are of utmost important to prevent 
progression to life-threatening conditions such as septic shock and multiple 
organ failure often resulting in death.51 However, most adults with febrile 
UTI present with a mild illness, and the vast majority will have a uncompli-
cated course and can be safely treated at home.36 In daily clinical practice, 
the risk of a complicated course and thereby need for clinical observation 
and hospital-based treatment is based on history, assessment of underlying 
disease, and on severity of local and vital signs.
Diabetes mellitus is a well-known risk factor for acquisition of febrile UTI.52;53 
It is widely held that a patient with diabetes also has a more complicated 
course of infection. However, we showed in our prospective multicentre co-
hort study among 140 diabetic and 718 non-diabetic patients that diabetes 
is not independently associated with a complicated course of febrile UTI.54 
(Chapter 4) The prevalence of complications was indeed higher in diabetic 
patients but all attributable to concurrent illnesses, especially cardiovascular 
comorbidities related to diabetes, and a higher age of the diabetic popula-
tion. This latter is in line with the fact that most of the diabetic patients 
had type II diabetes.55 Clinical and microbiological outcomes after 1 month 
did not differ significantly between diabetic and non-diabetic patients, while 
they were treated alike. Remarkably, patients with diabetes experienced less 
flank pain, possibly due to diabetic neuropathy as suggested previously.56 
The lack of flank pain in diabetic patients is an important reminder that 
flank pain has a low predictive value in the identification of complicated UTI. 
Instead of that, the presence of fever should be used in suspected UTI as 
the most reliable distinction between UTIs with and without tissue invasion.
Nevertheless, it is important to notice that fever itself is a sign of little speci-
ficity to identify a complicated course, as it may reflect the mere presence of 
local kidney infection but also of a serious impending urosepsis.
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So, as indicated above, clinical symptoms and medical history often fail to 
provide accurate guidance to the clinician which patients will run a com-
plicated course and need hospital admission. Currently, in the Netherlands 
about 90% of patients presenting with febrile UTI at Emergency Departments 
are admitted, because the chance of life-threatening complications cannot 
be reliably estimated. This has major implications for health care costs of 
febrile UTI.41 Clinical guidance in risk stratification is urgently needed to 
better identify patients at risk of complications thus allowing resources be 
focused to those who need it most.57
Inflammatory biomarkers may help to determine the severity of disease. 
Currently used conventional biomarkers include blood leucocyte count, 
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and procalci-
tonin (PCT). Because these were shown to have a limited role in the predic-
tion of a complicated course of disease, we evaluated a new biomarker: 
midregional pro-adrenomedullin (MR-proADM).57;58 MR-proADM is involved in 
regulation of complement activity, and has immune modulating, metabolic 
and bactericidal activity.59-62
In a prospective observational multicentre cohort study, as described in 
Chapter 5, we evaluated the prognostic value of the plasma biomarker pro-
ADM in predicting bacteraemia, need for hospital admission and a compli-
cated course of infection. The results were compared with those of currently 
used biomarkers like CRP, leucocyte count and PCT. We chose to recruit 
patients in both primary care and emergency department. We therewith 
were able to specifically assess the added value of the biomarker in the 
various clinical domains. It is important to realize that the predictive value 
of a certain biomarker in e.g. the Emergency Department (ED) setting is not 
the same as in primary care, in part due to selection of patients with mostly 
a more severe illness and a more profound inflammatory reaction. The added 
value of a biomarker is the highest if the pre-test possibility can chance 
substantially post-test due to the biomarker test result, and importantly, this 
pre-test possibility of infection depends on the clinical domain in which the 
assessment is done, e.g. primary care, ED, hospital ward or intensive care 
unit (ICU).
In the study 494 febrile UTI patients were included, of which 376 (76%) 
recruited at the ED. MR-proADM was significantly correlated with bacterae-
mia and ICU-admission. The discriminating accuracy for predicting 30-day 
mortality was higher than the more conventional biomarkers ESR, CRP, PCT 
and leucocyte count. A plasma level of 1.00 nmol/L was the optimal cut-
off to stratify 30-day mortality in our study population. Further studies are 
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needed to confirm and validate the selected cut-off value as a predictor 
of complicated course. Plasma level of MR-proADM was only measured at 
presentation. It would be of interest of daily follow-up measurements of 
MR-proADM will improve diagnostic accuracy, and if they are correlated to 
clinical recovery.
We compared the prognostic value of MR-proADM to other currently used 
biomarkers only among the ED patients, because in the Dutch primary care 
setting it is not a standard to perform routine laboratory research in every 
patient. For our analysis this presented no objection, because in this way 
we were able to compare the prognostic value of different biomarkers in the 
most outspoken clinical manifestation of febrile UTIs. Consistent herewith, 
we found significantly lower MR-proADM levels and a lack of 30-day mortality 
in primary care patients treated at home. One could argue whether a rapid 
MR-proADM measurement, if available in the primary care setting, could be 
used to select patients with low MR-proADM levels for outpatient treatment 
considering the favourable clinical course and outcome.
In a previous prospective study we derived a clinical bedside prediction 
rule, designated the APSI score, which reliably identifies low-risk febrile UTI 
patients with an acceptable low risk of a complicated course who can be 
safely treated at home.63 The present study showed that the plasma levels of 
MR-proADM correlated well with the APSI score. Whether or not MR-proADM 
can independently add acumen to the clinical prediction rule, is uncertain. 
Currently, we evaluate the use of biomarkers like pro-ADM and PCT in guiding 
the decision which patients with febrile UTI to admit to hospital and which 
patients to treat at home in a prospective clinical trial in which the clinical 
prediction rule is implemented at eight Emergency Departments.
Besides systemic plasma inflammatory biomarkers, one could argue that 
also locally produced biomarkers of host defense could be able to indicate 
the severity of the infection. In current clinical practice, urine is collected 
for nitrite test and urine culture. If we could find a bedside biomarker test, 
which is able to predict a complicated course, that would be of great value. 
We therefore set up a case-control study in febrile UTI patients to determine 
the role of certain urinary cytokines and antimicrobial proteins in predicting 
bacteraemia, i.e. IL-6, IL-8, cathelicidin (LL37), β-defensin 2 and uromodu-
lin. As described in Chapter 6, none of these urinary biomarkers were able 
to distinguish between patients with and without bacteraemia. Noteworthy, 
the inability to produce uromodulin, present in a few patients, increased the 
risk of developing bacteraemia substantially (OR 6.0, 95% CI: 1.2-29.2).64
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Vitamin D is known to play an important role in the first line of host defense 
against bacterial infection, e.g. by induction of the antimicrobial proteins 
cathelicidin and β-defensin, biomarkers described above.65-68 In vitro experi-
ments have shown that bladder epithelium from women taking vitamin D 
supplements are capable of producing larger amounts of cathelicidin upon 
infection.66 In this respect, one might hypothesize that higher vitamin D 
levels might to some extent have a protective effect against invasive UTI and 
bacteraemia e.g. via cathelicidin. This was explored in the study described 
in Chapter 6. An association of plasma vitamin D with urinary cathelicidin 
however was not found. Furthermore, there was no association between 
either vitamin D level or urinary cathelicidin with the presence of bacterae-
mia.64
The role of genetics in UTI
In most infectious diseases, in addition to exposure, environmental factors 
and strain virulence, genetic host variations play a role in susceptibility to 
disease.69;70 Likely, genetic factors also play in role in UTI, as illustrated by 
the finding that positive family history is a risk factor for recurrent UTI.71 
In daily clinical practice, it is noticeable that some patients seem to be ex-
tremely prone to UTIs, while others (nearly) never encounter a UTI. Possibly, 
this may be due to variations in genetic host susceptibility, affecting the 
production of urinary proteins involved in local host defense. To further in-
vestigate the attribution of genetic variations to susceptibility to febrile UTI, 
we genotyped 15 single nucleotide polymorphisms (SNPs) in 12 genes with a 
known role in the recognition, defense or immune response to uropathogens 
(Chapter 6).64 None of the SNP alleles or genotypes were found to be as-
sociated with susceptibility to febrile UTI when analysing febrile UTI patients 
versus healthy controls. A significant difference in β-defensin 2 production 
was found between the DEFB1 rs1800972 genotypes, as most individuals 
with a CC or CG genotype did not produce β-defensin 2 while the individuals 
with a GG genotype did. This was new evidence in the genetic pathways of 
UTI. No significant correlations were found between the 14 other genotypes 
and protein production, in contrast to other much smaller studies.72-75 
In conclusion, this genomic analysis of a large cohort showed that the role 
of genetics in the susceptibility of febrile UTI is marginally, at least in our 
cohort. The lack of association in our cohort as opposed to that reported in 
others may be due a difference in genetic background or due to the selection 
of elderly patients in our cohort, as at an elderly age comorbidity and an 
aging immune system may have more effect on susceptibility to UTI than 
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subtle genetic variations. This is supported by the fact that studies evaluating 
the role of genetic factors in UTI were mainly successful in children.72-74;76-78 
Moreover, we analysed the largest UTI cohort so far with more than 700 
febrile UTI patients, which makes the power to detect an association (if 
present) greater than in most of the other cohorts. Therefore, our study 
has gained new insight in the genetics of febrile UTI susceptibility in adults, 
valuable for future research in genetic pathways and cytokine production.
Future directions of research
Escherichia coli strains need specific virulence factors, like P-fimbriae, to be 
able to adhere to the renal epithelium to cause a febrile UTI.20 As the major-
ity of UTIs is caused by E. coli strains migrating from a gut reservoir to the 
urethra followed by ascending to the bladder and kidneys, future research 
should be directed to the composition and possibilities of alteration of the 
microbiome of the gut, perineum and vagina. A promising future strategy 
could possibly be the inhibition of the growth of periurethral uropathogenic 
bacteria by means of microbiome modulation, for instance by local application 
of specific lactobacilli strains or by fecal transplant. Herewith, colonisation 
with uropathogenic strains possessing virulence factors necessary to adhere 
to the renal epithelium, could be replaced by non-uropathogenic strains. An 
additional advantage of such a microbiome modulation is that herewith resis-
tant uropathogen are being replaced too, therewith theoretically preventing 
UTIs with a (multi-)resistant uropathogen.
Another promising strategy in the light of increasing antimicrobial resistance 
rates could be the local application of antibiotics, e.g. intravesical instilla-
tion, because this bypasses any effect of these on microbes in the gut.45;46 
Systemic antibiotics exert a major selecting pressure on gut flora, which 
leads to the selection of resistant strains and reduction of resident commen-
sal bacteria, facilitating e.g. Clostridium difficile infection. Moreover, UTIs 
are mainly (at least at the start) local infections of the urinary tract, which 
possibly can be sufficiently treated with local antibiotics only. Future trials 
should be designed to further investigate this issue in preferably a random-
ized controlled trial comparing locally applied versus oral antibiotics.
Finally, since clinical estimation of the severity of febrile UTI at first presenta-
tion is often not reliable and as the biomarker MR-proADM has shown to be a 
reliable predictor of a complicated course, further studies should be initiated 
to confirm and validate the role of MR-proADM in other febrile UTI cohorts. 
Furthermore, it would be of interest of daily follow-up measurements of 
MR-proADM will improve diagnostic accuracy, and if they are correlated to 
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clinical recovery. Ultimately, MR-proADM as a rapidly-available bedside test 
could then be used to stratify patients in risk categories of clinical course, 
and therapy could be tailored, e.g. home-based treatment in patients with 
an expected low risk of complications, or duration of antimicrobial treatment 
based on the level of MR-proADM.
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Een urineweginfectie is een ontsteking aan de binnenkant van de urinewegen. 
De urinewegen zijn de structuren in het lichaam waar urine passeert op weg 
naar buiten: het nierbekken, de urineleiders, blaas en plasbuis met bij man-
nen de prostaat (Figuur 1). Een infectie ontstaat wanneer bacteriën, meestal 
afkomstig vanuit het maagdarmstelsel, zich vasthechten aan de opening van 
de plasbuis. Van daaruit gaan zij zich vermenigvuldigen, raakt het slijmvlies 
ontstoken en stijgt de infectie hogerop. Een urineweginfectie die zich beperkt 
tot de plasbuis en blaas (blaasontsteking) wordt een lage urineweginfectie 
genoemd. Meestal geeft deze alleen lokale klachten, zoals een branderig 
gevoel bij plassen, vaak kleine beetjes plassen en troebele, stinkende urine. 
Een onbehandelde lage urineweginfectie kan soms overgaan in een nierbek-
kenontsteking (pyelonefritis), een prostaatontsteking bij mannen (prostati-
tis) of een bloedbaanontsteking met de aanwezigheid van bacteriën vanuit 
de urine in het bloed (bacteriëmie of urosepsis). Dit noemen we ook wel een 
hoge urineweginfectie of urineweginfectie met koorts (Figuur 1). Een hoge 



















Figuur 1. Anatomie van de urinewegen met weergave van de locatie van lage en hoge urineweginfecties. 
(bron: Kaper JB e.a. Pathogenic Escherichia coli. Nat Rev Microbiol 2004;2:123-140)
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met koorts, een algeheel ziek zijn en soms met flankpijn en koude rillingen. 
Een urineweginfectie met koorts heeft, zodra behandeling met antibiotica is 
gestart, over het algemeen een mild beloop met een voorspoedig herstel. 
Het kan echter ook een levensbedreigend karakter aannemen, vooral als er 
sprake is van een bacteriëmie, waarbij zelfs IC-opname noodzakelijk kan zijn 
en sommige patiënten overlijden.
Ondanks dat een urineweginfectie de meest voorkomende bacteriële infectie 
is en vele mensen ooit een urineweginfectie zullen doormaken, zijn er nog 
vrij veel onbeantwoorde vragen over de juiste aanpak en behandeling van 
de infectie. Zo is het bijvoorbeeld niet bekend wat de optimale duur van 
behandeling met antibiotica is, en of hierbij een verschil is tussen mannen 
en vrouwen.
Om hierover meer duidelijkheid te krijgen, is een groot wetenschappelijk 
onderzoek opgezet in de regio Leiden-Den Haag-Gouda. Aan dit onderzoek 
deden circa 35 huisartsenpraktijken en 7 Spoedeisende Hulpafdelingen mee. 
Elke volwassene met klachten van een urineweginfectie met koorts, die zich 
bij één van deze deelnemende centra meldde, werd gevraagd om deel te 
nemen aan het onderzoek. Bij toestemming werd bloed en urine afgenomen 
voor onderzoek en gedurende 3 maanden werd de patiënt meerdere malen 
bezocht of gebeld om de uitkomst van de urineweginfectie te monitoren. 
Met de verzamelde gegevens werden meerdere deelonderzoeken verricht, 
waarvan de resultaten in dit proefschrift beschreven staan.
Escherichia coli is de meest voorkomende bacteriële verwekker van urine-
weginfecties. Bij een urineweginfectie met koorts moet een antibioticum 
worden gegeven dat zowel werkt in de urine als ook in het nierweefsel en de 
bloedbaan. Ciprofloxacine is zo’n antibioticum, dat in tabletvorm kan worden 
gegeven. Dit middel wordt daarom als eerste keus gebruikt bij personen 
die thuis worden behandeld. Het probleem is echter dat Escherichia coli in 
toenemende mate ongevoelig (resistent) is voor ciprofloxacine, waardoor 
ciprofloxacine niet of minder werkzaam wordt. Daarom is het voor een 
arts belangrijk om in te kunnen schatten bij welke patiënten er rekening 
gehouden moet worden met zo’n resistente Escherichia coli, want dan kan 
daarmee bij de keuze van het antibioticum rekening worden gehouden. Om 
de risicofactoren voor ciprofloxacine resistentie te onderzoeken, hebben wij 
de patiënten met een urineweginfectie met koorts door een resistente Esche-
richia coli vergeleken met diegenen waarbij een gevoelige Escherichia coli de 
oorzaak was. Dit wordt beschreven in Hoofdstuk 1. Het onderzoek toont aan 




dat het individueel gebruik van fluorchinolonen (de groep antibiotica waar 
ciprofloxacine toe behoort) in de voorafgaande 6 maanden de belangrijkste 
risicofactor is voor een urineweginfectie met een resistente Escherichia coli.
Hoofdstuk 2 geeft een overzicht van de onderzoeken naar de optimale 
behandelduur van urineweginfecties met koorts die in het verleden zijn 
gepubliceerd. Momenteel is de standaardbehandeling meestal een kuur van 
10-14 dagen, maar eerdere onderzoeken lieten zien dat 5 tot 7 dagen al 
voldoende is bij jonge, verder gezonde vrouwen. Opvallend is echter dat er 
voor andere patiëntgroepen, zoals mannen, ouderen en patiënten met on-
derliggende aandoeningen, nauwelijks onderzoeken zijn gepubliceerd naar 
de optimale duur van behandeling. Wellicht profiteren ook zij van een kortere 
antibiotische behandeling met minder bijwerkingen en kans op resistentie 
ontwikkeling, maar dat is tot nu toe nooit onderzocht.
Om dit te onderzoeken hebben wij alle patiënten met een urineweginfectie 
met koorts die zich in een bepaalde periode bij hun huisarts of op de Spoedei-
sende Hulp meldden, gevraagd om mee te doen aan een onderzoek. Daarbij 
werd door loting bepaald of zij 7 of 14 dagen behandeld werden met antibi-
otica. Elke patiënt kreeg 14 dagen tabletten. In de 2e week was de inhoud òf 
placebo òf het antibioticum ciprofloxacine, maar dit was voor de patiënt en 
diens behandelaar niet bekend om de resultaten van het onderzoek niet te 
beïnvloeden. De resultaten van het onderzoek staan beschreven in Hoofd-
stuk 3. Uit ons onderzoek onder 200 patiënten blijkt dat vrouwen veilig en 
effectief kunnen worden behandeld met een korte kuur van 7 dagen, zelfs 
als zij een hoge leeftijd hebben en ernstige onderliggende aandoeningen. 
Mannen echter hebben vaker een recidief urineweginfectie als zij behandeld 
worden met een 7-daagse kuur, dus voor hen geldt het advies om minimaal 
14 dagen te behandelen.
Diabetes mellitus ('suikerziekte') is een bekende risicofactor voor het krijgen 
van een urineweginfectie. Het is echter controversieel of diabetes er ook voor 
zorgt dat de infectie ernstiger en met meer complicaties verloopt. Om hier 
duidelijkheid over te krijgen, hebben wij in een onderzoek het ziektebeloop 
van de urineweginfectie bij 140 patiënten met diabetes vergeleken met 718 
patiënten zonder diabetes. De uitkomsten van dit onderzoek staan beschre-
ven in Hoofdstuk 4. Alhoewel diabeten inderdaad vaker complicaties van 
de infectie hadden, bleek dit niet door de diabetes op zichzelf te worden 
veroorzaakt, maar door een hogere leeftijd en bijkomende aandoeningen.
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Voor een behandelend arts is het vaak lastig in te schatten welke patiënten 
met een urineweginfectie met koorts een gecompliceerd beloop zullen krij-
gen en een ziekenhuisopname nodig hebben. Dat blijkt wel uit het feit dat 
rond de 90% van alle patiënten die met een urineweginfectie met koorts 
op de Spoedeisende Hulpafdeling komt, wordt opgenomen omdat de kans 
op levensbedreigende complicaties niet met voldoende zekerheid kan wor-
den uitgesloten. In de praktijk blijkt de patiënt vaak na enkele dagen weer 
naar huis te kunnen, zonder dat er complicaties zijn opgetreden. Dit is een 
veilige aanpak, maar zorgt echter ook voor onnodig hoge zorgkosten. In 
Hoofdstuk 5 is daarom onderzocht of de kans op een gecompliceerd beloop 
kan worden voorspeld met behulp van een bloedtest. De uitslag daarvan 
zou de arts dan kunnen steunen bij de beslissing een patiënt al dan niet op 
te nemen in het ziekenhuis. De onderzochte test meet de waarde van het 
hormoon pro-adrenomedulline in het bloed, een stof die betrokken is bij de 
afweer tegen bacteriën. Uit het onderzoek blijkt dat pro-adrenomedulline 
beter dan andere ontstekingsmarkers in staat is een gecompliceerd beloop 
te voorspellen, met name de kans om binnen 30 dagen te overlijden. Mo-
menteel vindt er vervolgonderzoek plaats, waarbij onderzocht wordt of pro-
adrenomedulline samen met een klinische beslisregel (een soort beslisboom) 
inderdaad van waarde is in het beslisproces op Spoedeisende Hulpafdelingen.
Bij nagenoeg elke patiënt met een urineweginfectie wordt de urine wel on-
derzocht op aanwijzingen voor de infectie. Indien er een test zou kunnen 
worden ontwikkeld, die eenvoudigweg in de urine aantoont of er sprake is van 
een ernstige infectie met complicaties of juist niet, zou dat een waardevolle 
aanvulling zijn op de meer invasieve bloedtesten. Bij een urineweginfectie 
worden in de urine door de gastheer bepaalde stoffen (biomarkers) uitge-
scheiden als reactie op de aanwezigheid van bacteriën in het urinewegstel-
sel. Het doel hiervan is de bacteriën uit de urinewegen te verwijderen en zo 
een urineweginfectie te bestrijden. De hoogte van de waarde in de urine zegt 
mogelijk iets over de ernst en/of uitgebreidheid van de infectie. Hoofdstuk 6 
beschrijft een onderzoek, waarbij wordt gekeken of met behulp van urine 
biomarkers de aanwezigheid van een bacteriëmie kan worden voorspeld. Dit 
bleek echter geen relatie met elkaar te hebben.
In Hoofdstuk 6 werd tevens onderzocht of genetische factoren een rol 
spelen bij de gevoeligheid voor het krijgen van een urineweginfectie met 
koorts. In eerdere onderzoeken werd namelijk aangetoond dat het risico 
op herhaaldelijke urineweginfecties verhoogd is indien urineweginfecties in 




de familie voorkomen. Bovendien wekt de dagelijkse praktijk de indruk dat 
sommige patiënten buitengewoon gevoelig zijn voor een urineweginfectie, 
terwijl anderen die nauwelijks tot nooit krijgen. Mogelijk spelen hierbij 
gedragsfactoren, zoals seksuele activiteit, en anatomische urologische af-
wijkingen een rol, maar het is ook denkbaar dat er een erfelijke component 
aanwezig is. Wij hebben daarom het DNA van ruim 700 patiënten met urine-
weginfectie met koorts onderzocht op genetische variaties die betrokken zijn 
bij de afweerreactie en immuunrespons. Hierbij werden enkele genetische 
variaties ontdekt, maar de rol van genetische factoren bij urineweginfecties 
met koorts lijkt concluderend toch klein te zijn.
Tenslotte beschrijft Hoofdstuk 7 een onderzoek naar het verband tussen de 
mate van bloedstolling bij urineweginfecties met koorts en het optreden van 
bacteriëmie. Bacteriëmie of urosepsis, een ernstige vorm van urinewegin-
fectie met koorts waarbij er bacteriën in de bloedbaan aanwezig zijn, zorgt 
namelijk voor activatie van de stollingscascade, waardoor er vele kleine 
stolsels in de bloedbaan kunnen ontstaan, met alle vervelende gevolgen 
van dien. Ons onderzoek toont aan dat hierbij zogenaamde micropartikels 
met stollingsactiverende eiwitten betrokken zijn, die in de bloedbaan terecht 
komen als reactie op de aanwezigheid van Escherichia coli, de belangrijkste 
verwekker van urineweginfecties.
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lunches en jullie praktische ondersteuning. Ik denk er met veel genoegen 
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